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1Chapter 1
Introduction and
methodology
1.1 The guideline topic
Induced abortion is common: over 200 000 procedures are performed each year in Great Britain3,4
and at least one-third of British women will have had an abortion by the time they reach the age of
45 years.5 In a legal setting where sterile facilities are available, abortion is a safe procedure for
which major complications and mortality are rare at all gestations. Abortion accounts for a
significant proportion of the workload of many gynaecologists. The RCOG views induced abortion
as a healthcare need as well as an important public health intervention, and reiterates the
recommendation of the RCOG Working Party on Unplanned Pregnancy (1991)6 that ‘health
authorities should accept responsibility for the abortions needed by women resident in their
districts’.
Over 98% of induced abortions in Britain are undertaken because of risk to the mental or physical
health of the woman or her children.3,4 This guideline has been developed in relation to the care of
women seeking abortion on such grounds. Separate RCOG publications address legal, ethical and
service issues relating to the minority of abortions undertaken because of fetal abnormality.7
Data on abortion rates in relation to age, gestation, grounds for abortion and so on are routinely
collected and published annually in Great Britain. These data are available for England and Wales
from the DH8 and for Scotland from the Information Services Division.9
In Chapter 3 of this guideline, legal issues directly relevant to the context of service provision are
summarised. In 2007, the RCOG provided evidence to the House of Commons Science and
Technology Committee, which was undertaking an inquiry into the scientific developments relating
to the Abortion Act 1967.1 A number of issues were highlighted for Members of Parliament to
consider. Those relevant to the recommendations made in this guideline and to the provision of
services included:
• the case for removing the need for the signature of two doctors authorising the abortion
• recommendations allowing greater responsibility for nurses already involved in service provision
• the recommendation that there were no reasons of safety, efficacy or acceptability for not
allowing women to undergo the second stage of medical abortion at home.
Although the House of Commons chose not to amend the law relating to induced abortion in any
of the above respects, the RCOG would still support these changes should any change in the
regulations allow them to take place.
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There are large geographical variations in access to NHS-funded abortion. In Scotland almost all
abortions take place in NHS hospitals,4 while in England and Wales the NHS has funding
arrangements with the independent sector. In 2009, 94% of abortions were funded by the NHS; of
which over half (60%) took place in the independent sector under NHS contract.3 Notably, too, the
independent sector undertakes the majority of abortions at late gestations. Thus, the clinical
management of women requesting abortion spans a number of care sectors involving a range of
professionals; these guidelines are written with this in mind.
The RCOG acknowledges the substantial role that nurses now take in the provision of abortion
services and recognises the lack of a national standard for training for this role. The RCOG
recommends that the RCN gives thought to developing and implementing specialist training
programmes for nurses working in abortion care.
1.2 Aim of the guideline
Clinical guidelines have been defined as systematically developed statements which assist
clinicians and patients in making decisions about appropriate treatment for specific conditions.
The aim of this guideline is to ensure that all women considering induced abortion have access to
a service of uniformly high quality. It is hoped that this guideline will be implemented across all
relevant healthcare sectors and will promote a consistent standard regardless of the sectors in which
an individual woman is managed.
The guideline does not cover prevention of unintended pregnancy other than to recommend robust
arrangements for contraceptive provision after abortion. Counselling to assist individuals in making
the decision to have an abortion, rather than to continue the pregnancy, is not discussed in detail.
The starting point of this guideline is the point at which a woman presents to a health provider
requesting induced abortion of an unintended/unwanted pregnancy.
1.3 For whom is the guideline intended?
The guideline has been developed under the auspices of the RCOG for its Fellows and Members
practising in Great Britain. The guideline is also intended for other professional groups who share
in caring for women considering abortion: primary care teams, sexual health services, gynaecology
nurses, staff participating in non-NHS assessment centres and clinics and all those professionals
providing abortion counselling. Those with responsibilities for planning and/or commissioning
abortion services, for example directors of public health, local government, NHS trust managers and
managers of primary care groups, may also find the guideline helpful.
In this guideline, the term ‘clinician’ is used to refer to all healthcare professionals who participate
in direct clinical patient care. Thus, the term includes doctors, nurses and midwives.
The guideline has been developed taking into account abortion legislation and available resources
in Great Britain. The guideline may be used for reference in other countries, but readers should bear
in mind that legislation, resources and facilities will be different.
The content of the guideline falls naturally into a number of chapters documenting the process of
managing induced abortion. The text in each chapter gives supporting evidence for the
recommendations. Inevitably, there is considerable overlap between chapters, and referring to one
single recommendation out of context of the guideline in its entirety may lead to misinterpretation.
The Care of Women Requesting Induced Abortion
2
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 2
Introduction and methodology
3
1.4 Local protocol development
It is anticipated that this national guideline will be used as the basis for the development of local
protocols or guidelines which will take into account local service provision and the needs and
preferences of the local population. Such local adaptation should take place in a similar
multidisciplinary group in consultation with all stakeholders affected by the recommendations. It is
essential that commissioners of health care, as well as general practitioners (GPs), specialists and
service users, take part in such a process.10
1.5 Methods used in the development of the guideline
Literature search strategy
The aim of the literature review was to identify and synthesise relevant evidence within the
published literature, thus enabling clinical practice recommendations to be based on evidence
wherever possible.
In developing the earlier versions of this guideline, searches were carried out for each topic of
interest. The electronic database MEDLINE (Ovid version including foreign language publications)
was searched for the period January 1966 to September 2003. The searches were performed using
relevant medical subject headings (MeSH) terms and text words. In addition, the electronic
database EMBASE was searched between 1974 and September 2003 to identify publications,
usually European, not indexed on MEDLINE. The Cochrane Library was searched to identify
systematic reviews, meta-analyses and controlled clinical trials. Reference lists of non-systematic
review articles and studies obtained from the initial search were trawled and journals in the RCOG
library were hand-searched to identify articles not yet indexed. There was no systematic attempt to
search the ‘grey literature’ (conferences, abstracts, theses and unpublished trials).
In developing this edition, similar literature searches were carried out covering the period 2003 to
February 2011.
Rather than undertaking a new search, where available, systematic reviews were used, including
those undertaken for the revision of the WHO guidelines for safe abortion.2 These reviews are listed
in Appendix 2 together with the tables of evidence used in the absence of appropriate published
reviews. For WHO, Cochrane systematic reviews including randomised clinical trials (RCTs) were
the primary source of evidence. Relevant Cochrane systematic reviews were identified and the need
for updating these was determined. Relevant and possibly relevant Cochrane systematic reviews
were identified and those that were considered outdated were updated using their specific, standard
search strategies. Additionally, three systematic reviews were conducted outside of the Cochrane
Database of Systematic Reviews and were published in peer-reviewed journals. The search
strategies and the specific criteria for including and excluding trials identified by the search are
provided in the corresponding systematic review.
Sifting and reviewing the literature
For both the original and updated literature searches, a preliminary scrutiny of titles and abstracts
was undertaken and full papers were obtained if they were relevant to the topic. Articles not
relevant to the subject in question were rejected, as were articles where relevant outcomes were
not reported. For all the subject areas, published systematic reviews or meta-analyses were used, if
available. If these did not exist, RCTs were sought. For subject areas where a body of systematic
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review or randomised trial evidence was available, studies of less robust design were not system-
atically sought. Where there were no relevant published RCTs, other appropriate experimental or
observational studies were sought.
Synthesising the evidence
Identified articles were assessed methodologically and the best available evidence was used to form
and support the recommendations. If a good systematic review, meta-analysis or RCT existed in
relation to a topic, studies of a weaker design were ignored. The evidence was synthesised using
qualitative methods. These involved summarising the content of identified papers in the form of
evidence tables and agreeing brief recommendation statements that accurately reflected the
relevant evidence. Quantitative techniques (meta-analyses) were not performed by the GDG
because of time constraints and the difficulty of combining studies of various designs.
Forming and grading the recommendations
The definitions of the types of evidence used in this guideline originate from the US Agency for
Health Care Policy and Research (Table 1.1).11 Recommendations were based on, and explicitly
linked to, the evidence that supports them. Recommendations were derived from available research
evidence using consensus methods. Where there were areas without available research evidence,
consensus was again used.
As part of the consensus process, the recommendations published in the 2004 guideline were
circulated to members of the GDG. For each recommendation, members were asked to indicate
whether they thought that the recommendation should be included as it stood, included with
modifications or excluded, and whether any new recommendations should be developed. This
approach ensured that all Group members had an equal opportunity to express their views on
recommendations. The Group used an informal consensus process to agree modified
recommendations.
The recommendations were then graded according to the level of evidence upon which they were
based. The grading scheme used was formulated by the Clinical Outcomes Group and
recommended by the NHS Executive.12
The strength of the evidence on which each recommendation is based is shown in Table 1.2. It is
accepted that, in this grading system, the evidence itself is not graded according to quality, although
it is discussed narratively in the text supporting each recommendation. It is also accepted that RCTs
may not always be the most appropriate study design (for example, to investigate diagnostic tests).11
Similarly, there may be clinical questions that cannot easily be answered by experiment but
nevertheless represent good practice. Such recommendations will automatically be graded C or .
The Care of Women Requesting Induced Abortion
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Table 1.1 Levels of evidence
Level Evidence
Ia Evidence obtained from meta-analysis of randomised trials
Ib Evidence obtained from at least one randomised controlled trial
IIa Evidence obtained from at least one well-designed controlled study, without randomisation
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study
III Evidence obtained from well-designed non-experimental descriptive studies, correlation studies and case studies
IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities
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The validity of some grade C and  recommendations may be questionable, as they are not based
upon incontrovertible evidence. However, the views of the 2010/2011 GDG, combined with
comments from extensive peer review, as detailed below, suggest that the recommendations with
this grading are acceptable to a wide body of expert opinion.
Scope and methods of peer review
Successive drafts of the original guideline were written and discussed by the GDG until a formal
peer review process was undertaken. Members of the Group suggested names of individuals or
organisations from the area of practice that they represented and the draft guideline was sent to
individuals chosen by the DH and the RCOG. The draft was also posted on the RCOG website and
comments were invited from any member of the public. Comments received were reviewed by the
development team and changes were made to the document where necessary. Equal consideration
was given to comments made by the nominated peer reviewers and members of the public, and all
comments were taken into account when finalising the document.
1.6 Implementation and review
This updated guideline was published in 2011. The RCOG will maintain a watching brief on the
need to review recommendations in the light of new research evidence.
Table 1.2 Forming recommendations
Grade of Evidence
recommendation level
A Requires at least one randomised controlled trial as part of a body of literature of overall good
quality and consistency addressing the specific recommendation (evidence levels Ia, Ib)
B Requires the availability of well-conducted clinical studies, but no randomised clinical trials
on the topic of the recommendation (evidence levels IIa, IIb, III)
C Requires evidence obtained from expert committee reports or opinions and/or clinical
experience of respected authorities; indicates an absence of directly applicable clinical studies
of good quality (evidence level IV)
Good practice points  Recommended best practice based on the clinical experience of the Guideline Development
Group
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Chapter 2
Summary of
recommendations
2.1 Commissioning and organising services
Access to services
4.1 Commissioners and providers of abortion services should have local strategies in place
for providing information for women and healthcare professionals on routes of access,
including self-referral.
4.2 Commissioners should ensure that women have access to abortion services locally.
4.3 Services should have arrangements which facilitate access without delay for referrals
from a wide range of sources.
4.4 Where services have no on-site provision for emergency care, there must be robust and
timely pathways for referral.
4.5 Commissioners should ensure that abortion providers do not restrict access on the
grounds of age, ethnicity, religious beliefs, disability or sexual orientation.
4.6 Commissioners should ensure that access is not restricted on the grounds of marital status
or the number of previous abortions.
4.7 Professionals who are ethically opposed to abortion have a duty of care to refer onward
women requesting abortion without delay.
4.8 Services should facilitate access for all women, particularly those who traditionally have
difficulties accessing health services.
Tailored care
4.9 Services should make sure that a female member of staff is available if requested.
4.10 Services should be culturally sensitive and professional interpreters should be available
if required.
Information provision
4.11 Services should make sure that written, objective, evidence-guided information is
available for women considering abortion to take away before the procedure.
Information should be available in a variety of languages and formats.
6

B
C
C
B



C


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4.12 Services are encouraged to adapt nationally developed patient information for local use.
4.13 Staff providing abortion services should provide up-to-date evidence-guided
information, supported by local data where robust, about complications and sequelae of
abortion.
4.14 Women should have access to objective information and, if required, counselling and
decision-making support about their pregnancy options.
4.15 Information for women and providers should emphasise the duty of confidentiality.
Initial assessment
4.16 There should be a pathway to tertiary medical care for women with significant medical
conditions.
4.17 Women who decide to continue with the pregnancy should be referred for antenatal care
without delay.
4.18 Women who have a non-viable pregnancy require appropriate management, not
forgetting contraception and sexual health care.
4.19 Services should identify issues which make women particularly vulnerable (for example,
child protection needs and domestic abuse/gender-based violence) and refer/signpost
them on to appropriate support services in a timely manner.
4.20 The assessment (including support services such as ultrasound) should be provided
within a dedicated time and space and by a team committed to women requesting
abortion, specifically separate from miscarriage and antenatal services.
4.21 Elements of the assessment consultation can be provided via the telephone and/or the
internet. However, women should be able to access face-to-face consultation, if
preferred.
Arrangements for the procedure
4.22 A system should be in place to ensure that doctors within the abortion service complete
form HSA1 (Certificate A in Scotland) if a woman refers herself, or if the referring doctor
is not willing to support the abortion.
4.23 With respect to the method used to induce the abortion, service arrangements should be
such that:
• Services should be commissioned for all women requesting induced abortion at all
gestations.
• If a service cannot offer an abortion by any method after a specific gestation, timely
onward referral must be ensured.
• All services should be able to offer abortion by at least one of the recommended
methods for each gestation band.
• All services should be able to offer a choice of recommended methods for each
gestation band.
• Services should provide surgical abortion under both local and general anaesthesia.
C



C
C
C



C

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4.24 To minimise delay, service arrangements should be such that:
• Referral to an abortion provider should be made within 2 working days.
• Abortion services must offer assessment within 5 working days of referral or self-
referral.
• Services should offer women the abortion procedure within 5 working days of the
decision to proceed.
• The total time from seeing the abortion provider to the procedure should not exceed
10 working days.
• Women requiring abortion for urgent medical reasons should be seen as soon as
possible.
4.25 Women should be informed that they have a right to delay or cancel appointments
and/or the procedure should they wish.
4.26 Upon referral, women should be given the service provider’s contact details.
4.27 Inpatient services, provided in an appropriate centre and clinical setting, should be
available for women who are unsuitable for or who do not desire home or day case care.
4.28 Services should have a protocol in place allowing early discharge after misoprostol for
women undergoing medical abortion up to 9 weeks of gestation.
4.29 The setting for abortion should be sensitive and responsive to women’s needs, and
should respect the need for privacy and dignity.
4.30 Commissioners should ensure that services meet the recommendations relating to:
• B Contraception after the abortion
• A and C Antibiotic prophylaxis
• B Screening for sexually transmitted infections (STIs)
• C Information provision after the abortion
• C Counselling after the abortion
2.2 Adverse effects, complications and sequelae of abortion: 
what women need to know
5.1 Women should be informed that abortion is a safe procedure for which major
complications and mortality are rare at all gestations.
5.2 Complications and risks should be discussed with women in a way that they can
understand and should emphasise the overall safety of the procedure.
5.3 Services should provide women with information about the physical symptoms and
sequelae that may be experienced after abortion.
5.4 Service providers should inform women about the range of emotional responses that may
be experienced during and following an abortion. Providers should be aware that
women with a past history of mental health problems are at increased risk of further
problems after an unintended pregnancy.
The Care of Women Requesting Induced Abortion
8
C
C


B





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Abortion complications
5.5 Women should be informed of the following rare but serious complication that may
occur:
• Uterine rupture has been reported in association with medical abortion at late
gestations. The risk is less than 1 in 1000.
5.6 Women should be informed of the uncommon complications that may occur and of their
possible clinical consequences. These may include:
• Severe bleeding requiring transfusion; the risk is lower for early abortions, occurring
in less than 1 in 1000, rising to around 4 in 1000 at gestations beyond 20 weeks.
• Uterine perforation (surgical abortion only); the risk is in the order of 1–4 in 1000 and
is lower for early abortions and those performed by experienced clinicians.
• Cervical trauma (surgical abortion only); the risk of damage to the external os is no
greater than 1 in 100 and is lower for early abortions and those performed by
experienced clinicians.
• Women must be informed that, should one of these complications occur, further
treatment in the form of blood transfusion, laparoscopy or laparotomy may be
required.
Failed abortion and continuing pregnancy
5.7 Women should be informed that surgical and medical methods of abortion carry a small
risk of failure to end the pregnancy (less than 1 in 100) , necessitating another procedure.
5.8 Women should be informed that there is a small risk (usually much less than 5%) of the
need for further intervention, such as surgical intervention following medical abortion or
re-evacuation following surgical abortion.
Post-abortion infection
5.9 Women should be informed that infection of varying degrees of severity may occur after
medical or surgical abortion and is usually caused by pre-existing infection. Prophylactic
antibiotic use and bacterial screening for lower genital tract infection reduces this risk.
Breast cancer
5.10 Women should be informed that induced abortion is not associated with an increase 
in breast cancer risk.
Future reproductive outcome
5.11 Women should be informed that there are no proven associations between induced 
abortion and subsequent ectopic pregnancy, placenta praevia or infertility.
Preterm birth
5.12 Women should be informed that induced abortion is associated with a small increase in
the risk of subsequent preterm birth, which increases with the number of abortions.
However, there is insufficient evidence to imply causality.
B
B
B
C
B
A
B
B
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 9
Psychological sequelae
5.13 Women with an unintended pregnancy should be informed that the evidence suggests
that they are no more or less likely to suffer adverse psychological sequelae whether they
have an abortion or continue with the pregnancy and have the baby.
5.14 Women with an unintended pregnancy and a past history of mental health problems
should be advised that they may experience further problems whether they choose to
have an abortion or to continue with the pregnancy.
2.3 Pre-abortion management
6.1 Prior to referral, pregnancy should be confirmed by history and a reliable urine
pregnancy test.
The abortion decision
6.2 Healthcare staff caring for women requesting abortion should identify those who require
more support in the decision-making process.
6.3 Women who are certain of their decision to have an abortion should not be subjected to
compulsory counselling.
6.4 Pathways to additional support, including counselling and social services, should be
available.
6.5 Women should be given information about the different methods of abortion appropriate
to gestation, the potential adverse effects and complications, and their clinical
implications.
6.6 Where possible, women should be given the abortion method of their choice.
Blood tests
6.7 Pre-abortion assessment should always include:
• determination of rhesus blood status.
Where clinically indicated, pre-abortion assessment should also include:
• determination of blood group with screening for red cell antibodies
• measurement of haemoglobin concentration
• testing for haemoglobinopathies.
6.8 It is not cost-effective or necessary to routinely cross-match women undergoing induced
abortion.
Venous thromboembolism risk assessment
6.9 All women undergoing an abortion should undergo a venous thromboembolism (VTE)
risk assessment.
The Care of Women Requesting Induced Abortion
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Cervical cytology
6.10 Women who have not had cervical cytology screening within the recommended interval
should be offered screening within the abortion service, or advised on when and where
to obtain it.
Ultrasound scanning
6.11 Use of routine pre-abortion ultrasound scanning is unnecessary.
6.12 Ultrasound scanning must be available to all services as it may be required as part of the
assessment.
6.13 Ultrasound scanning should be provided in a setting and manner sensitive to the
woman’s situation.
6.14 Before ultrasound is undertaken, women should be asked whether they would wish to
see the image or not.
Prevention of infective complications
6.15 Services should offer antibiotic prophylaxis effective against Chlamydia trachomatis and
anaerobes for both surgical abortion (evidence grade: A) and medical abortion (evidence
grade: C).
6.16 The following regimens are suitable for peri-abortion antibiotic prophylaxis:
• azithromycin 1 g orally on the day of abortion, plus metronidazole 1 g rectally or
800mg orally prior to or at the time of abortion
OR
• doxycycline 100 mg orally twice daily for 7 days, starting on the day of the abortion,
plus metronidazole 1 g rectally or 800mg orally prior to or at the time of the abortion
OR
• metronidazole 1 g rectally or 800mg orally prior to or at the time of abortion for
women who have tested negative for C. trachomatis infection.
STI screening
6.17 All women should be screened for C. trachomatis and undergo a risk assessment for other
STIs (for example, HIV, gonorrhoea, syphilis), and be screened for them if appropriate.
6.18 A system for partner notification and follow-up or referral to a sexual health service
should be in place.
6.19 Services should make available information about the prevention of STIs and offer
condoms for STI prevention to women undergoing abortion.
Contraception
6.20 All appropriate methods of contraception should be discussed with women at the initial
assessment and a plan agreed for contraception after the abortion.
B
C
C
C
B
C
C
A
C



3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 11
Feticide
6.21 Feticide should be performed before medical abortion after 21 weeks and 6 days of
gestation to ensure that there is no risk of a live birth.
2.4 Abortion procedures
Surgical methods
Vacuum aspiration
7.1 Vacuum aspiration is an appropriate method of surgical abortion up to 14 weeks of
gestation.
7.2 Either electric or manual vacuum aspiration may be used as both are effective and
acceptable to women and clinicians.
7.3 Vacuum aspiration under 7 weeks of gestation should be performed with appropriate
safeguards to ensure complete abortion, including inspection of aspirated tissue.
7.4 Vacuum aspiration may be performed from 14 to 16 weeks of gestation; large-bore
cannulae and suction tubing may be required to complete the procedure without the use
of forceps to remove larger fetal parts.
7.5 During vacuum aspiration, the uterus should be emptied using the suction cannula and
blunt forceps (if required) only. The procedure should not be routinely completed by
sharp curettage.
7.6 Access to ultrasound during vacuum aspiration is recommended but not routinely
required for uncomplicated procedures.
Dilatation and evacuation
7.7 Surgical abortion by dilatation and evacuation (D&E), preceded by cervical preparation,
is appropriate for pregnancies above 14 weeks of gestation.
7.8 Continuous ultrasound guidance during D&E is recommended to reduce the risk of
surgical complications.
Cervical preparation for surgical abortion
7.9 Cervical preparation should be considered in all cases.
7.10 The following regimens are recommended for cervical preparation up to 14 weeks of
gestation:
• Misoprostol 400micrograms administered vaginally 3 hours prior to surgery or
sublingually 2–3 hours prior to surgery.
7.11 Vaginal misoprostol can be administered either by the woman herself or by a clinician.
7.12 After 14 weeks of gestation, osmotic dilators provide superior dilatation to medical
methods; however, misoprostol is an acceptable alternative up to 18 weeks of gestation.
7.13 Use of medications containing oxytocin or ergometrine is not recommended for
prophylaxis to prevent excessive bleeding at the time of vacuum aspiration.
The Care of Women Requesting Induced Abortion
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Pain relief for surgical abortion
Anaesthesia
7.14 Services should be able to provide surgical abortions without resort to general
anaesthesia.
7.15 If conscious sedation is used during surgical abortion, it should be undertaken only by
trained practitioners and in line with DH guidance.
Analgesia
7.16 Women should routinely be offered pain relief such as non-steroidal anti-inflammatory
drugs (NSAIDs) during surgical abortion.
7.17 Prophylactic paracetamol (oral or rectal) is ineffective in reducing pain after surgical
abortion and is not recommended.
Medical methods
7.18 Medical abortion regimens using 200 mg oral mifepristone and misoprostol are effective
and appropriate at any gestation.
Medical abortion at ≤ 63 days of gestation (early medical abortion)
7.19 The following regimens are recommended for early medical abortion:
• at ≤ 63 days of gestation, mifepristone 200 mg orally followed 24–48 hours later by
misoprostol 800 micrograms given by the vaginal, buccal or sublingual route
• at ≤ 49 days, 200 mg oral mifepristone followed 24–48 hours later by 400 micrograms
of oral misoprostol.
7.20 For women at 50–63 days of gestation, if abortion has not occurred 4 hours after
administration of misoprostol, a second dose of misoprostol 400 micrograms may be
administered vaginally or orally (depending upon preference and amount of bleeding).
Place of misoprostol administration
7.21 It is safe and acceptable for women who wish to leave the abortion unit following
misoprostol administration to complete the abortion at home. There must be an adequate
support strategy and robust follow-up arrangements for these women.
Medical abortion at 9–13 weeks of gestation
7.22 The following regimen is recommended for medical abortion between 9 and 13 weeks
of gestation:
• mifepristone 200mg orally followed 36–48 hours later by misoprostol 800 micro -
grams vaginally. A maximum of four further doses of misoprostol 400 micrograms
may be administered at 3-hourly intervals, vaginally or orally.
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Medical abortion at 13–24 weeks of gestation
7.23 The following regimen is recommended for medical abortion between 13 and 24 weeks
of gestation:
• mifepristone 200mg orally, followed 36–48 hours later by misoprostol 800micro -
grams vaginally, then misoprostol 400 micrograms orally or vaginally, 3-hourly, to a
maximum of four further doses.
• If abortion does not occur, mifepristone can be repeated 3 hours after the last dose of 
misoprostol and 12 hours later misoprostol may be recommenced.
7.24 Surgical evacuation of the uterus is not required routinely following medical abortion
between 13 and 24 weeks of gestation. It should be undertaken only if there is clinical
evidence that the abortion is incomplete.
Pain relief for medical abortion
7.25 Women should routinely be offered pain relief (for example, NSAIDs) during medical
abortion.
7.26 Oral paracetamol has not been shown to reduce pain more than placebo during medical
abortion and is not recommended.
7.27 Some women may require additional narcotic analgesia, particularly after 13 weeks of
gestation.
Histopathology
7.28 Routine histopathological examination of tissue obtained at abortion procedures is not
recommended.
Gestational trophoblastic neoplasia
7.29 Routine screening of women for gestational trophoblastic neoplasia (GTN) at the time of
abortion is not recommended; providers should be aware of the signs and symptoms
and, where appropriate, facilitate referral into a GTN monitoring programme.
2.5 Care after the abortion
Rhesus prophylaxis
8.1 Anti-D IgG should be given, by injection into the deltoid muscle, to all non-sensitised
RhD negative women within 72 hours following abortion, whether by surgical or
medical methods.
Information after abortion
8.2 On discharge, all women should be given a letter providing sufficient information about
the procedure to allow another practitioner elsewhere to manage any complications.
The Care of Women Requesting Induced Abortion
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8.3 Following abortion, women should be provided with verbal and written information
about:
• symptoms they may experience, emphasising those which would necessitate an
urgent medical consultation
• symptoms suggestive of continuing pregnancy.
8.4 Independent providers of abortion services should have arrangements in place for
referring women into NHS services for emergency assessment/admission.
8.5 A 24-hour telephone helpline number should be available for women to use after
abortion if they have any concerns.
Follow-up after abortion
8.6 There is no medical need for routine follow-up after surgical abortion or after medical
abortion if successful abortion has been confirmed at the time of the procedure.
8.7 Women having a medical abortion in whom successful abortion has not been confirmed
at the time of the procedure should be offered follow-up to exclude continuing
pregnancy.
8.8 All women having an abortion should be able to choose to return for routine follow-up
if they so wish.
8.9 Referral should be available for any woman who may require additional emotional
support or whose mental health is perceived to be at risk.
8.10 All women should be advised where to seek help if they have any concerns or if they
need further contraceptive advice or provision.
8.11 Ultrasound examination should not be used routinely to screen women for incomplete
abortion.
8.12 The decision to evacuate the uterus following incomplete abortion should be based on
clinical signs and symptoms and not on ultrasound appearance.
Contraception after abortion
8.13 Abortion services should be able to provide all methods of contraception, including
long-acting methods, immediately after abortion.
8.14 Women should be advised of the greater effectiveness of long-acting reversible methods
of contraception.
8.15 Before she is discharged, future contraception should have been discussed with each
woman and contraceptive supplies should have been offered.
8.16 The chosen method of contraception should be initiated immediately.
8.17 Intrauterine contraceptives can be inserted immediately following medical and surgical
abortion at all gestations as long as it is reasonably certain that the woman is not still
pregnant.
8.18 Women who choose not to start a contraceptive method immediately should be given
information about local contraceptive providers in addition to their GP.
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8.19 Abortion services should have an agreed pathway of care to local community sexual
health services.
Sterilisation
8.20 Sterilisation can be safely performed at the time of induced abortion, although this may
be more likely to be associated with regret and failure.
The Care of Women Requesting Induced Abortion
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Chapter 3
Legal aspects of abortion
3.1 The Abortion Act
The Abortion Act 1967,13 as amended by the Human Fertilisation and Embryology Act 1990,14
governs abortion in England, Scotland and Wales (Great Britain). Legal requirements apply to
certification and notification of abortion procedures. An abortion can take place only if two
registered medical practitioners are of the opinion, formed in good faith, that an abortion is justified
within the terms of the Act. Within the terms of the Abortion Act, only a registered medical
practitioner* (doctor) can terminate a pregnancy. The notification form must be completed by the
doctor taking responsibility for the procedure. In practice, a nurse or midwife* (clinicians) may
administer the drugs used for medical abortion once these have been prescribed by a doctor. The
Abortion Act requires that ‘any treatment for the termination of pregnancy’ must take place in an
NHS hospital or approved premises. ‘Treatment’ includes prescription and administration of both
drugs used for the two stages of medical abortion.15
The Abortion Act was amended in 1990 to make clear that selective reduction of a multiple
pregnancy is covered by abortion legislation. A woman who is carrying more than one fetus can
have an abortion only if two doctors agree she has grounds under the Act. In addition, in 1990,
Section 1(3A) of the Abortion Act16 was inserted to give the Secretary of State for Health (who also
covers Wales and Scotland) the power to approve ‘a class of places’ outside NHS hospitals for
medical abortion. This provision has never been used.
Abortion forms
Doctors are under a legal obligation to complete the following forms:
• HSA1 (Certificate A in Scotland): Two doctors are required to sign the HSA1 form, which is the
certificate of opinion before an abortion is performed under Section 1(1) of the Abortion Act.16
The HSA1 form must be kept for 3 years.
• HSA2 (Certificate B in Scotland): To be completed by the doctor within 24 hours of an
emergency abortion and kept for 3 years. In cases such as these, the requirement for the opinion
of two doctors does not apply.
• HSA4: Must be completed by the doctor and sent to the Chief Medical Officer (CMO) either
manually or electronically within 14 days of the abortion taking place. As is the case with the
manual form, only doctors terminating the pregnancy are able to authorise the electronic form.
In Scotland, the equivalent Notification Form must be sent to the CMO in Scotland within 7 days
of the abortion taking place. There are as yet no electronic means of notification.
* Registered medical practitioners will be referred to as doctors throughout this chapter. The term
clinicians refers to nurses and midwives in this chapter.
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For England, the 2002 amendments to the abortion regulations17 changed the content of the HSA4
form through which doctors notify the CMO of every abortion performed. Guidance notes on
completing the amended form have been published.18 Wales has also adopted the amended HSA4.
Application of the Abortion Act in Northern Ireland
The Abortion Act13 does not apply in Northern Ireland. It is lawful to perform an abortion in
Northern Ireland only where:
• it is necessary to preserve the life of the woman, or
• there is a risk of real and serious adverse effect on the woman’s physical or mental health, which
is either long-term or permanent.
As is the position with the Abortion Act, where there is a real and serious threat to the life of the
woman, there is no limit set on the gestational age at which the abortion may be carried out. In any
other circumstance it would be unlawful to perform such a procedure. Fetal abnormality is not
recognised as a ground in itself for abortion. The Department of Health, Social Services and Public
Safety publishes statistics on the number of abortions undertaken in Northern Ireland.
Application of the Abortion Act in Crown Dependencies
The Abortion Act does not apply in the Isle of Man, Jersey or Guernsey and women from these
countries are not considered to be residents of Great Britain.
Statutory grounds for termination of pregnancy
Abortion is legal in Great Britain if two doctors decide in good faith that in relation to a particular
pregnancy one or more of the grounds specified in the Abortion Act are met.
A The continuance of the pregnancy would involve risk to the life of the pregnant woman greater
than if the pregnancy were terminated: Abortion Act 1967 as amended, Section 1(1)(c).
B The termination is necessary to prevent grave permanent injury to the physical or mental
health of the pregnant woman: Section 1(1)(b).
C The pregnancy has not exceeded its 24th week and the continuance of the pregnancy would
involve risk, greater than if the pregnancy were terminated, of injury to the physical or 
mental health of the pregnant woman: Section 1(1)(a).
D The pregnancy has not exceeded its 24th week and the continuance of the pregnancy would
involve risk, greater than if the pregnancy were terminated, of injury to the physical or 
mental health of any existing child(ren) of the family of the pregnant woman: Section 
1(1)(a).16
E There is a substantial risk that if the child were born it would suffer from such physical or
mental abnormalities as to be seriously handicapped: Section 1(1)(d).
The Act also permits abortion to be performed in an emergency if a doctor is of the opinion formed
in good faith that termination is immediately necessary:
F to save the life of the pregnant woman: Section 1(4)
G to prevent grave permanent injury to the physical or mental health of the pregnant woman:
Section 1(4).
The Care of Women Requesting Induced Abortion
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Most abortions are undertaken on ground C: that the pregnancy has not exceeded its 24th week and
that continuance would involve risk, greater than if the pregnancy were terminated, of injury to the
physical or mental health of the woman.
The number of abortions has risen steadily since 1992. However, more recently there has been a
small decrease in the total number of abortions. In England and Wales in 2009, the vast majority
(97%) of abortions were carried out under ground C and a further 1% under ground D. A similar
proportion was carried out under ground E. Grounds A and B together accounted for less than 0.5%
of abortions. Abortions are rarely carried out under grounds F or G.3 In Scotland in 2009, 98.6% of
abortions were undertaken on grounds C or D and 1% on ground E. Grounds A/B and grounds F/G
each accounted for less than 0.1% of all abortions in 2009.4 Further details on abortion statistics for
England, Wales and Scotland can be found at: http://www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsStatistics/DH_116039 and http://www.isdscotland.org/isd/1918.html.
Place of abortion
Treatment for abortion (medical and surgical) must be carried out in an NHS hospital (hospital
vested in an NHS trust, primary care trust or foundation trust) or approved independent sector place.
For these purposes, if it is not clear whether the NHS premises fall within this definition, legal
advice should be sought. Independent sector providers in England must register with the Care
Quality Commission and seek Secretary of State for Health approval in order to operate.
Independent sector providers in Scotland must register with Healthcare Improvement Scotland and
seek Scottish Ministers’ approval in order to operate.
3.2 Good professional practice
The role of doctors
Where a doctor prescribes the treatment for the abortion, remains in charge and accepts
responsibility throughout and the treatment is carried out in accordance with his/her directions, the
pregnancy is ‘terminated by a registered medical practitioner’ for the purposes of the Abortion Act
1967 (as amended).13 Doctors providing abortion care are bound by the same duties of a doctor, as
laid down by the General Medical Council (GMC) in its Good Medical Practice Guidance (2008),19
for all other aspects of their clinical practice. These principles of good practice bear repetition here:
• make the care of your patient your first concern
• protect and promote the health of patients and the public
• provide a good standard of practice and care
• keep your professional knowledge and skills up to date
• recognise and work within the limits of your competence
• work with colleagues in the ways that best serve patients’ interests
• treat patients as individuals and respect their dignity
• treat patients politely and considerately
• respect patients’ right to confidentiality
• work in partnership with patients
• listen to patients and respond to their concerns and preferences
• give patients the information they want or need in a way they can understand
• respect patients’ right to reach decisions with you about their treatment and care
• support patients in caring for themselves to improve and maintain their health
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• be honest and open and act with integrity
• act without delay if you have good reason to believe that you or a colleague may be putting
patients at risk
• never discriminate unfairly against patients or colleagues
• never abuse your patients’ trust in you or the public’s trust in the profession.
Doctors are legally required under the Abortion Act 1967 (as amended)13 to complete abortion
forms for every abortion performed, whether carried out in the NHS or an approved independent
sector place and whether or not the woman is a Great Britain resident. See Section 3(1) of the Act20
covering abortion forms for further details on this.
The role of nurses
In accordance with the Abortion Act 1967,13 the authorisation and provision of any abortion is the
legal responsibility of a doctor. In the case of medical abortion, this means that a doctor has to
remain in charge throughout the abortion process and will prescribe the drugs and sign the relevant
paperwork.21 The RCN guidance on abortion care for nurses, midwives and specialist community
public health nurses (2008) sets out good practice in this area and on wider abortion care.22 In
essence, a nurse or midwife may administer the drugs used for medical abortion at any gestation
once these have been prescribed by the doctor concerned. Nurses cannot perform surgical
abortions. In law, nurses have similar rights to conscientious objection as doctors. See Section 3(3)
of the Act for further details on conscientious objection.20
3.3 Professionals’ rights: conscientious objection to abortion
The Abortion Act has a conscientious objection clause, which permits doctors (and nurses) to refuse
to participate in any treatment authorised by the Act if it conflicts with their religious or moral
beliefs. This clause does not apply where it is necessary to save life or prevent grave permanent
injury to the woman’s physical or mental health.13 The scope of the Act’s conscientious objection
clause was clarified in the House of Lords 1988 Janaway case.23 In that case it was held that
‘participate’ should be given its ordinary and natural meaning of actually taking part in treatment,
and did not extend to typing a referral letter. It is therefore likely that a refusal to participate in
paperwork, administration or routine care (outside of treatment) connected with abortion
procedures lies outside the terms of the conscientious objection clause. The Court considered, but
did not decide, whether a refusal to sign a certificate of opinion was covered by the conscientious
objection clause.
Doctors who have a conscientious objection to abortion must tell women of their right to see
another doctor. NHS GPs who have contracted to provide contraceptive services and who have a
conscientious objection to the abortion must, where appropriate, refer women promptly to another
doctor.
The GMC’s guidance covering personal beliefs and medical practice (2008) states: ‘If carrying out
a particular procedure or giving advice about it conflicts with your religious or moral beliefs, and
this conflict might affect the treatment or advice you provide, you must explain this to the patient
and tell them they have the right to see another doctor. You should make sure that information about
alternative services is readily available to all patients. Children and young people in particular may
have difficulty in making alternative arrangements themselves, so you must make sure that
arrangements are made for another suitably qualified colleague to take over your role as quickly as
possible.’19
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In law, nurses have similar rights to conscientious objection. These are summarised in the RCN
guidance on abortion care (2008);22 the Nursing and Midwifery Council (NMC) has also produced
some helpful guidance on this subject.24 Like doctors, nurses have the right to refuse to take part in
abortion but not to refuse to take part in emergency treatment.
Hospital managers have subsequently been asked to apply the principles as described above, at
their discretion, to those ancillary staff involved in handling fetuses and fetal tissue.
3.4 Confidentiality
All women seeking abortion have the right to confidentiality. Only in exceptional circumstances,
where the health, safety or welfare of a minor or other persons is at risk, may information be
disclosed to a third party. The DH published Confidentiality; NHS Code of Practice in 2003.25 This
document sets out required practice for those who work within or under contract to NHS
organisations. In addition, the Department for Education (formerly Department for Children, School
and Families) published in 2008 Information Sharing: Guidance for Practitioners and Managers.26
This guidance is designed to provide an overview of information sharing for those working directly
with children, young people and vulnerable adults.
In Scotland, the leaflet NHS Code of Practice on Protecting Patient Confidentiality provides step-by-
step advice for all staff on issues such as the laws governing data protection, how to obtain consent
from patients for their information to be used and patients’ rights of access to their personal health
records.27
Abortion service providers must make women aware that the contents of the HSA4 form used to
inform the CMO of abortions will be used for statistical purposes by the DH. The data published
are anonymised. Similar arrangements apply in Scotland.
3.5 Disposal of fetal tissue
Fetal tissue must be treated with dignity and respect in accordance with local policies which reflect
the Human Tissue Authority’s Code of Practice 5, Disposal of human tissue for fetuses born dead at
or before 24 weeks of gestation.28 The Sands (2007) guidelines for professionals also argue the need
for sensitive disposal.29 In addition, the RCOG produced good practice guidance in 2005 on
Disposal Following Pregnancy Loss Before 24 Weeks of Gestation.30
Women should be made aware that information on disposal options is available. Any personal
wishes expressed should be met wherever possible.
In general, abortion service providers arrange for fetal material from late medical and surgical
abortions to be incinerated. Some have chosen to have a contract with local crematoria or burial
authorities for cremation or burial.
Women may decide to arrange disposal themselves and they are free to do so. The RCN guidance
for nurses and midwives on Sensitive Disposal of All Fetal Remains (2007) looks at the options.31
Among women who have an early medical abortion (up to 63 days), some choose to pass the
products of conception outside of hospital or clinic premises. The DH advises that abortion service
providers should make provision for women to return products of conception to the provider for
disposal if they so wish.32 Women should be made aware that information on disposal options is
available if they wish to have access to it. If they then decide not to receive any information about,
or take part in, the disposal of the fetal tissue, their wishes should be respected.
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Abortions carried out after 24 weeks of gestation are required by law to be registered as stillbirths
and the body to be buried or cremated. However, these circumstances lie outwith the scope of this
guideline.
The Scottish Government is currently producing a national policy on the disposal of fetal remains,
which will be available in 2011.
3.6 Use of fetal tissue for research purposes
In England and Wales, research on the fetus or fetal tissue is subject to the requirements of the
Human Tissue Act 200433 and should be conducted in accordance with Codes of Practice published
by the Human Tissue Authority.34 Specific guidance on consent to the use of fetal tissue is contained
in Code of Practice 1, Consent (this Code of Practice does not apply to Scotland but is
recommended as good practice).35
3.7 Issues relating to consent to treatment
The British Medical Association’s (BMA) guidance on Law and Ethics of Abortion updated in 200736
and the GMC’s guidance Consent: patients and doctors making decisions together published in
200837 set out good practice in this area. In 2009, the DH updated its comprehensive reference
guide to consent for examination or treatment.38 The advice which follows has been updated with
particular reference to the latter document.
Adults with capacity
In the case of an adult woman (that is, aged over 18 years, or 16 years in Scotland), for consent to
be valid it must be given voluntarily and the woman must have the capacity to consent to the
intervention in question. It should be assumed that an adult has full capacity to make a decision for
themselves (the right to autonomy) unless it can be shown that they lack capacity.39
The test for assessing capacity to consent to or refuse medical treatment has been established by the
Court and is now set out in the Mental Capacity Act (2005).40 This test is based on the patient having
the ability to:
• understand the information relevant to the decision
• retain the information relevant to the decision
• use or weigh the information
• communicate the decision (by any means).
Adults without capacity: England and Wales
The Mental Capacity Act 2005 applies in England and Wales.40 The 2005 Act defines a person who
lacks capacity as a person who is unable to make a decision for themselves because of an
impairment or disturbance in the functioning of their mind or brain. It does not matter if the
impairment or disturbance is permanent or temporary. If the person meets this diagnostic test, the
next question is whether or not they can make a particular decision for themselves. This is decided
by reference to the criteria set out below.
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• Consider whether the woman is likely to regain capacity and, if so, whether the decision can
wait.
• Involve the women as fully as possible in the decision that is being made on her behalf.
• As far as possible consider:
• the woman’s past and present wishes and feelings (in particular if they have been written
down)
• any beliefs and values and any other relevant factors
• the other factors that the woman would be likely to consider if she were able to do so.
• As far as possible, consult other people if it is appropriate to do so and take into account their
views as to what would be in the best interest of the woman, especially:
• anyone previously named by the woman as someone to be consulted
• anyone engaged in caring for or interested in the woman’s welfare
• any attorney appointed under a Lasting Power of Attorney
• any deputy appointed by the Court of Protection to make decisions for the woman.
• For decisions about serious medical treatment, where there is no-one appropriate other than paid
staff, healthcare professionals have to instruct an independent mental capacity advocate.
Provided that the issues of the woman’s capacity and best interests are clear and beyond doubt, and
the terms of the Abortion Act are complied with, there is no need for a High Court declaration to
authorise the carrying out of an abortion. However, an application to the court should be made in
any case of doubt, including where there is any dispute about the woman’s capacity or her best
interests, where the Abortion Act has not been strictly complied with or in other exceptional
circumstances.41
Adults without capacity: Scotland
In Scotland, Part 5 of the Adults with Incapacity (Scotland) Act 2000 provides a framework for the
medical treatment of incapacitated adults (those aged 16 years or over).42 If an adult lacks the
capacity to make healthcare decisions, a certificate of incapacity must, in normal circumstances, be
issued by the practitioner primarily responsible for the patient’s care and treatment, consulting with
all those who have an interest in the patient’s health and wellbeing as necessary before treatment
commences. It is, however, recognised that this will not always be possible in life-threatening
situations. (Dental practitioners, ophthalmic opticians or registered nurses who have undergone
training on the assessment of incapacity can also complete the certificate, but only for a specific
treatment they need to provide.) Once a certificate has been issued, doctors can act under the
general authority to treat. However, before abortion can be carried out on an adult who lacks
capacity, under the terms of the Adults with Incapacity (Specified Medical Treatments) (Scotland)
Regulations 2002,43 approval by a practitioner appointed by the Mental Welfare Commission is
required (and in the case of an adult who is 16 or 17 years of age and is incapable in relation to a
decision about that treatment, the medical practitioner appointed by the Mental Welfare
Commission must have a qualification, or have special experience, in child and adolescent
psychiatry or in another relevant specialism); the requirements of the Abortion Act must also be met.
If patients who are detained under the Mental Health (Care and Treatment) (Scotland) Act 200344
require treatment for a physical condition, they should be assessed for their capacity to consent to
such treatment and, if appropriate, treatment considered under the provisions of the Adults with
Incapacity (Scotland) Act 2000.42
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Young people with capacity
Young people aged 16–17 years: England and Wales
By virtue of Section 8 of the Family Law Reform Act 1969, people aged 16 or 17 years are presumed
to be capable of consenting to their own medical treatment and any ancillary procedures involved
in that treatment, such as anaesthesia.45 However, unlike the case with adults, the refusal of a
competent person aged 16 or 17 years may, in certain circumstances, be overridden by a person with
parental responsibility or by a court. In order to establish whether a young person aged 16 or 17 years
has the requisite capacity to consent to an intervention, the same criteria as for adults should be used.
If the requirements for valid consent are met, it is not legally necessary to obtain consent from a
person with parental responsibility. However, it is good practice to involve the young person’s family
in decision making, unless the young person specifically wishes to exclude them.
Young people aged under 16 years: England and Wales
The House of Lords ruling in the Gillick case46 was followed by the issuing of guidance by the DH
in the form of a Health Circular [HC(FP)(86)1].47 The legal position was stated as ‘any competent
young person, regardless of age, can give valid consent to medical treatment’.
The same working test for assessing capacity as described in relation to the adult with capacity
should be applied. Although a young person may have the capacity to give consent, this is only
valid if it is given voluntarily. To be valid, consent must be given voluntarily and freely, without
pressure or undue influence being exerted on the person to either accept or refuse treatment.
Lord Fraser provided the Fraser criteria to guide doctors asked to provide contraception for girls
aged under 16 years who refuse to involve their parents.48A doctor or clinician is justified in
proceeding without the parents’ consent or knowledge if:
• the young person will understand the advice
• she cannot be persuaded to inform her parents or to allow the doctor/clinician to inform her
parents that she is seeking an abortion
• she cannot be persuaded to inform her parents or to allow the doctor/clinician to inform her
parents that she is seeking contraceptive advice
• she is likely to begin or to continue having sexual intercourse with or without contraceptive
advice
• unless she receives contraceptive advice or treatment, her physical or mental health, or both, is
likely to suffer
• her best interests require the clinician/doctor to give her contraceptive advice, treatment or both
without parental consent.
The case of Axon vs The Secretary of State for Health confirmed that the Gillick judgement also
extends to cover abortion.49 Doctors have an obligation to encourage a young person to involve her
parent(s) or another adult (such as another family member or a specialist youth worker) but
generally should not override the patient’s views. Further guidance is contained in Working
Together to Safeguard Children.50
Young people aged under 16 years: Scotland
Legislation in Scotland relating to consent for medical, surgical and dental procedures is based on
the Age of Legal Capacity (Scotland) Act 1991.51 Under the terms of this Act, the situation regarding
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the ability of children under 16 years of age to consent to medical treatment is similar to the rest of
Great Britain, but the overriding test is whether the child is ‘capable of understanding the nature
and consequences of the procedure or treatment’ (Section 2(4) of the 1991 Act).
Young people without capacity
Young people aged under 16 years: England and Wales
Only a holder of ‘parental responsibility’, or the Court, can give consent to treatment on behalf of
a minor. Adults who do not hold parental responsibility cannot give such consent. In rare cases,
where a young person seeking abortion is not felt to be competent to provide valid consent and
where a parent (or other person holding parental responsibility) cannot give consent on the child’s
behalf, it may be wise to obtain a court order. A court order would also be needed if the parent or
other person with parental responsibility refused to give their consent. Similar advice is provided by
the BMA.36
Wards of court
The main exception to this general guidance is if the young woman is a ward of court. In such cases,
the courts would need to approve an abortion.52 It is therefore particularly important that medical
records make it clear if a child is a ward of court.
Young people aged under 16 years: Scotland
Similar to the above, in Scotland persons having parental responsibilities in relation to a child under
16 years of age have the right to act as the child’s legal representative (which includes the right to
make decisions about the medical treatment of a child under 16 years of age who lacks the capacity
to give such consent themselves). In addition, under Section 5 of the Children (Scotland) Act 1995,
persons over 16 years of age who have care or control of a child under the age of 16 years, but who
do not have parental rights or responsibilities in relation to that child, can nevertheless give consent
to any surgical, medical or dental treatment or procedure where the child is not able to give such
consent on their own behalf and it is not within the knowledge of the person that a parent of the
child would refuse to give the consent in question.53 This does not, however, apply to a person who
has care of control of a child in a school setting.
Where questions arise as to parental rights and responsibilities, the matter can be referred to the
sheriff court or the Court of Session.
3.8 Abuse of children and vulnerable people
There are special difficulties in managing suspected child abuse, incest or abuse of the very
vulnerable in abortion services. The need for a decision on an abortion may be urgent because of
advanced gestation and both the girl and any accompanying adult may conceal the truth from
assessing staff. The girl may have travelled away from her home area to assist with the concealment.
Staff must be alert to the possibility of abuse, particularly when the girl refuses to involve her parents
or GPs, has a history of repeat abortions or is accompanied by a controlling adult such as a male
relative who wishes to remain particularly close to her.
When abuse is suspected, the primary concern must be the wellbeing of the girl and children she
may have care or concern for. Clear protocols must be in place for all assessors, medical staff,
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nurses and counsellors on action to be taken should abuse be suspected. It is suggested that all
services should designate a small number of doctors/clinicians and counsellors to assess all girls
under 16 years of age. Within the terms of confidentiality, it is the doctor’s responsibility to liaise
with the appropriate children’s social care team in the local authority when it is thought that a girl
has been abused or when other children are likely to be at risk. Guidance on this is contained
within Working Together to Safeguard Children, published in 2010; particular paragraphs of interest
are 5.25–5.31 and 6.2–6.4.50 Similar considerations can arise in the case of vulnerable women
(perhaps because of a learning disability).
Under Section 5 of the Sexual Offences Act 2003, a girl under 13 years of age is not considered
capable of giving her consent to sexual intercourse.54 The duty of a doctor who learns of such an
allegation or has other reason to suspect abuse is to protect the child and secure the best possible
outcome for that child. Where a doctor believes that a patient (whether or not that patient is a child)
may be the victim of abuse or neglect, the patient’s interests are paramount, and will usually require
a doctor to disclose information to the children’s social care team in the local authority or to the
police. In cases where the police are informed, doctors/clinicians should be mindful of the need to
preserve evidence. In the case of children, the responsibilities of healthcare professionals are set out
in What to do if you’re worried a child is being abused, published in 2006.55
Disclosure is not invariably required but it is usual in order that the interests of the child, which are
paramount, may be protected. A doctor or clinician may be called upon to justify the action that he
or she has taken before the court or the statutory professional body. When such concerns arise in
the context of abortion, whether during counselling or subsequently, the duty of the doctor or
clinician is clear, and those who practise in this field should ensure that they are familiar with the
procedures to be observed. They should also bear in mind that other children in a family may be
in need of protection.
3.9 Rights of the spouse or partner
The decision to have an abortion rests with the woman and her doctors. Legally, the woman’s
spouse and/or the putative father of the child has no right to demand or refuse an abortion. In
individual cases which attracted much media attention (Kelly 1997,56 Hansell 200157), male partners
brought unsuccessful legal actions in attempts to prevent women obtaining abortions. In Paton vs
BPAS,58 a husband applied unsuccessfully for an injunction to prevent a clinic from carrying out a
termination of his wife’s pregnancy. The case went to the European Commission of Human Rights.59
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Chapter 4
Commissioning and
organising services
Abortion services should aim to provide high-quality, efficient, effective and comprehensive care
which respects the dignity, individuality and rights of women to exercise personal choice over their
management. An abortion service should be an integral component of a broader service for
reproductive and sexual health, encompassing contraception, management of STIs and support.
While this guideline is primarily intended for clinicians providing services, the provision of care is
a shared responsibility with commissioners of services. Commissioning is the means of ensuring that
the healthcare services are provided effectively and meet the needs of the population. It is a process
that includes assessing population needs, prioritising health outcomes, procuring services,
monitoring service provision, ensuring meaningful consumer involvement and managing service
providers.
It is the responsibility of the commissioners and providers of abortion services to ensure that the care
is provided in accordance with current evidence and best practice identified within this guideline.
National, regional and local data should also be used to inform the commissioning of services. The
national service specification usefully defines the datasets to collect, recognising the importance of
monitoring and evaluating services to inform needs and service delivery.
A full range of services should be commissioned, to include a choice of medical and surgical
procedures for all gestations up to the legal limit, as part of a pathway of care. Individual local
referral pathways should be used to support this, to include a clear process for managing women
presenting at late gestation.60
Abortion care should be commissioned and delivered within a robust clinical governance
framework to assure accessibility, clinical quality and patient safety.61 Clinical staff working within
the service must be appropriately trained and experienced. Clinical appraisal/revalidation
procedures ensure that clinicians keep up to date with the continuing professional development
requirements set down by their professional body and commissioners must monitor compliance to
these standards.
Increasingly the independent sector is providing abortion care. In 2009, 94% of abortions were
funded by the NHS; of these, over half (60%) took place in the independent sector under NHS
contract.3 This has been identified as a significant issue for clinical training and mentorship of
clinicians undertaking abortions, particularly at later gestations.62 The independent sector has
neither the resources nor the responsibility to provide training, and as the amount of abortions
performed in the independent sector increases, the opportunities for training in NHS facilities
decrease.
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The following recommendations relating to the organisation of abortion services are the joint
responsibility of commissioners and providers of services.
4.1 Access to services
RECOMMENDATION 4.1
Commissioners and providers of abortion services should have local strategies in place for
providing information for women and healthcare professionals on routes of access, including
self-referral.
Evidence supporting recommendation 4.1
People faced with an unintended pregnancy need information on their options and on relevant
service provision. Information should include what local services, including general practices, do
and do not offer.63 The information should be available in a range of formats and provided in a range
of settings. Inadequate provision, delayed access to services and lack of public awareness are
strongly associated with subsequent adverse health outcomes.64
RECOMMENDATION 4.2
Commissioners should ensure that women have access to abortion services locally.
Evidence supporting recommendation 4.2
Access to both early and late abortion services varies significantly across the country and some
women continue to face difficulties. The Medical Foundation for AIDS & Sexual Health64 urges
commissioners to improve access to abortions and locate services in more community-based
settings.
A full range of services should be commissioned according to the service specification for the NHS
contract for abortion service providers (England),65 including confirmation of pregnancy, referral
procedures for all gestations and methods, and continuing care.66
Funding of NHS abortion services differs in various parts of the country. In some areas, the NHS will
pay for abortions provided by the independent sector, but in other areas some women may need to
pay for themselves. Women can contact the independent sector without being referred by a doctor.
However, the NHS may not pay for this.
It is the responsibility of the commissioning organisation to ensure that eligible women have access
to abortion care, irrespective of the funding arrangements or any other criteria that could restrict
access.
RECOMMENDATION 4.3
Services should have arrangements which facilitate access without delay for referrals from a
wide range of sources.
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Evidence supporting recommendation 4.3
The earlier in pregnancy an abortion is performed, the safer it is. The proportion of procedures
performed in England and Wales under 10 weeks of gestation has increased to 75%, reflecting an
improvement in access; however, there is wide local variation.3 Although advances in abortion care
now mean that abortion at later gestations is safe, this is not provided by all services, which can
lead to delay and the need to travel for care. The proportion of women accessing late abortion care
has been remarkably static over time and research indicates that the reasons for late abortions (after
13 weeks of gestation) are complex but include service failures.64 Women requesting abortion late
are often vulnerable and may have complex difficulties. The development of an agreed best practice
protocol for managing late abortion has been recommended by the CMO but not yet actioned.64
Commissioners and providers should jointly agree local pathways to ensure that women do not
suffer any undue delay.
Telephone referral services with the provision of dedicated outpatient appointment time facilitate
earlier abortion.67
RECOMMENDATION 4.4
Where services have no on-site provision for emergency care, there must be robust and timely
pathways for referral.
RECOMMENDATION 4.5
Commissioners should ensure that abortion providers do not restrict access on the 
grounds of age, ethnicity, religious beliefs, disability or sexual orientation.
RECOMMENDATION 4.6
Commissioners should ensure that access is not restricted on the grounds of marital status or
the number of previous abortions.
Evidence supporting recommendations 4.5 and 4.6
The Equality Impact Assessment for National Sexual Health Policy68 ensures services are provided
fairly to all populations regardless of age, gender, ethnicity, language, disability, sexual orientation
and religious or personal circumstances. It is the responsibility of both commissioners and providers
to ensure that all strategies, service specifications, policy documents and service information are
impact assessed. Data on age, ethnicity, language, disability and sexual orientation should be
collected and analysed against data for the resident population to ensure equity of access.
RECOMMENDATION 4.7
Professionals who are ethically opposed to abortion have a duty of care to refer onward
women requesting abortion without delay.
Evidence supporting recommendation 4.7
According to the GMC, ‘you must treat your patients with respect, whatever their life choices and
beliefs’.19 The NMC document Standards of conduct, performance and ethics for nurses and


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midwives clearly identifies this duty.69 Physicians, nurses and others who refuse to provide referral
or undertake abortions on religious grounds have a duty of care and must refer their patients
(without delay) to non-objecting practitioners or agencies.
Some clinicians apply gestational limits to the abortion care they offer on the grounds of compe -
tency. This does not constitute conscientious objection.
RECOMMENDATION 4.8
Services should facilitate access for all women, particularly those who traditionally have
difficulties accessing health services.
Evidence supporting recommendation 4.8
Teenagers, women with complex social problems and young women from minority ethnic groups
are all at risk of unintended pregnancy and are known to have difficulty accessing healthcare
services.70–74
4.2 Tailored care
RECOMMENDATION 4.9
Services should make sure that a female member of staff is available if requested.
RECOMMENDATION 4.10
Services should be culturally sensitive and professional interpreters should be available if
required.
Evidence supporting recommendation 4.10
It should be noted that while women may choose to use family or friends as interpreters, in gaining
consent to a procedure the provider needs to be absolutely certain that the woman is fully
consenting. This can be guaranteed only if an independent professional interpretation service is
used.
4.3 Information provision
RECOMMENDATION 4.11
Services should make sure that written, objective, evidence-guided information is available
for women considering abortion to take away before the procedure. Information should be
available in a variety of languages and formats.
RECOMMENDATION 4.12
Services are encouraged to adapt nationally developed patient information for local use.
The Care of Women Requesting Induced Abortion
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RECOMMENDATION 4.13
Staff providing abortion services should provide up-to-date evidence-guided information,
supported by local data where robust, about complications and sequelae of abortion.
RECOMMENDATION 4.14
Women should have access to objective information and, if required, counselling and
decision-making support about their pregnancy options.
Evidence supporting recommendations 4.11–4.14
All women attending an abortion service will require a discussion to determine the degree of
certainty of their decision and their understanding of its implications as part of the process of
gaining consent. Careful and sensitive enquiry as to the reasons for requesting an abortion should
be made, with the opportunity for further discussion, especially where women express any doubts
or suggestion of pressure or coercion.
All information provided at the initial consultation must be backed up by good-quality, accurate,
impartial written information that is well presented and easy to understand. People want to receive
written information about medical and surgical interventions and, when given written information,
are more likely to be satisfied with their care.75
A 2002 study examined the quality of information relating to medical abortion available to the public
on the internet.76 Incorrect and inappropriate information was common. Locally produced leaflets are
often of poor quality.77 Services should make use of the RCOG website78 or Family Planning
Association (FPA) patient information79 and base local leaflets on this information. Where good-
quality information is collected from audits of local services with sufficient throughput of women to
allow robust data (such as local statistics for complication rates etc.), these should be provided.
RECOMMENDATION 4.15
Information for women and providers should emphasise the duty of confidentiality.
Evidence supporting recommendation 4.15
Abortion is still highly stigmatised and, without a guarantee of confidentiality, vulnerable women
could be deterred from seeking help.
Women of all ages accessing such services have the right to confidentiality under the NHS code of
practice.25 Confidentiality is a key issue for young people. However, the right to confidentiality is
not absolute and, if there are issues of safeguarding/child protection, information may need to be
shared with or without the consent of the young person (for example, in cases of exploitation). All
practitioners and front-line staff who have responsibilities for safeguarding and promoting the
welfare of children should be appropriately trained and should have ready access to expert child
protection advice.
The BMA states that decisions must be made on the basis of an assessment of the child’s best
interests, taking into consideration all relevant factors.80
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4.4 Initial assessment
RECOMMENDATION 4.16
There should be a pathway to tertiary medical care for women with significant medical
conditions.
RECOMMENDATION 4.17
Women who decide to continue with the pregnancy should be referred for antenatal care
without delay.
Evidence supporting recommendation 4.17
Women who delay seeking maternity care (and their babies) have worse outcomes than when care
is accessed at an earlier stage of pregnancy.81 Delayed presentation is particularly likely among
women who misuse substances (alcohol and/or drugs), women who are recent migrants, asylum
seekers or refugees, women who have difficulty reading or speaking English, young women aged
under 20 years and women who experience domestic abuse.82
RECOMMENDATION 4.18
Women who have a non-viable pregnancy require appropriate management, not forgetting
contraception and sexual health care.
RECOMMENDATION 4.19
Services should identify issues which make women particularly vulnerable (such as child
protection needs and domestic abuse/gender-based violence) and refer/signpost them on to
appropriate support services in a timely manner.
Evidence supporting recommendation 4.19
The rate of domestic abuse is higher in women seeking abortion, especially repeat abortion,83 and
this has child protection implications. Abortion services offer an opportunity to identify such
vulnerable women and enable them to receive support from or referral to trained advocates.84–86
A child who is pregnant and under 13 years of age has suffered a statutory rape and the appropriate
authorities must be informed. Other underage children who present for an abortion may have been
subject to abuse or violence. It is necessary to be aware of this and to give any underage girl the
chance to disclose during a private moment when a parent or adult is not present.87
RECOMMENDATION 4.20
The assessment (including support services such as ultrasound) should be provided within a
dedicated time and space and by a team committed to women requesting abortion,
specifically separate from miscarriage and antenatal services.
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RECOMMENDATION 4.21
Elements of the assessment consultation can be provided via the telephone and/or the
internet. However, women should be able to access face-to-face consultation, if preferred.
Evidence supporting recommendation 4.21
Increasingly, services are using technology as an alternative to some of the face-to-face consult -
ations and service delivery. Anecdotally, women find telephone consultation (with a clinician) for
the initial assessments highly acceptable. Protocols that require in-person follow-up after abortion
may not be the best use of a woman’s time, or that of the medical system.88–92 Commissioners and
providers should monitor the outcomes of all aspects of the assessment to ensure they meet
women’s needs and provide the necessary amount of information and opportunity for decision
making.
4.5 Arrangements for the procedure
RECOMMENDATION 4.22
A system should be in place to ensure that doctors within the abortion service complete form
HSA1 (Certificate A in Scotland) if a woman refers herself, or if the referring doctor is not
willing to support the abortion.
RECOMMENDATION 4.23
With respect to the method used to induce the abortion, service arrangements should be such
that:
• Services should be commissioned for all women requesting induced abortion at all 
gestations.
• If a service cannot offer an abortion by any method after a specific gestation, timely 
onward referral must be ensured.
• All services should be able to offer abortion by at least one of the recommended 
methods for each gestation band.
• All services should be able to offer a choice of recommended methods for each 
gestation band.
• Services should provide surgical abortion under both local and general anaesthesia.
Evidence supporting recommendation 4.23
The GDG views induced abortion as a healthcare need. The Group therefore considers that services
for a population should be able to provide abortion, by at least one recommended method, for
women at any gestation at which abortion is permitted within the law.
Medical and surgical methods of abortion have unique advantages and disadvantages. These
include the procedure duration, number of required visits, effectiveness, adverse effects and
complication profile. A small number of trials have compared medical with surgical methods in an
effort to determine which is optimal. However, few have included modern techniques and all were
underpowered to precisely assess differences in rare complications such as continuing pregnancy
or uterine perforation.
C
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Medical abortion with mifepristone and misoprostol is associated with a longer duration of
bleeding, more pain and gastrointestinal adverse effects, and a higher likelihood of being
incomplete than vacuum aspiration under general anaesthetic up to 14 weeks of gestation.93,94 One
partially randomised preference trial, in which 1528 women received their method of choice and
349 were randomised to a vacuum aspiration under general anaesthetic or medical abortion, also
found that rates of unplanned or emergency admissions were higher after medical than surgical
procedures (4.2% and 0.7%, respectively), mainly owing to retained products of conception.94
Overall complications were also more frequent in the medical group (5.0% and 2.6%, respectively);
however, this difference achieved statistical significance in the preference arm only.
Similarly, in the limited number of comparative trials of D&E and medical abortion with
mifepristone and misoprostol after 14 weeks of gestation, pain and bleeding were shown to be
higher in women undergoing medical management.95,96 One small trial found that cumulative
adverse events were higher in the medical abortion group; however, these were limited to fever
greater than 38°C and the need for curettage.95
Level III evidence and that which can be extrapolated from attempts at RCTs of medical and surgical
methods confirms that many women have an a priori preference and value being offered a choice
between medical and surgical options.94–99 In addition, obtaining their method of choice is a
predictor of satisfaction with treatment.100,101 Where women have been willing to be randomised, a
majority report greater acceptability with surgical methods in the weeks following the
abortion.94,96,100,101 
Therefore, the GDG recommends that services should be able to offer a choice of methods in each
gestation band (Figure 7.1). Abortion by D&E requires special expertise, an adequate case load and
particular staff attitudes. Specialist independent sector providers perform the majority of D&E
procedures in Great Britain. Given recent evidence regarding preferences and acceptability of D&E
compared with medical abortion, development of these services within the NHS should be a
priority.
Where a service cannot provide an abortion by either method above a specific gestation, prompt
referral is indicated. Delays between consultation and procedure contribute to the number of
women obtaining abortions in the second trimester, particularly at 18 weeks of gestation or greater
when the number of providers offering services decreases.102,103 Abortion-related morbidity and
mortality also increase with gestational age,104–106 emphasising the importance of facilitating access
as quickly as possible.
The issue of choice is important. With respect to minimising delay, recommendation 4.23 relates to
service arrangements and should not affect a woman’s right to wait or to delay appointments.
RECOMMENDATION 4.24
To minimise delay, service arrangements should be such that:
• Referral to an abortion provider should be made within 2 working days.
• Abortion services must offer assessment within 5 working days of referral or self-referral.
• Services should offer women the abortion procedure within 5 working days of the decision
to proceed.
• The total time from seeing the abortion provider to the procedure should not exceed 10
working days.
• Women requiring abortion for urgent medical reasons should be seen as soon as possible.
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RECOMMENDATION 4.25
Women should be informed that they have a right to delay or cancel appointments and/or the
procedure should they wish.
Evidence supporting recommendations 4.24 and 4.25
Currently, the specification for termination of pregnancy services (England) states that all service users
should be offered an assessment appointment within 5 calendar days of referral or self-referral.65
An increase in the proportion of abortions performed under 10 weeks of gestation would result in
significant cost savings for the NHS as a result of greater use of non-surgical and local anaesthetic
methods, as well as the reduced risks to women consequent to reduced gestation.107
Appointments should be expedited for women who present beyond 12 completed weeks of
gestation or who require abortion for urgent medical reasons, to minimise further risk to health.
Services which provide abortions only up to a certain gestational age should ensure rapid transfer
of these women to appropriate providers via robust care pathways.
Women who need more time to reach a decision should be free to delay the procedure and be
provided with further counselling if requested. It is essential to ascertain that a woman is sure of her
choice to proceed with abortion; however, when that is confirmed, there is no advantage in further
delay since the risks associated with abortion increase with increasing gestation. Women should
also be informed that they can change their mind at any time before the procedure and cancel the
abortion.
RECOMMENDATION 4.26
Upon referral, women should be given the service provider’s contact details.
RECOMMENDATION 4.27
Inpatient services, provided in an appropriate centre and clinical setting, should be available
for women who are unsuitable for or who do not desire home or day case care.
Evidence supporting recommendation 4.27
Day case care is cost-effective. The availability of abortion as a day case procedure can minimise
disruption to women and their families. Treatment with mifepristone prior to mid-trimester abortion
with a prostaglandin analogue reduces induction-to-abortion intervals to such an extent that many
women undergoing these procedures may be managed as day cases. In a series of 500 women
undergoing mid-trimester abortion carried out using prostaglandin analogues, over two-thirds were
managed as day cases.108
Reasons why women might need to undergo induced abortion as inpatients rather than day cases
include:
• medical problems requiring assessment prior to anaesthetic or overnight stay following the 
abortion
• social indications, such as lack of an adult companion at home
• geographical factors, such as distance or transport problems
• the woman’s choice.
C
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The percentage of women undergoing abortion requiring an overnight stay is very low. The
availability of beds for these women must be agreed locally to reflect local circumstances and the
need to respond to women’s choices.
RECOMMENDATION 4.28
Services should have a protocol in place allowing early discharge after misoprostol for
women undergoing medical abortion up to 9 weeks of gestation.
Evidence supporting recommendation 4.28
Early discharge after the administration of misoprostol for medical abortion up to 63 days of
gestation is acceptable to women, allowing them to spend less time in hospital and thus maintaining
their privacy and reducing disruption to their family.109 This practice is within the terms of the
Abortion Act13 and could offer considerable savings to the NHS. It is not suitable or acceptable to
all women, but services should have protocols in place to allow it to happen and to make
arrangements to confirm complete abortion in women who choose to go home.
Currently in Great Britain, abortions are permitted only in NHS hospitals and independent sector
sites approved by the DH. In various other countries, gynaecologists provide medical abortions in
their office with no reports of increased rates of adverse effects or complications.110 The 1990
amendment to the Abortion Act introduced a subsection 1(3A)16 giving the Secretary of State for
Health the power to approve a ‘class of place’ for medical abortions. Although this has never been
enacted, a mechanism exists for places to be approved specifically for medical abortion. A pilot on
early medical abortion in a community setting reported positive results.110
Since the first edition of this guideline (2000), the published literature on the safety, efficacy and
acceptability of taking the misoprostol at home has grown.110–119 A systematic review of the literature
concluded that this process is safe, effective and acceptable.120 While taking misoprostol at home is
not legal in Great Britain, the evidence would support its use were that to be possible at some time
in the future.
RECOMMENDATION 4.29
The setting for abortion should be sensitive and responsive to women’s needs and should
respect the need for privacy and dignity.
RECOMMENDATION 4.30
Commissioners should ensure that services meet the recommendations relating to:
• B Contraception after the abortion
• A and C Antibiotic prophylaxis
• B STI screening
• C Information provision after the abortion
• C Counselling after the abortion
Evidence for recommendation 30
See chapters 6 and 8.
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Chapter 5
Adverse effects, complications
and sequelae of abortion:
what women need to know
RECOMMENDATION 5.1
Women should be informed that abortion is a safe procedure for which major complications
and mortality are rare at all gestations.
RECOMMENDATION 5.2
Complications and risks should be discussed with women in a way that they can understand
and should emphasise the overall safety of the procedure.
Evidence supporting recommendations 5.1 and 5.2
National reporting systems record major complications (including haemorrhage, sepsis and uterine
perforation) that occur prior to discharge. Estimated complication rates are 1–2 per 1000 abortions,3
although lack of standardisation of reporting criteria hampers collection of accurate data.
Although the absolute risk of major complications is low, there is evidence that complications
increase with increasing gestation.121 A Cochrane systematic review comparing surgical and medical
methods of abortion in the first trimester93 identified no significant difference in complications
between methods, although there were few sufficiently powered randomised studies to identify
different rates for rare events. A comparison of surgical and medical methods of abortion122,123 after
13 weeks of gestation, by contrast, suggests that medical abortion is associated with higher all-cause
adverse events, although this evidence is dependent on a few very small, underpowered
randomised trials and cohort studies.
A recent large registry-based cohort study from Finland of more than 42 000 women compared
complication rates (haemorrhage, infection, incomplete abortion, surgical injury, thromboembolic
disease, psychiatric morbidity and death) in the first 6 weeks following medical and surgical
abortion. Both methods are generally safe. The incidence of haemorrhage and incomplete abortion
observed was higher in women undergoing medical abortion while complications requiring surgical
treatment, although rare, were more common after surgical events. The rates of infection and
serious morbidity did not differ between groups.124
Service providers should inform women that the risks of mortality associated with induced abortion
are extremely low. In the triennium 2006–08, there were 107 direct maternal deaths in the UK and
B
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154 indirect maternal deaths out of 2.29 million mothers who gave birth (overall maternal mortality
rate 11.39/100 000 maternities). Of the 107 direct deaths, only two were associated with abortion
and both of these were from genital tract sepsis, out of a total number of 628 342 abortions in the
same time frame (maternal mortality rate 0.32/100 000 maternities).125
Communicating the risk of complications associated with abortion in an understandable way to
women undergoing abortion is essential for informed decision making. Women need to be informed
about which options for abortion are available to them and the risks and uncertainties associated
with each procedure. Perception of risk is more important than actual risk and may vary widely
among individuals.126,127 Risk should be communicated in the form of numbers as well as words. This
guideline recommends using the modified Calman scheme (Table 5.1)128 to quantify risk alongside
descriptors in a way that is straightforward for both clinicians and women to interpret.
Table 5.1 Quantification of risk (modified from Calman et al., 1997128)
Verbal descriptor Risk 
Very common 1 in 1 to 1 in 10
Common 1 in 10 to 1 in 100
Uncommon 1 in 100 to 1 in 1000
Rare 1 in 1000 to 1 in 10 000
Very rare Less than 1 in 10 000
Women can also be referred to current RCOG guidance: Understanding how risk is discussed in
healthcare – information for you.129
RECOMMENDATION 5.3
Services should provide women with information about the physical symptoms and sequelae
that may be experienced after abortion.
Evidence supporting recommendation 5.3
Women experience a range of physical symptoms following medical and surgical abortion that are
considered within the normal range. The most common of these are pain and bleeding;
gastrointestinal symptoms are frequent, particularly after medical abortion. Women should be
advised of this and of which features should alert them to seek further advice.
Compared with women undergoing surgical abortion, women undergoing medical abortion at less
than 14 weeks of gestation report significantly more pain and gastrointestinal symptoms during the
procedure94,98,100,101,130 and more bleeding over the first 2 weeks of follow-up. This is hardly surprising,
since during surgical abortion placental tissue and blood are removed by vacuum aspiration, while
loss of the products of conception continues gradually for some days/weeks after medical abortion
until the uterus is empty. A similar proportion of women who have had either surgical or medical
procedures are still bleeding at 2 weeks after their abortion (around 22%), although women
undergoing medical abortion report heavier blood loss.94 The duration of bleeding is consistently
reported to be longer after medical than surgical abortion and longer for abortion at 10–13 weeks
The Care of Women Requesting Induced Abortion
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of gestation (when the placenta and therefore the source of bleeding, the placental site, is larger)
compared with abortion at 9 weeks of gestation or earlier. Women are more likely to seek medical
help for bleeding after medical than surgical abortion and report bleeding that is heavier than they
expected.93,98,101,131,132
RECOMMENDATION 5.4
Service providers should inform women about the range of emotional responses that may be
experienced during and following an abortion. Providers should be aware that women with
a past history of mental health problems are at increased risk of further problems after an
unintended pregnancy.
Evidence supporting recommendation 5.4
Women experience a range of emotions during and after abortion that includes relief, sadness,
anger, guilt and regret.133 Such reactions are normal. For some women, recurring thoughts can also
occur later when triggered by other life events such as difficulties with subsequent pregnancies, life
milestones and birthdays. Most major life decisions result in complex feelings and the decision to
have an abortion is for most women a difficult choice. The circumstances that lead to the unplanned
pregnancy, how women are supported when faced with indecision and how they are enabled to
make the right choice for them will influence the emotions they may experience during and after
abortion. Women with more severe problems may need to be referred for counselling.134–136 Women
with a prior history of mental health problems are more likely to develop a mental health problem
after unintended pregnancy whether the pregnancy is continued or not (see recommendation
5.14).137
5.1 Abortion complications
RECOMMENDATION 5.5
Women should be informed of the following rare but serious complication that may occur:
• Uterine rupture has been reported in association with medical abortion at late gestations.
The risk is less than 1 in 1000.
Evidence supporting recommendation 5.5
Uterine rupture during abortion is rare. Case reports138–141 have described uterine rupture in women
who have had previous caesarean section undergoing medical abortion at a gestation between 13
and 24 weeks with varied regimens. A large retrospective review of over 600 women undergoing
mid-trimester medical abortion142 suggested an almost 20-fold increase in the risk among women
who have had a previous caesarean section, although more recent retrospective reviews of women
undergoing abortion at different gestations failed to identify any cases of uterine rupture.143,144 Recent
systematic review evidence does support the finding that previous caesarean section is a risk factor
for uterine rupture during abortion; the absolute risk is less than 0.4%,145,146 which many women
may find acceptable.

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RECOMMENDATION 5.6
Women should be informed of the uncommon complications that may occur and of their
possible clinical consequences. These may include:
• Severe bleeding requiring transfusion; the risk is lower for early abortions, occurring in less
than 1 in 1000, rising to around 4 in 1000 at gestations beyond 20 weeks.
• Uterine perforation (surgical abortion only); the risk is in the order of 1–4 in 1000 and is
lower for early abortions and those performed by experienced clinicians.
• Cervical trauma (surgical abortion only); the risk of damage to the external os is no greater
than 1 in 100 and is lower for early abortions and those performed by experienced clinicians.
Women must be informed that, should one of these complications occur, further treatment in
the form of blood transfusion, laparoscopy or laparotomy may be required.
Evidence supporting recommendation 5.6
Haemorrhage is most commonly defined as blood loss greater than 500 ml or severe bleeding
requiring transfusion. It is difficult to get a true estimate of the risk of haemorrhage at the time of
abortion owing to the lack of standardised definitions and poor reporting. Many studies do not
distinguish between immediate and later haemorrhage, its severity and the underlying aetiologies.
Nonetheless, national estimates suggest that fewer than 0.2% of procedures are complicated by
haemorrhage of more than 500 ml and the proportion requiring transfusion is less than this.3 The
risk is lower for early abortions (0.88 in 1000 at less than 13 weeks of gestation) than for late
abortions (4.0 in 1000 at more than 20 weeks of gestation).
Although systematic review evidence comparing complications of medical and surgical abortion at
different gestations suggested that haemorrhage is more common following medical than surgical
abortions, this did not reach statistical significance.93,122 A Finnish cohort study124 demonstrated rates
of haemorrhage of 2.1% for early surgical abortion compared with 15.6% for early medical
procedures, although this was based on coded diagnosis over the 6 weeks following abortion, did
not distinguish severity and may represent greater help seeking for bleeding problems among this
group. The much smaller proportion of women in this group requiring surgical intervention were
also significantly more likely to have had medical rather than surgical procedures (2.9% compared
with 0.9%). Studies of mid-trimester procedures suggest that severe haemorrhage occurs in up to
0.9% of women undergoing D&E, with 0.2% requiring transfusion.147–151 In an observational study
of mid-trimester medical abortion, 0.7% of women required transfusion; however, a comparative
cohort study of medical and surgical abortions failed to demonstrated a difference in transfusion
rates between the two methods.152
Although the evidence overall may suggest that women are more likely to suffer heavy bleeding
following medical rather than surgical procedures, it is important to note that the risk of severe
haemorrhage across all methods and gestations remains uncommon.
Evidence table 3 summarises rates of uterine perforation during surgical abortion reported in large
case series (more than 4000 women) that were identified during the development of the previous
edition of this guideline. Series for inclusion were selected on the basis of study size (more than
4000 subjects). The more recent Danish cohort study153 (56 117 subjects), published in 2002,
reported a rate of uterine perforation of 2.3 in 1000 surgical abortions.
Evidence table 4 summarises incidences of cervical injury during surgical abortion at up to 12
weeks of gestation reported in large case series identified during development of the earlier edition
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of this guideline. Rates vary considerably, with older studies reporting rates of around 1%154,155 and
more recent studies suggesting the rate is less than 0.2%,151,156–159 which may be more typical of
today’s practice and reflect greater use of cervical preparation. However, some of the variation
reflects the lack of an agreed definition of cervical injury and deficiencies in data collection. No
new studies were identified.
5.2 Failed abortion and continuing pregnancy
RECOMMENDATION 5.7
Women should be informed that surgical and medical methods of abortion carry a small risk
of failure to end the pregnancy (less than 1 in 100), necessitating another procedure.
Evidence supporting recommendation 5.7
The reported rate of failure from a study of 33 090 cases when suction aspiration was performed at
12 weeks of gestation or earlier was 2.3/1000 abortions.160 The risk was greater for multiparous
women, abortions performed at 6 weeks of gestation or earlier, when small cannulae were used,
when the procedure was performed by a less experienced surgeon or if the woman had uterine
abnormalities.
A meta-analysis of the efficacy of medical abortion161 indicated that ‘viable pregnancy’ rates after all
studied regimens increased with length of gestation. A comparative review of medical and surgical
methods for early abortion reported continuing pregnancy rates of 0.9% for
mifepristone/misoprostol abortion and 0.5% for vacuum aspiration,162 while an observational study
of 4132 cases indicated a continuing pregnancy rate of 0.1% at gestations up to 49 days and 0.5%
at gestations of 50–63 days.130
RECOMMENDATION 5.8
Women should be informed that there is a small risk (usually much less than 5%) of the need
for further intervention, such as surgical intervention following medical abortion or re-
evacuation following surgical abortion.
Evidence supporting recommendation 5.8
Rates of surgical evacuation following either medical or surgical abortion vary according to
experience, diagnostic criteria and intervention thresholds, and these will vary between centres.
Local rates of repeat procedures should be quoted wherever possible.
There are few randomised trials of surgical versus medical methods. However, in a partially
randomised study, significantly more women having surgical abortions did not require further
surgical intervention (98% of women undergoing surgical abortions versus 94% of women
undergoing medical abortions),163 with a further study yielding similar results for procedures at
10–13 weeks of gestation (98% versus 95%).131 The Finnish registry-based study of more than
42 000 women undergoing medical and surgical abortions at up to 9 weeks of gestation
demonstrated that 6% of women having medical abortions needed surgical intervention for retained
products of conception compared with fewer than 1% of those having surgical abortions.124 In a
further observational study of 4132 cases of medical abortion at less than 9 weeks of gestation,
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2.3% required surgical evacuation, of which 1.6% were incomplete abortions, 0.35% delayed
miscarriage and 0.3% continuing pregnancy.130
For medical abortion after 13 weeks of gestation, surgical evacuation may be required either at the
time for retained placenta or later for persistent retained products of conception. Quoted rates for
surgical intervention vary widely between studies and across different regimens, from 2.5% in one
study164 up to 53% in a UK multicentre study.165
5.3 Post-abortion infection
RECOMMENDATION 5.9
Women should be informed that infection of varying degrees of severity may occur after
medical or surgical abortion and is usually caused by pre-existing infection. Prophylactic 
antibiotic use and bacterial screening for lower genital tract infection reduces this risk.
Evidence supporting recommendation 5.9
Genital tract infection, including pelvic inflammatory disease, is a recognised complication of
abortion. Post-abortion infection may later result in tubal infertility or ectopic pregnancy as well as
causing morbidity in the immediate post-abortion period. Studies have shown that the presence of
C. trachomatis, Neisseria gonorrhoea166–168 and bacterial vaginosis169,170 in the lower genital tract at
the time of abortion is associated with an increased risk of infection. Incidence rates among the
control groups in trials of prophylactic antibiotics for abortion suggest that infective complications
occur in up to 10% of cases.171–176
In a systematic review of 46 421 women investigating the frequency of infection following medical
abortion at all gestations, the incidence was low at 0.92%.177 This is lower than has been reported
in previous UK studies (2.54%), perhaps owing to variations in both diagnostic criteria and
thresholds for prescribing antibiotics. Eligible studies included both confirmed and presumptive
diagnoses of infection treated with antibiotics. In a registry-based Finnish study of 42 619 women
undergoing both medical and surgical abortion,124 the rate of reported infection in the 6 weeks
following the procedure, based on outpatient and inpatient attendances, was 1.7%, with no
difference seen between medical and surgical procedures. True ascertainment of rates is difficult
owing to variations in diagnostic criteria, antibiotic thresholds and use of follow-up services.
5.4 Breast cancer
RECOMMENDATION 5.10
Women should be informed that induced abortion is not associated with an increase in breast
cancer risk.
Evidence supporting recommendation 5.10
In the past there has been conflicting evidence presented concerning a possible link between
induced abortion and breast cancer,178,179 and in the last edition of this guideline the Group
concluded that there was no evidence that abortion increased the risk of breast cancer. Findings of
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the 2003 report by the American College of Obstetricians and Gynecologists (ACOG),180 which
summarised evidence from the most methodologically robust studies, failed to demonstrate any
associations, concluding that ‘Rigorous recent studies argue against a causal relationship between
induced abortion and a subsequent increase in breast cancer risk’. Since then, there has been a
growing body of evidence lending further support to these findings. Published evidence from a
number of large cohort and case–control studies,181–183 together with the European Prospective Study
on the Investigation into Cancer184 and the Nurses Health Study 2,185 showed no increase in the
relative risk of breast cancer in women undergoing induced abortion regardless of age, number of
abortions or timing of the abortion.
Furthermore, an international collaboration involving over 40 000 women with breast cancer from
53 studies worldwide concluded that women with a history of one or more pregnancies that ended
as an induced abortion were not at an increased risk of breast cancer compared with women with
no such history (relative risk [RR] of breast cancer = 0.93; 95% confidence interval [CI] 0.89–0.96;
P = 0.0002). There was evidence that studies yielded misleading results if women were asked about
their history of induced abortion after they developed breast cancer, possibly because the women
who had developed breast cancer were, on average, more likely than women without breast cancer
to disclose to study investigators that they had a history of previous induced abortions. Continued
claims that induced abortion does cause breast cancer tend to lend undue weight to these studies
rather than the more reliable studies that recorded women’s history of induced abortion before they
developed breast cancer.186
WHO has concluded that induced abortion does not increase breast cancer risk.187 Similarly, in a
recent review of the evidence, ACOG concluded that ‘The relationship between induced abortion
and the subsequent development of breast cancer has been the subject of a substantial amount of
epidemiologic study. Early studies of the relationship between prior induced abortion and breast
cancer risk were methodologically flawed. More rigorous recent studies demonstrate no causal
relationship between induced abortion and a subsequent increase in breast cancer risk.’188
5.5 Future reproductive outcome
RECOMMENDATION 5.11
Women should be informed that there are no proven associations between induced abortion
and subsequent ectopic pregnancy, placenta praevia or infertility.
Evidence supporting recommendation 5.11
No new evidence of a relationship between abortion and subsequent placenta praevia, ectopic
pregnancy, subfertility or miscarriage was identified in the course of updating this guideline and
much of the evidence presented is based on a review article of the long-term health consequences
of abortion published in 2002 by Thorp et al.189
Placenta praevia
Thorp and colleagues reported an association between induced abortion and placenta praevia
across a number of heterogeneous studies of variable quality. Subsequent studies, however, have
reported more reassuring findings. A Danish cohort study based on national registry data linkage
involved 15 727 women whose first pregnancy was terminated and a reference cohort of 46 026
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women.190 No association with placenta praevia was seen. A case–control study from the USA
involved 192 cases of placenta praevia and 622 controls.191 The investigators concluded that risk of
placenta praevia might have increased in a dose–response fashion with sharp curettage abortions,
but that vacuum aspiration did not confer an increased risk.
Ectopic pregnancy
Thorp et al. reviewed seven case–control and two cohort studies relating to abortion and
subsequent ectopic pregnancy.189 Only two of the nine studies reported a positive association; these
were relatively small case–control studies which relied on self-report of previous abortion. Large
studies based on record linkage showed no association.
Subfertility
Published studies strongly suggest that infertility is not a consequence of uncomplicated induced
abortion.192–194 Although women with a previous induced abortion appeared to be at an increased
risk of infertility in countries where abortion is illegal and therefore usually unsafe, this is not the
case in legal settings. There are some discrepancies among studies,195 but none was of sufficient
power to detect a small association. In the review by Thorp et al., three case–control studies and
four cohort studies relating to abortion and infertility were appraised. Two relatively small
case–control studies, both from Greece, showed a positive association of abortion with
subfertility.195,196 Other studies found no association. Thorp et al.189 commented on the
methodological limitations of all studies which date from before 1999. No relevant new studies
were identified during the updated literature search.
Miscarriage
Thorpe et al. reviewed two cohort and three case–control studies examining associations between
induced abortion and miscarriage, and no significant association was identified.189 Moreover, those
that analysed data according to the number of abortions found no dose–response effect. However,
some studies report conflicting findings. A study by Zhou suggests that women who become
pregnant within 3 months of abortion are at increased risk of miscarriage.197 A further cohort study
from Shanghai of nearly 3000 women comparing primigravid women with women undergoing
abortion by vacuum aspiration reported an adjusted odds ratio (OR) of 1.72 for miscarriage (95%
CI 1.09–2.72) between abortion and reference cohorts.198
Preterm birth
RECOMMENDATION 5.12
Women should be informed that induced abortion is associated with a small increase in the
risk of subsequent preterm birth, which increases with the number of abortions. However,
there is insufficient evidence to imply causality.
The Care of Women Requesting Induced Abortion
44
B
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 44
Adverse effects, complications and sequelae of abortion
45
Evidence supporting recommendation 5.12
A systematic review and meta-analysis by Shah et al. in 2009199 reported that a history of abortion
is associated with a small increase in the risk of preterm birth, giving an adjusted odds ratio of 1.27
(95% CI 1.12–1.44) increasing to 1.62 (95% CI 1.27 to 2.07) with more than one abortion. A recent
large Australian population study of 42269 births200 comparing term with preterm deliveries
supports these findings. Among women with no history of miscarriage or induced abortion, 7.1%
had a preterm birth compared with 8.9% of women who had one or more induced abortion (OR
1.25, 95% CI 1.13–1.40). Among women with a history of one or more miscarriages, 8.4% had a
preterm birth, which also represents a borderline increased risk (OR 1.11, 95% CI 1.00–1.23).
However, these findings should be interpreted with caution since few of the reviewed studies
controlled for important confounders associated with preterm birth (such as socioeconomic status),
and the associations have not yet been shown to have a causal relationship.
In addition, the Shah review was confined to surgical methods of abortion. Where medical
(mifepristone and prostaglandin) and surgical methods have been compared, there has been no
significant difference reported in the risk of preterm birth.201–203
Furthermore, evidence increasingly points to an association between miscarriage and preterm birth.
While previous reviews have been conflicting,189,204,205 a recent systematic review206 suggests that the
odds of preterm birth are similarly increased for both miscarriage and induced abortion. It has been
postulated that the increased risk may be related to instrumentation of the cervix and uterus at the
time of surgical evacuation.
Further research is needed to understand this and other risk factors for preterm birth as well as
abortion methods and gestation.
5.6 Psychological sequelae
RECOMMENDATION 5.13
Women with an unintended pregnancy should be informed that the evidence suggests that
they are no more or less likely to suffer adverse psychological sequelae whether they have an
abortion or continue with the pregnancy and have the baby.
RECOMMENDATION 5.14
Women with an unintended pregnancy and a past history of mental health problems should
be advised that they may experience further problems whether they choose to have an
abortion or to continue with the pregnancy.
Evidence supporting recommendation 5.13 and 5.14
For most women the decision to have an abortion is not easy and the experience is stressful and
probably unpleasant. Most women will experience a range of emotions around the time of the
decision and the abortion procedure.133 However, long-term feelings of sadness, guilt and regret
appear to linger in a minority of women.207
The great majority of women who have abortions do not experience adverse psychological
sequelae. Two recent systematic reviews addressed the relationship between unintended pregnancy,
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abortion or childbirth and mental health; both concluded that abortion of an unintended pregnancy
was no more likely to be associated with poor mental health outcomes than if the pregnancy
continued.208,209 The quality of the studies included in the reviews was mostly poor to fair, with large
variation in the study design, measurement methods and outcomes reported: sample sizes were
variable and sometimes small, and there was a lack of adequate control for confounding variables
including pregnancy intention and previous pregnancy history.
A good-quality population-based cohort study, published in 2010, linked information from a
number of Danish registries to explore rates of first-time psychiatric contact (inpatient admission or
outpatient visit) for any type of mental disorder within the 12 months after the abortion or childbirth
compared with the 9-month period preceding the event.210 Data from 84 620 girls and women
having an abortion and 280 930 having a baby between 1995 and 2008 were used. The relative
risk of a psychiatric contact did not differ significantly after abortion compared with before abortion
(P = 0.19) but did increase after childbirth compared with before childbirth (P < 0.001). The authors
concluded that there is no evidence of an increased risk of mental disorders after a first-trimester
induced abortion.
A systematic review on the mental health impact of induced abortion was undertaken in 2010 by
the National Collaborating Centre for Mental Health in the UK.137 This review aimed to build upon
the American Psychological Association and Charles reviews to establish a better understanding of
the complex relationship between abortion and mental health, and included the Danish study
discussed above. The review concluded that whether a woman with an unintended pregnancy opts
for an abortion or continues the pregnancy, the mental health outcomes will be the same. For
women who have a prior history of mental health problems, there is a higher likelihood of mental
health problems following both abortion and birth.
The Care of Women Requesting Induced Abortion
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Chapter 6
Pre-abortion management
RECOMMENDATION 6.1
Prior to referral, pregnancy should be confirmed by history and a reliable urine pregnancy
test.
Evidence supporting recommendation 6.1
Confirmation of pregnancy from a clinical history and with a reliable CE-marked* urinary
pregnancy test before referring a woman to an abortion service will avoid a needless consultation
which wastes time and money for both the woman and the receiving service.
6.1 The abortion decision
RECOMMENDATION 6.2
Healthcare staff caring for women requesting abortion should identify those who require
more support in the decision-making process.
RECOMMENDATION 6.3
Women who are certain of their decision to have an abortion should not be subjected to
compulsory counselling.
Evidence supporting recommendations 6.2 and 6.3
All women attending an abortion service will require a discussion to determine the degree of
certainty of their decision and their understanding of its implications. Clinic staff must be sensitive
to the different stages of decision making that individual women have reached and must be able to
identify those who may require additional support and counselling. These may include young
women, women with mental health problems, women with poor social support and where there is
evidence of coercion. This help should be tailored to age, comprehension and social circumstances.
Not all women requesting an abortion will require intensive counselling.211 In an English study of
231 women presenting for abortion in the early 1980s, 91% of women had an unwanted preg -
nancy, only 6% were unsure of their decision to have an abortion and only 3% had a pregnancy
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which had initially been wanted.212 More recently, a formal measure of intendedness of pregnancy
was used in two studies in Scotland. In the first,213 92% of 316 women and in the second 89.7% of
women requesting an abortion had a clearly unintended pregnancy.214
RECOMMENDATION 6.4
Pathways to additional support, including counselling and social services, should be available.
Evidence supporting recommendation 6.4
While only a small minority of women experience clinically significant psychological sequelae after
abortion (see recommendation 8.9), screening tests to identify women at risk and allow timely
intervention may be useful. In a 2-year follow-up study of 80 Norwegian women, pressure from a
male partner was found to be the strongest predictor of emotional distress 2 years after an abortion,
whereas women who chose abortion because they ‘had enough children’ had slightly better
psychological outcomes than average.215
For the minority of women who require formal, therapeutic counselling, services should have
referral pathways in place with access to trained counsellors with appropriate expertise.
The GDG favours the use of the term ‘support’ rather than ‘counselling’ to describe the routine
responsibilities of an abortion service, but acknowledges that any of three recognised forms of
counselling identified in the Human Fertilisation & Embryology Authority Code of Practice216 may
be required by women considering or undergoing induced abortion:
• Implications counselling: aims to enable the person concerned to understand the implications of
the proposed course of action for themselves and for their family.
• Support counselling: aims to give emotional support at times of particular stress.
• Therapeutic counselling: aims to help people with the consequences of their decision and to
help them resolve problems that may arise as a result.
RECOMMENDATION 6.5
Women should be given information about the different methods of abortion appropriate to 
gestation, the potential adverse effects and complications and their clinical implications.
RECOMMENDATION 6.6
Where possible, women should be given the abortion method of their choice.
Evidence supporting recommendations 6.5 and 6.6
Women will vary in the amount and type of information that they require prior to deciding on their
preferred method of abortion. They should be provided with information that is relevant to their
gestation, in a format that is appropriate for their age and degree of comprehension. The information
should include the characteristics, potential adverse effects and complications (including their long-
term implications) of the different abortion methods.
Several studies have shown that the reasons for women preferring a particular abortion method are
numerous and complex. The most common reason for choosing surgical abortion is to avoid
repeated visits to the abortion facility. Medical abortion is favoured because of fear of surgery and
a perception that it is easier, less painful and maintains privacy.98,217
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Provision before the abortion consultation of written information about choices of abortion method
has been shown to help women make more informed decisions. In an RCT there was no significant
difference in the abortion method chosen by women in Great Britain who were given an
information leaflet compared with those who were not, but the former group were better informed,
found decision making easier and had lower risk-perception scores about both methods and more
positive attitudes about medical abortion than those who did not receive written information.218
A partially randomised study assessed 445 Scottish women’s preferences for, and acceptability of,
medical and surgical abortion at 10–13 weeks of gestation. Despite having a preference for a
particular method, women were content with alternatives; however, women were more likely to
choose the same abortion method again if they had shown a preference for that method prior to
abortion. The authors concluded that the availability of medical abortion is an important option for
many women who wish to avoid surgery or anaesthesia and should be offered routinely in the late
first trimester.219
In a randomised study of 1080 women assessing the predictors of acceptability of medical abortion,
the authors concluded that satisfaction with medical abortion may be limited by differences
between women’s expectations of pain and bleeding and their actual symptoms.220 Information
regarding the severity of symptoms, including risk of failure, should be incorporated into patient
information sources and counselling.
6.2 Initial assessment
Blood tests
RECOMMENDATION 6.7
Pre-abortion assessment should always include:
• determination of rhesus blood status.
Where clinically indicated, pre-abortion assessment should also include:
• determination of blood group with screening for red cell antibodies
• measurement of haemoglobin concentration
• testing for haemoglobinopathies.
Evidence supporting recommendation 6.7
Ascertainment of rhesus status is required in order that anti-D prophylaxis can be instituted as
appropriate.221,222 If clinically indicated by a woman’s history or family history, the ‘group and
screen’ procedure should also include screening for IgG antibodies in case cross-matching and
blood transfusion are required.
A systematic review investigating routine preoperative testing found that haemoglobin was lower
than 10.0–10.5 g/dl in fewer than 5% of patients.221 The National Institute for Health and Clinical
Excellence (NICE) was unable to identify any direct evidence that measuring preoperative
haemoglobin, haematocrit and full blood count in adults improved health outcomes for patients.223
A retrospective American study demonstrated that the prevalence of anaemia (defined as
haemoglobin < 9 g/dl) among 9586 patients scheduled for elective low-risk surgery was 0.8%, and
C
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that those who required transfusion (0.05%) all had clear pretest clinical indictors of potential
anaemia.224 The National Abortion Federation (NAF) Clinical Policy Guidelines recommend
haemoglobin testing before first-trimester medical or surgical abortion in women with a history of
significant anaemia and in all women undergoing second-trimester surgical or medical
abortion.225,226 However, the NAF 2010 Clinical Policy Guidelines make no reference to
haemoglobin testing for either medical or surgical abortion at any gestation.225
The GDG was unable to find any evidence for routine screening for sickle cell trait prior to abortion
or routine gynaecological surgery. However, sickle cell screening should be considered in those
who have not been tested previously and have a family history of sickle cell disease or trait and/or
who belong to one of the following ethnic groups: North African, West African, South/Sub-Saharan
African, Afro-Caribbean.223
RECOMMENDATION 6.8
It is not cost-effective or necessary to routinely cross-match women undergoing induced
abortion.
Evidence supporting recommendation 6.8
The incidence of haemorrhage after surgical abortion (with or without transfusion) ranges from 0.07
to 1.5 in 1000 with vacuum aspiration up to 14 weeks of gestation, increases in the mid-trimester
to 5.6–8.6 in 1000 and has been reported to be as high as 21 in 1000 when D&E is performed with
urea feticide.227 The risk of haemorrhage requiring transfusion after early medical abortion has been
reported as 1.3 in 1000228 and 6 in 1000 in second-trimester medical abortion.152 Given such low
rates of haemorrhage requiring transfusion it is not cost-effective or necessary to routinely cross-
match women undergoing abortion.
VTE risk assessment
RECOMMENDATION 6.9
All women undergoing an abortion should have a VTE risk assessment.
Evidence supporting recommendation 6.9
From June 2010, all providers of NHS acute services, including the independent sector, are required
to report the proportion of admitted adult patients who have been assessed for a risk of VTE using
local admission procedures which use or incorporate the elements of the national VTE risk
assessment tool. Women undergoing surgical abortion and women who are admitted for medical
abortion should have a VTE risk assessment, in line with NICE clinical guideline 92.229
Non-admitted day cases and outpatients are out of the scope of the national policy with respect to
reporting but nevertheless still require assessment of VTE risk.
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6.3 Cervical cytology
RECOMMENDATION 6.10
Women who have not had cervical cytology screening within the recommended interval
should be offered screening within the abortion service, or advised on when and where to 
obtain it.
Evidence supporting recommendation 6.10
A woman’s attendance at an abortion service is an opportunity to review broader aspects of her
reproductive health care. If cervical cytology is due and the woman has missed or defaulted from
a previous appointment, consideration should be given to her having cytology during pregnancy.
The NHS Cancer Screening Programme recommends that unscheduled cervical screening is not
justified in association with pregnancy unless a previous screening test was abnormal, providing the
woman is in the age group to be screened and has undergone screening within the previous 3–5
years.230 Providers need to be aware of the different age for the commencement of cervical cytology
screening in Scotland and Northern Ireland compared with England and Wales.
The GDG is of the view that it is entirely appropriate for abortion services, particularly within the
NHS, to embrace these broader aspects of reproductive health care. However, cervical cytology
screening should not be an essential function of an abortion service. Where abortion services are
provided through agency arrangements with independent providers, services might lack appropriate
mechanisms for ensuring that results of cytology are followed up appropriately. If a cervical
cytology screen is taken within the abortion service, mechanisms are essential to ensure that the
result is communicated to both the woman and, with permission, her GP, acted upon appropriately
and recorded within the local cervical cytology programme. If the woman declines to give
permission for correspondence with her GP, she should be advised to attend her GP or local
contraceptive and sexual health service for a smear 6 weeks after the abortion.
6.4 Ultrasound scanning
RECOMMENDATION 6.11
Use of routine pre-abortion ultrasound scanning is unnecessary.
RECOMMENDATION 6.12
Ultrasound scanning must be available to all services as it may be required as part of the
assessment.
RECOMMENDATION 6.13
Ultrasound scanning should be provided in a setting and manner sensitive to the woman’s
situation.
C
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Evidence supporting recommendations 6.11–6.13
Ultrasound is used commonly to assess pregnancies in women before they undergo abortion to
confirm gestation and identify abnormalities such as ectopic pregnancy or uterine anomalies. This
practice started when medical abortion was introduced with a strict upper limit for eligibility of 9
weeks of gestation, and has now become routine. However, there is no direct evidence that routine
ultrasound improves either the safety or efficacy of abortion procedures and no RCTs have been
undertaken comparing the outcome of abortions with and without routine preprocedure ultrasound.
A number of studies have compared the estimation of gestation as assessed by ultrasound with that
estimated by clinical assessment (pelvic examination and/or the date of the last menstrual
period).231–236 None of the studies was randomised and in all cases the evidence is weak. It is clear,
however, that while there are inevitably discrepancies between clinical estimation of gestation and
ultrasound estimation, the discrepancy is rarely large. In one US study, 87% of physicians correctly
assessed the gestational age of 1016 women presenting for early medical abortion as being less than
63 days and gestation was underestimated in only 1% of cases.233 In a second US study, ultrasound
dating matched clinical dating in 81% of cases.232 A UK study reported discrepancy between
ultrasound estimation and clinical estimation of dates in 30% of cases, but in 50% the discrepancy
underestimated gestation by more than 7 days while in the other 50% gestation was
overestimated.234 Unsurprisingly, a Cochrane review on the use of ultrasound for fetal assessment in
early pregnancy involving 11 studies and 37 505 women concluded that routine ultrasound in early
pregnancy improves gestational dating.236
Since both medical and surgical methods are now considered to be appropriate methods for
inducing abortion at all gestational ages, a small discrepancy in gestational age should not make a
difference to the outcome of the procedure. Medical abortion is provided safely in resource-poor
settings which do not have access to routine ultrasound114 and pre-abortion ultrasound is not routine
before early medical abortion in France. A recent study undertaken in the USA tested the feasibility
and efficacy of foregoing the routine use of ultrasound for the determination of eligibility for
medical abortion. In ten clinics involving 4484 women undergoing medical abortion, reliance on
the date of the last menstrual period together with physical examination resulted in only 63 in 4008
women (1.6%) being accepted for medical abortion outside 63 days of gestation on ultrasound.237
The insistence of the need for routine pre-abortion ultrasound limits the settings in which abortion
can be offered in Great Britain. Where ultrasound is routine, it adds to the costs of the service and,
in some places, limits the number of assessment appointments that can be made available. Many
women are certain of the date of their last menstrual period and some even know the date of
conception.238 Unless women are uncertain of the date of their last menstrual period, there are
clinical reasons to suspect ‘wrong dates’ or the woman is obese or difficult to examine, in the
absence of a uterus that is palpable above the pubic symphysis, ultrasound is arguably not indicated
to confirm the gestation and the absence of access to routine ultrasound should not be used as a
reason to limit options for service delivery. A recent review of provision of medical abortion without
the routine use of ultrasound reached a similar conclusion.239
Inevitably, ultrasonography will identify abnormalities such as ovarian cysts which would be missed
on clinical examination; however, many of these are incidental findings which do not change the
management of the woman. Selective preprocedure ultrasound in the first trimester, only performed
in case of discrepancy between last menstrual period and uterine size, bleeding or symptoms
indicative of ectopic pregnancy, has been reported as being both safe and effective when women
are cared for by experienced clinicians.240
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RECOMMENDATION 6.14
Before ultrasound is undertaken, women should be asked whether they would wish to see the
image or not.
Evidence supporting recommendations 6.14
A systematic review240 considered the acceptability of the woman seeing the ultrasound image pre-
abortion. The majority of women who chose to view the image found it a positive experience
(although some did not). None of the women changed their mind about having the abortion after
seeing the ultrasound image.
6.5 Prevention of infective complications
RECOMMENDATION 6.15
Services should offer antibiotic prophylaxis effective against C. trachomatis and anaerobes for
both surgical abortion (evidence grade: A) and medical abortion (evidence grade: C).
RECOMMENDATION 6.16
The following regimens are suitable for peri-abortion antibiotic prophylaxis:
• azithromycin 1 g orally on the day of abortion plus metronidazole 1 g rectally or 800 mg
orally prior to or at the time of abortion
OR
• doxycycline 100 mg orally twice daily for 7 days starting on the day of abortion, plus
metronidazole 1 g rectally or 800 mg orally prior to or at the time of abortion
OR
• metronidazole 1 g rectally or 800mg orally prior to or at the time of abortion for women
who have tested negative for C. trachomatis infection.
Evidence supporting recommendations 6.15 and 6.16
Genital tract infection, including pelvic inflammatory disease, occurs in up to 10% of women
undergoing induced abortion.171–176 This is particularly relevant in procedures which access the
endometrial cavity through the cervix as some bacterial contamination is inevitable.241 Post-abortion
infection not only causes immediate morbidity but may also lead to tubal subfertility and an
increased risk of ectopic pregnancy.171
Five to ten percent of sexually active women under the age of 24 years in Great Britain are currently
infected with C. trachomatis, the majority of whom are asymptomatic.242 The presence of C.
trachomatis, N. gonorrhoea166–168 or bacterial vaginosis169,170 in the lower genital tract at the time of
abortion is associated with an increased risk of post-abortion infection.
There are three main strategies commonly in use to minimise infective complications following
abortion:
C
C
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• universal prophylaxis
• universal screening and treatment of positive cases (‘screen and treat’)
• universal screening and universal prophylaxis (so-called ‘belt and braces’).
Antibiotic prophylaxis for surgical abortion
A systematic review by Sneiders et al.243 concluded that the use of antibiotics was effective in
preventing pelvic inflammatory disease after first-trimester surgical abortion. Nitromidazoles (e.g.
metronidazole), penicillin and tetracycline were the most effective antibiotic agents studied. Single-
dose pre- or peri-abortion antibiotic administration was as effective as a short course of antibiotics.
The SFP in the USA241 recommends the universal routine use of antibiotic prophylaxis prior to
surgical abortion, preferably with a single dose or short course (3 days) of doxycycline initiated on
the day of the procedure. While the optimal antibiotic and dosing regimens remain unclear, both
tetracyclines (e.g. doxycycline) and nitromidazoles are proven to confer significant and comparable
protection against post-abortion upper genital tract infection.
A wide range of antibiotic regimens for peri-abortion antibiotic prophylaxis are recommended
around the world. All have been shown to be better than placebo244 and practice changes as more
evidence accrues. The above regimen suggested by the GDG is felt to be practical, affordable and
covers both anaerobes (including bacterial vaginosis) and C. trachomatis, whose presence in the
lower genital tract at the time of abortion is associated with an increased risk of subsequent infective
morbidity. Both doxycycline and azithromycin have been shown in vitro to have some activity
against certain strains of N. gonorrhoea.245 The recommended regimen represents an approach
which combines prophylaxis and treatment and maximises efficacy and likely compliance.
Doxycycline, azithromycin and metronidazole rarely cause allergic reactions and are well absorbed
when taken orally. Single-dose regimens should minimise the risk of adverse reactions and
antibiotic resistance. Based upon indirect pharmacokinetics, an 800mg dose of metronidazole (2
tablets of 400mg) would achieve similar serum concentrations to a 1 g rectal dose.246
Given the finding that antibiotic prophylaxis at the time of surgical abortion is also of benefit to
women with negative C. trachomatis testing, the RCOG recommends that metronidazole on its own
would be appropriate for the prophylaxis/treatment of anaerobic organisms in these women.
A large retrospective analysis of the rates of ‘serious’ infection (defined as fever and pelvic pain
treated with intravenous antibiotics, or sepsis, or death caused by infection) among women having
early medical abortion in Planned Parenthood clinics in the USA247 compared rates over a 3-year
period. During this time, routine treatment protocols for early medical abortion varied with respect
to the route of administration of misoprostol, testing for C. trachomatis and the introduction of
prophylactic antibiotic therapy.247 Among the 227 823 women having medical abortion in this study,
92 ‘serious’ infections were reported. The analysis demonstrated a considerable reduction in the
rate of serious infection over time, from 0.25/1000 abortions to 0.06/1000 (76%). The study was
retrospective and observational and not only the administration of antibiotics but also the route of
administration of misoprostol changed during the period of study; however, the sample size was
huge.247
Clostridium sordellii is a Gram-positive anaerobic bacillus that has been reported as a cause of
infection in eight deaths in women undergoing medical abortion in North America (data up to
2010).248 No such deaths have been reported in Europe, where experience with medical abortion is
greater. It has been hypothesised that this may be attributable to differences in modes of
administration of misoprostol in Europe and the USA or greater use of antibiotic prophylaxis in
Europe.247
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Both doxycycline and metronidazole show in vitro efficacy against C. sordelli.249,250 It has been
estimated (based upon the Planned Parenthood study data) that approximately 5000 women would
need to be treated with doxycycline to prevent one case of ‘serious infection’. However, given the
importance of preventing serious infection and the rare fatalities owing to clostridial toxic shock,
antibiotic prophylaxis for women undergoing medical abortion is recommended by the RCOG
using the same suggested regimens as for surgical abortion.
Neither WHO2 nor the SFP241 recommends universal routine antibiotic prophylaxis prior to medical
abortion. However, the NAF guidelines recommend that antibiotics should be given to all women
at the time of surgical abortion and that women undergoing medical abortion should be able to
have antibiotic prophylaxis if they are considered to be ‘high risk’ or upon request.225
In the context of service delivery in Great Britain, the GDG agreed to recommend antibiotic
prophylaxis for all women undergoing abortion regardless of the method.
STI screening
RECOMMENDATION 6.17
All women should be screened for C. trachomatis and undergo a risk assessment for other STIs
(such as HIV, gonorrhoea, syphilis), and be screened for them if appropriate.
RECOMMENDATION 6.18
A system for partner notification and follow-up or referral to a sexual health service should be
in place.
RECOMMENDATION 6.19
Services should make available information about the prevention of STIs and offer condoms
for STI prevention to women undergoing abortion.
Evidence supporting recommendations 6.17–6.19
Ten to thirteen percent of women attending abortion services screen positive for C. trachomatis
infection.251 Routine universal antibiotic prophylaxis without prior screening for STIs misses the
opportunity to identify women with STIs and the opportunity to screen and treat their sexual
partners. Bacteriological screening of the lower genital tract before abortion, with treatment of those
found to be carrying genital tract organisms, is considered by some to be a cheaper and more
appropriate strategy.166,167,170–176,242,243,247,252
Sepsis (particularly associated with group A streptococcal infection) was the leading cause of direct
maternal death in Great Britain in the 2006–2008 triennium, accounting for 29 deaths.253 While
abortion is not specifically mentioned, the report recommends that appropriate antibiotic
prophylaxis is crucial peri-abortion and that women should be given information regarding the
risks, signs and symptoms of genital tract infection.
With regard to treatment regimens, the British Association for Sexual Health and HIV recommends
doxycycline 100mg twice daily for 7 days or azithromycin 1 g orally for the treatment of
uncomplicated C. trachomatis.242 The Scottish Intercollegiate Guidelines Network endorses
azithromycin 1g orally together with follow-up and partner notification of all positive women.254

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Treatment of bacterial vaginosis is recommended by the British Association for Sexual Health and
HIV and involves metronidazole, either 400 mg twice daily for 5–7 days or 2 g as a single dose.255
Abortion services protocols should include policies on offering HIV tests in line with the UK
national guidelines for HIV testing,256 and should take into account the local prevalence of HIV and
resource constraints. Similar criteria should apply to testing for gonorrhoea. In areas where more
than 2 in 1000 people in the general population have diagnosed HIV, the guidelines recommend
that an HIV test is considered for everyone at GP registration and hospital admission.256 In areas of
low HIV prevalence, testing should be offered to all women requesting abortion who come from a
country of high HIV prevalence; who report sexual contact abroad or in the UK with someone from
a country of high HIV prevalence; who have symptoms that may indicate HIV; who are diagnosed
with an STI; or whose partner is known to be HIV positive.257 Where abortion services choose to
offer HIV testing, local protocols must ensure that verbal consent is obtained.256
It may be appropriate to offer immunisation to women at high risk of hepatitis B, regardless of the
results of pre-abortion testing. High-risk groups include intravenous drug users and commercial sex
workers. However, hepatitis B immunisation should not be an essential function of an abortion
service. Where abortion services are provided through agency arrangements with independent
providers, services might lack appropriate mechanisms for ensuring that the immunisation regime
is completed once the woman returns home. If hepatitis B immunisation is initiated within the
abortion service, mechanisms are essential to ensure that this is communicated to both the woman
and, with permission, her GP, and acted upon appropriately. When managing such women,
abortion service staff should seek guidance from their local virology department regarding the need
for immunisation and the appropriate vaccine course.
There should be a clear pathway for referring women who test positive for HIV or other complex
STIs into a specialist genitourinary medicine service.
6.6 Contraception
RECOMMENDATION 6.20
All appropriate methods of contraception should be discussed with women at the initial 
assessment and a plan agreed for contraception after the abortion.
Evidence to support recommendation 6.20
The evidence regarding the value of discussing contraceptive options before the abortion is
conflicting.
A randomised trial of 420 Icelandic women comparing pre-abortion contraceptive counselling with
post-abortion counselling demonstrated no significant effect on contraceptive use 4–6 months after
the abortion (86% and 85%, respectively).258 By contrast, a retrospective case note review of 272
US women undergoing abortion found an increase in the number attending for follow-up and a
decrease in the number of women without a contraceptive plan among those counselled about
contraception before the abortion.259
In the absence of good evidence, the GDG agreed that advising women about contraception at
every opportunity during the abortion process seems sensible.
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6.7 Feticide
RECOMMENDATION 6.21
Feticide should be performed before medical abortion after 21 weeks and 6 days of gestation
to ensure that there is no risk of a live birth.
Evidence supporting recommendation 6.21
Inducing fetal death before medical abortion may have beneficial emotional, ethical and legal
consequences.260 The RCOG guidance on termination of pregnancy for fetal abnormality (published
in 2010) clearly explains the legal situation around late-stage abortions (see Chapter 2).7 Where a
decision to abort a pregnancy after 21 weeks and 6 days is taken, feticide should be routinely
offered. In abortions where the fetal abnormality is not compatible with life, abortion without
feticide may be preferred. However, in cases where the fetal abnormality is not lethal or the
abortion is not for fetal abnormality and is being undertaken after 21 weeks and 6 days of gestation,
failure to perform feticide could result in a live birth and survival, which contradicts the intention
of the abortion.261 Regarding fetal pain and awareness, the RCOG has published guidance and
concluded that ‘In reviewing the neuroanatomical and physiological evidence in the fetus, it was
apparent that connections from the periphery to the cortex are not intact before 24 weeks of
gestation and, as most neuroscientists believe that the cortex is necessary for pain perception, it can
be concluded that the fetus cannot experience pain in any sense prior to this gestation.’262
Very few abortions on grounds C or D are undertaken at late gestations. Only 9% of abortions occur
after 13 weeks and only 1.5% occur after 20 weeks of gestation.3 In Great Britain, those few are, for
the most part, undertaken within the specialist independent sector. When the method of abortion
chosen by a specialist practitioner is surgical (D&E), the nature of the procedure ensures that there
is no risk of a live birth, although in one study 91% of women indicated a preference that the fetus
was dead.263 When medical abortion is chosen, special steps are required to ensure that the fetus is
dead at the time of abortion. The RCOG recommends feticide for abortions over 21 weeks and 6
days of gestation, except in the case of lethal fetal abnormality, and that feticide should always be
performed by an appropriately trained practitioner (under consultant supervision) using aseptic
conditions and with continuous ultrasound.7
The RCOG recommends intracardiac potassium chloride (KCl) 2–3 ml strong (15%) injection into
a cardiac ventricle. A repeat injection may be required if asystole has not occurred after 30–60
seconds. Asystole should be observed for at least 2 minutes and fetal demise should be confirmed
by ultrasound scan after 30–60 minutes.7
Fetal demise may also be induced by intra-amniotic or intrathoracic injection of digoxin (up to 1
mg) and by umbilical venous or intracardiac injection of 1% lidocaine (up to 30 ml); however,
neither procedure consistently induces fetal demise.7
A dose of digoxin 1 mg given either intra-amniotically or intrafetally will cause fetal death in 87%
of cases; the latter method is much more rapid.264 A dose of digoxin 1.5 mg given intra-amniotically
caused death within 20 hours (in most cases there was still fetal cardiac activity at 4 hours).265 In a
large retrospective review, Molaei et al. (2008) concluded that the overall failure rate with digoxin
was 7%, although there were no failures with an intrafetal dose of 1mg.266 Importantly, in this
review there were no adverse effects at any of the doses used.
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Intracardiac injection of either KCl or intrathoracic injection of digoxin requires considerably more
skill than intra-amniotic injection of digoxin. While the latter may be slightly less effective in
inducing fetal demise, its use may be an option for services that lack personnel with sufficient skill
in administering intracardiac injections.
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Chapter 7
Abortion procedures
Abortion on grounds relating to the physical or mental health of the woman or of any existing
children can be performed within the law at gestations up to 24 weeks.16 At all gestations up to this
limit, abortion can be performed using either surgical or medical methods; however, different
abortion techniques are appropriate at different gestations. Figure 7.1 summarises those methods
considered by the GDG to be appropriate for use in abortion services in Great Britain for women
presenting in different gestation bands. As this guideline focuses on abortion for maternal health
reasons, methods for abortion beyond 24 weeks of gestation are not discussed. General
recommendations about abortion procedures are discussed in Chapter 4, while recommendations
in this chapter relate to specific techniques.
Since many of the recommendations refer to abortions at different gestations, the GDG has
produced Table 7.1 reminding readers of the duration of pregnancy in days for each week of
gestation as determined from the first day of the last menstrual period.
Table 7.1 Clarifying gestation
7.1 Surgical methods of abortion
Vacuum aspiration
RECOMMENDATION 7.1
Vacuum aspiration is an appropriate method of surgical abortion at gestations up to 14 weeks.
Completed 0 1 2 3 4 5 6 7 8 9 10 11 12
weeks
Days 0–6 7–13 14–20 21–27 28–34 35–41 42–48 49–55 56–62 63–69 70–76 77–83 84–90
Completed 13 14 15 16 17 18 19 20 21 22 23 24
weeks
Days 91–97 98–104 105– 112– 119– 126– 133– 140– 147– 154– 161– 168–
111 118 125 132 139 146 153 160 167 174
B
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RECOMMENDATION 7.2
Either electric or manual vacuum aspiration may be used as both are effective and acceptable
to women and clinicians.
Evidence supporting recommendations 7.1 and 7.2
It is accepted practice in Great Britain, and a recommendation in the WHO abortion guidance,2 that
vacuum aspiration is preferable to sharp curettage for surgical abortion. An updated Cochrane
review,267 which included only two trials (dating from the 1970s), identified few statistically
significant differences between methods, but vacuum aspiration was associated with shorter
operating times than sharp curettage. Comparative trials of evacuation methods for miscarriage
management also found that vacuum aspiration takes less time to perform, as well as being
associated with significantly less blood loss and pain than sharp curettage.268
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4 5 6 7 8 9 10

11 12 13 14 15 16 17 18 19 20 21 22 23 24
 
Early vacuum
aspiration to strict
protocola
(< 49 days)
 
Electric or manual 
vacuum aspirationb  
Vacuum
aspiration (large-
bore cannula)c
Dilatation and evacuation 
(13+0 to 24+0 weeks)d 
Mifepristone and one 
dose of misoprostol 
(≤ 63 days)e
Mifepristone and multiple doses of misoprostol 
(64 days to 24+0 weeks)f
a. Surgical abortion by means of vacuum aspiration at gestations below 7 weeks. To increase confidence
that the gestation sac has been removed, protocols should include safeguards such as examination of the
aspirate for the presence of the gestational sac and follow-up serum human chorionic gonadotrophin
estimation if needed.
b. Surgical abortion using electric or manual vacuum aspiration. The uterus is emptied using a suction
cannula. Sharp curettage is not recommended.
c. Surgical abortion using vacuum aspiration which may require large-bore suction cannula and tubing.
d. Surgical abortion using a combination of vacuum aspiration and specialised forceps.
e. Medical abortion using a single oral dose of the antiprogesterone mifepristone, followed by a single dose
of a prostaglandin analogue.
f. Medical abortion using a single oral dose of the antiprogesterone mifepristone, followed by multiple
doses of a prostaglandin analogue.
Figure 7.1 Summary of abortion methods appropriate for use in abortion services in Great Britain by gestational age in
weeks
A
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Manual vacuum aspiration (MVA) is a uterine evacuation technique employing a hand-held syringe.
Local anaesthesia and analgesia are commonly used for pain management during the procedure;
however, it can also be performed under general anaesthetic or conscious sedation. In comparative
trials with electric vacuum aspiration, there were no differences in complications, duration of
procedure or women’s preferences.267 Clinicians did report more frequent difficulty when
performing the abortion by MVA at gestations greater than 9 weeks. Thus, either an electric or
manual device may be used for vacuum aspiration procedures; however, clinicians must be aware
of their skill level when using MVA at gestations higher than 9 weeks.
One randomised trial found no statistically significant differences in cervical injury, febrile
morbidity, blood transfusion, antibiotic use or incomplete evacuations with flexible compared with
rigid vacuum cannulae.267 A small randomised trial has investigated the usefulness of a specially
lubricated cannula for early surgical abortion.269 Results were inconclusive and no recommendation
can be made.
RECOMMENDATION 7.3
Vacuum aspiration under 7 weeks of gestation should be performed with appropriate safe -
guards to ensure complete abortion, including inspection of aspirated tissue.
Evidence supporting recommendation 7.3
A prospective cohort study of abortion procedures performed in the 1970s found that electric
vacuum aspiration (EVA) performed at 6 weeks of gestation or less had a higher failure rate than
when performed at 7–12 weeks of gestation.160 This finding led to the recommendation that surgical
abortion should be avoided at very early gestations. However, in a series of 2399 surgical abortions
undertaken to a rigorous protocol – which included pre-abortion urinary pregnancy testing and
ultrasound assessment, MVA, inspection of aspirated products and follow-up by serum human
chorionic gonadotrophin (hCG) estimation in those women in whom no gestation sac was verified
in the aspirate – the failed abortion rate at 6 weeks or less was only 0.13% or lower.270
A subsequent study using a rigorous similar protocol reported on the outcome of 1132 procedures
performed at three clinics.271 The treatment algorithm differed in that surgeons could use either
electric or manual vacuum evacuation. The failed abortion rate was 1.5% for the total study
population and 2.3% among the 750 women successfully followed up at 2 weeks. EVA was used
in 40% of cases and, although not statistically significantly different, procedures performed by MVA
were associated with the lowest continuing pregnancy rate (1.1%). Nevertheless, this is higher than
the rate reported by Creinin and Edwards270 and also higher than the rate of 0.1% among women at
less than 49 days of gestation reported by Ashok et al. in a UK series of early medical abortions.130
The GDG was unable to identify any RCTs comparing such protocols with mifepristone and
misoprostol for early medical abortion. A number of randomised trials have compared
prostaglandin-analogue-only regimens or mifepristone with other prostaglandin analogues and
vacuum aspiration.93,272–277 The results of these studies did not strongly favour either method as
continuing pregnancy was rarely, if ever, reported.
In view of these findings, the GDG recognises that very early surgical abortion is an option, but
advises that the procedure should be undertaken using a rigorous protocol and appropriate
safeguards. Women should be advised of the potential need for further evaluation with serum blood
testing and additional follow-up visits if there is suspicion of a failed procedure.
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RECOMMENDATION 7.4
Vacuum aspiration may be performed from 14 to 16 weeks of gestation; large-bore cannulae
and suction tubing may be required to complete the procedure without the use of forceps to
remove larger fetal parts.
Evidence supporting recommendation 7.4
Vacuum aspiration can be performed from 14 to 16 weeks of gestation using large-bore cannulae
(15.9 mm in diameter) and suction tubing.278 Cannulae greater than 12 mm in diameter may not be
readily available in Great Britain, in which case intrauterine manipulation with forceps may be
necessary to remove larger fetal parts. The method of choice at gestations above 13 weeks therefore
varies according to resources and the skills and experience of local clinicians.
A cohort study from Oxford has shown that morbidity after first-trimester abortion is directly related
to gestation and inversely related to the seniority of the surgeon.279 This finding suggests that
abortion procedures, particularly those at 12 weeks and above, should not be delegated to junior
team members without appropriate supervision.
RECOMMENDATION 7.5
During vacuum aspiration, the uterus should be emptied using the suction cannula and blunt
forceps (if required) only. The procedure should not be routinely completed by sharp
curettage.
RECOMMENDATION 7.6
Access to ultrasound during vacuum aspiration is recommended but not routinely required
for uncomplicated procedures.
Evidence supporting recommendations 7.5 and 7.6
Clinicians differ in the techniques they use to ensure that the uterus has been completely emptied.
The GDG believes there is no need to undertake routine sharp curettage at the end of a vacuum
aspiration. The ‘gritty’ sensation resulting from the completely emptied uterus clamping down
around the suction cannula provides sufficient reassurance. A report of a comparative trial also
highlighted the risks of sharp curettage, including Asherman’s syndrome, and suggested routine
intraoperative ultrasound as a means of obviating the need for sharp curettage.280
GDG members report that ultrasound is commonly used to assess the uterus during and after
vacuum aspiration to confirm a complete abortion, particularly where closed suction systems are
used or when the procedure is challenging. No trials were identified that specifically evaluated the
use of ultrasound to assess the uterus during and after vacuum aspiration to confirm a complete
abortion.
Two trials were identified which evaluated the impact of ultrasound at the time of vacuum
aspiration on intra- and postoperative complications. In each study, routine sharp curettage was also
performed. In the first trial, continuous abdominal ultrasound did not significantly affect the
incidence of immediate complications. The use of ultrasound was associated with a significant
reduction in the rate of evacuation for retained products of conception (0% versus 4.7%) and
infection (1.9% versus 7.5%); however, the complication rate in the control group was higher than
The Care of Women Requesting Induced Abortion
62

A
C
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 62
Abortion procedures
63
published in other studies.281 Other outcomes such as blood loss, procedure time, days of analgesia
use, postoperative bleeding and convalescence were also lower in the intervention group. In the
other trial, a single transvaginal ultrasound examination was performed at the completion of the
evacuation and a repeat aspiration performed in most cases if the endometrial thickness was ≥ 8
mm.282 Retained products of conception were later diagnosed significantly less frequently in the
intervention groups; however, these results should be interpreted with caution. Other studies have
shown that the uterine cavity has a variable appearance following successful evacuation283,284 and
that endometrial thickness is not a useful predictor of the need for subsequent uterine evacuation
for retained products of conception.285
Therefore, while access to ultrasound may prove useful in some cases, routine use is not a
requirement for the safe performance of vacuum aspiration procedures.
Dilatation and evacuation (D&E)
RECOMMENDATION 7.7
Surgical abortion by D&E, preceded by cervical preparation, is appropriate for pregnancies
above 14 weeks of gestation.
RECOMMENDATION 7.8
Continuous ultrasound guidance during D&E is recommended to reduce the risk of surgical
complications.
Evidence supporting recommendations 7.7 and 7.8
D&E is a safe and effective method of surgical abortion following specialised training.122,286 A
retrospective cohort study of 297 women compared the complication rates of D&E with
misoprostol-only regimens of medical abortion.287 Overall, women who underwent medical
abortion were significantly more likely to have a complication than women who underwent D&E
(29% versus 4%). Women who underwent medical abortion with misoprostol were less likely to
have complications than women treated with other regimens, but still had more complications than
those having D&E (22% versus 4%). The most common complication of medical abortion was
retained products of conception requiring surgical evacuation but, even when these cases were
excluded, women who underwent medical abortion still had more complications, including one
case of uterine rupture. A recent study from the USA involved a retrospective case note review of
242 women between 14 and 24 weeks gestation undergoing either D&E or medical abortion
following either unintended pregnancy (121 women) or fetal demise (121 women). The primary aim
of the study was to compare induced abortion and the treatment of fetal demise, but there were no
statistically significant differences in morbidity between the two conditions. Medical abortion
(induction of labour) was associated with higher rates of morbidity compared with D&E for both
groups of women. However, treatment with intravenous antibiotics for ‘presumed infection’
accounted for all the excess morbidity in women undergoing medical abortion and the authors
suggested that shivering and pyrexia commonly associated with prostaglandin induction of labour
had been mistakenly attributed to infection.288
The use of real-time ultrasound scanning during D&E can reduce the perforation rate. In a study
comparing 353 elective abortions (at 16 and 24 weeks of gestation) performed without ultrasound
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with 457 abortions in which ultrasound was routinely employed,289 the rate of uterine perforation
was 0.2% in the scanned group compared with 1.4% in the control group.
Historically, it has been considered that D&E is a risk factor for subsequent adverse pregnancy
outcomes, including cervical weakness, pregnancy loss and preterm birth. A retrospective case
series included 600 women who underwent mid-trimester D&E between 1996 and 2000.290
Interpretation of the findings is difficult, as no reference cohort of women who had not undergone
D&E was described. Nevertheless, rates of adverse pregnancy outcomes appeared similar to those
of unselected populations. The authors concluded that ‘second-trimester D&E is not a risk factor for
mid-trimester pregnancy loss or spontaneous preterm birth’.
D&E is the most common method used at gestations above 14 weeks in non-NHS abortion services
in England. Few surgeons in the NHS perform D&E. D&E can be undertaken safely by providers
who have been trained in the technique and have the necessary instruments and a caseload
sufficient to maintain their skills. For those lacking the necessary expertise and caseload, medical
abortion using mifepristone and a prostaglandin analogue is appropriate.
Cervical preparation for surgical abortion
RECOMMENDATION 7.9
Cervical preparation should be considered in all cases.
RECOMMENDATION 7.10
The following regimens are recommended for cervical preparation up to 14 weeks of
gestation:
• misoprostol 400 micrograms administered vaginally 3 hours prior to surgery or sublin -
gually 2–3 hours prior to surgery.
RECOMMENDATION 7.11
Vaginal misoprostol can be administered either by the woman herself or by a clinician.
RECOMMENDATION 7.12
After 14 weeks of gestation, osmotic dilators provide superior dilatation to medical methods;
however, misoprostol is an acceptable alternative up to 18 weeks of gestation.
Evidence supporting recommendations 7.9–7.12
Routine cervical preparation before surgical abortion may be beneficial in all cases, but is
particularly beneficial where risk factors for cervical injury or uterine perforation exist, such as
adolescents aged ≤ 17 years, advanced gestational age (particularly among multiparae), cervical
anomalies or previous surgery, or when a less experienced surgeon is operating.121,155 The existing
evidence is insufficient to determine at what gestational age cervical priming should be routine. The
risk of complications tends to increase after 9 weeks of gestation and even more in the 12th and
13th weeks of gestation. The current WHO recommendation is that cervical preparation may be
considered at any gestational age, but is recommended at 12–14 weeks of gestation.2
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Methods of cervical ripening include pharmacological agents and osmotic dilators. All methods are
generally safe, although their efficacy and adverse effects vary.291 No published study has investi -
gated whether pharmacological methods of cervical priming reduce uncommon complications
such as uterine perforation and cervical laceration. However, medical methods do decrease the
duration of the abortion procedure. This may be particularly important with increasing gestational
age when mechanical dilation takes longer and becomes more difficult. The adverse effects that
women experience with cervical ripening, such as pain, need to be balanced against the reduction
in the time taken to complete the procedure. Mifepristone 200 mg, osmotic dilators and misoprostol
400 micrograms administered either vaginally or sublingually are all effective for cervical
preparation.291 Nitric oxide donors are not recommended as they are ineffective.292
Gemeprost 1 mg vaginally 3 hours prior to surgery or mifepristone 200 mg orally 36–48 hours prior
to surgery are both effective and are licensed preparatory regimens. Although misoprostol is not
licensed for cervical preparation, it is recommended by the GDG based on its overall profile of
effectiveness, adverse effects, cost and ease of use. Women may be reassured that these regimens
are evidence based, safe and widely used.
Misoprostol by the vaginal route is associated with the fewest gastrointestinal adverse effects and 3
hours is the optimal duration of use. Efficacy is not compromised if women self-administer the
vaginal tablets; women find self-administration acceptable.109,293,294 Sublingual administration for 2–3
hours is superior to vaginal administration but is associated with more gastrointestinal adverse
effects.
Administration of cervical priming agents can be associated with painful cramps, bleeding and
unexpected expulsions. Therefore, extending the duration of use beyond those recommended
should be avoided.291
Cervical dilation for D&E must be sufficient to allow passage of operative instruments and fetal parts
without causing injury to the cervical canal.295 Few RCTs exist from which to determine the optimal
regimen for cervical preparation before D&E, particularly beyond 20 weeks.296 Buccal misoprostol
in doses ranging from 400 to 800 micrograms appears to achieve adequate cervical preparation up
to 18 weeks of gestation.149,150,297 Repeated doses are sometimes necessary and additional manual
dilatation is frequently required.
Overnight placement of osmotic dilators results in greater cervical dilation and easier subsequent
manual dilatation than prostaglandin analogues administered on the day of surgery.298,299 The
addition of misoprostol shortly before D&E did not significantly improve initial cervical dilation in
women at 13–21 weeks of gestation.300 A recent systematic review concluded that osmotic dilators
were superior to prostaglandins with respect to cervical dilation throughout the second trimester
and with respect to procedure time within the early second trimester.301
The only study which examines mifepristone for cervical preparation prior to D&E302 compared a
combination regimen with misoprostol alone. Greater initial cervical dilation was achieved with the
addition of mifepristone; however, several women in this group aborted spontaneously before
surgery.
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Prophylactic uterotonics
RECOMMENDATION 7.13
Use of medications containing oxytocin or ergometrine are not recommended for prophylaxis
to prevent excessive bleeding at the time of vacuum aspiration.
Cohort studies from the 1970s suggested that blood loss with vacuum aspiration increases with
gestational age and could be reduced with the administration of uterotonics such as oxytocin and
ergometrine.303,304 Routine or prophylactic use of uterotonics subsequently became commonplace.
Four RCTs have since been published assessing the effect of routine administration of oxytocin on
blood loss during first-trimester vacuum aspiration under general anaesthetic (see evidence table
6).305–308 Two trials also included an arm to test the utility of ergometrine. All of the studies were small
and therefore underpowered to determine the utility of uterotonics in reducing rare complications
such as haemorrhage. One study in 64 women undergoing vacuum aspiration at 9 weeks of
gestation or greater demonstrated a median blood loss in those receiving oxytocin of 17.6 ml (range
6.1–72.7ml) compared with 24.5 ml (range 6.7–94.3 ml) in the placebo group.306 Although this was
statistically significant (P = 0.02), the reduction in blood loss was of a magnitude unlikely to be of
clinical relevance. None of the remaining studies showed any statistical difference in blood loss
with uterotonics compared with placebo or no treatment. Women who received ergometrine were
more likely to experience postoperative vomiting.308
Based on these randomised trials, there appears to be no benefit to the routine or prophylactic use
of uterotonic medications at the time of vacuum aspiration. However, the use of oxytocin is likely
to be effective at inducing uterine contraction sufficient to reduce blood loss in the event of heavy
bleeding.
Regimens intended to reduce blood loss associated with paracervical block have been tested. One
clinical trial in which women undergoing abortion by D&E were randomised to one of four
paracervical block regimens containing 0.5% bupivacaine alone or in combination with dilute
adrenaline (epinephrine) and/or 0.2 mg methylergonovine* failed to demonstrate any significant
differences in blood loss between groups.309 In a double-blind, randomised, placebo-controlled
trial,310 women undergoing D&E were randomised to a paracervical block containing 4 units of
vasopressin in 20 ml 1% mepivacaine or a block containing only 20ml mepivacaine. No
differences were seen in women undergoing D&E at ≤ 14 weeks of gestation, but statistically
significant reductions in blood loss were seen with the addition of vasopressin in women at later
gestations, with a difference in blood loss of 81 ml at 15–16 weeks (P > 0.001), 147ml at 17–18
weeks (P < 0.001) and 221 ml at ≥ 19 weeks (P < 0.01). There were also fewer women with blood
loss ≥ 500 ml in the vasopressin group (1.7% versus 8.4%; P = 0.004). One subsequent small trial
of 33 women found no differences in uterine artery blood flow in women undergoing D&E with a
mean gestational age of 16.8 weeks (SD 1.7) who were randomly assigned to paracervical injection
of saline (10ml) with or without the addition of 4 units of vasopressin.311 There were also no
differences in blood loss, but the study was underpowered to assess this outcome. Vasopressin is
not used for vasoconstriction in the UK.
The Care of Women Requesting Induced Abortion
66
A
* ergot alkaloid, marketed in the USA
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 66
Abortion procedures
67
Pain relief for surgical abortion
Anaesthesia
RECOMMENDATION 7.14
Services should be able to provide surgical abortions without resort to general anaesthesia.
Evidence supporting recommendation 7.14
In the 1970s, the relative safety of surgical abortion performed with either local or general
anaesthesia had not been clearly established. A number of observational and partially randomised
studies comparing the two techniques demonstrated the benefits of local anaesthesia on a variety
of outcomes (evidence table 7). A more recent study from India suggested that women see
advantages in local anaesthesia and some are willing to accept additional short-term pain in
exchange for these advantages.312
Local anaesthesia may be preferable to service providers because it can be administered outside a
theatre setting and with fewer personnel, making it less costly. For women, its use removes the need
to fast in preparation for the procedure, has quicker recovery and avoids the drowsiness and other
after effects of the sedating medication given with general anaesthesia or conscious sedation.
Women and clinicians in Great Britain are relatively unfamiliar with abortion under local
anaesthesia, although its use is increasing. The GDG feels strongly that services should make the
option of abortion under local anaesthesia available, starting with low-gestation procedures and
advancing in gestational age as experience increases.
A paracervical block is the usual local anaesthesia for first-trimester surgical abortion, although data
on its effectiveness are heterogeneous and limited.313–316 The technique is not standardised, but some
variations do show a small reduction in pain compared with others. The pain of cervical dilation is
reduced with deep injection of the paracervical block,317,318 with waiting 3 minutes between
injection and dilation319 and with adding a 4% intrauterine lidocaine infusion.320 Deep injections
and intrauterine infusions also decreased pain with aspiration, while premedication with ibuprofen
or naproxen improved intra- and postoperative pain.321,322
An alternative to an injected local anaesthetic is the application of a topical anaesthetic jelly to the
cervical canal.332
RECOMMENDATION 7.15
If conscious sedation is used during surgical abortion, it should be undertaken only by trained
practitioners and in line with DH guidance.
Evidence supporting recommendation 7.15
Conscious sedation is used in place of general anaesthesia by some abortion providers. Regimens
typically include an intravenous opioid (such as fentanyl) plus an intravenous sedative (such as
midazolam or propofol).
In a Cochrane review of pain control for first-trimester surgical abortion,323 three studies
investigating conscious sedation were discussed. The authors concluded that the addition of
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conscious intravenous sedation using diazepam and fentanyl to paracervical block decreased
procedural pain.
Two UK reports set out the requirements for services choosing to offer conscious sedation.324,325
Analgesia
RECOMMENDATION 7.16
Women should routinely be offered pain relief (for example, NSAIDs) during surgical abortion.
Evidence supporting recommendation 7.16
In routine clinical practice, analgesia is offered to women following surgical abortion and both
during and after medical abortion. One randomised trial evaluated the use of an NSAID, diclofenac,
at the time of cervical priming with oral misoprostol prior to suction termination under sedation
with sublingual lorazepam,326 but reported no differences in pain control with aspiration or
postoperatively, or with acceptability of pain control. However, this study provided reassurance that
treatment with an NSAID did not reduce the efficacy of misoprostol cervical priming.
There is little research evidence to guide the choice of analgesic regimens.
RECOMMENDATION 7.17
Prophylactic paracetamol (oral or rectal) is ineffective in reducing pain after surgical abortion
and is not recommended.
Evidence supporting recommendation 7.17
Four randomised trials have assessed the utility of prophylactic oral or rectal paracetamol on pain
after surgical abortion.327–330 None demonstrated a benefit of paracetamol over placebo. A Cochrane
review on pain control in first-trimester surgical abortion also concluded that there was no benefit
to premedication with paracetamol or a compound containing paracetamol with codeine.313 This
review found the most consistent reduction in pain postoperatively occurred in women who had
received an opioid (particularly fentanyl) together with propofol and some benefit to premedication
with intramuscular ketorolac or diclofenac or oral lornoxicam.
7.2 Medical methods of abortion
RECOMMENDATION 7.18
Medical abortion regimens using 200 mg oral mifepristone and misoprostol are effective and
appropriate at any gestation.
Evidence supporting recommendation 7.18
Evidence from a randomised trial (Level Ib evidence) indicates that a dose of 200 mg has similar
efficacy compared with 400mg or 600mg.331 This study used the prostaglandin analogue
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gemeprost, but Level III evidence from large case series using 400 micrograms of oral misoprostol
following either 200mg or 600mg of mifepristone confirmed that there was no difference in
efficacy between the two doses of mifepristone.332
An early WHO multicentre trial included women at gestations up to 56 days.331 WHO has since
conducted a similar trial involving 896 women at gestations of 57–63 days comparing 200 mg and
600 mg of mifepristone in combination with gemeprost 1 mg vaginally.333 Again, both regimens had
similar efficacy.
Some studies have investigated whether the dose of mifepristone could be lowered further. One
multicentre trial (1224 women at gestations of less than 57 days) investigated the impact of reducing
the dose of mifepristone to 50 mg; however, this dose was associated with a 1.6-fold higher failure
rate than the 200 mg dose.334
A more recent study aimed to determine whether 100 mg and 200 mg mifepristone followed by
800micro grams of vaginal misoprostol taken 24 or 48 hours later were equivalent in efficacy.335
Equivalence was demonstrated between both the doses of mifepristone and the two intervals for
administration of misoprostol. This suggests that a dose of 100 mg mifepristone may be adequate.
However, verification from studies in other centres is required before this dose is adopted in routine
practice.
The GDG evaluated systematic reviews of the studies that resulted in the combined mifepristone
and prostaglandin analogue regimens in current use for early medical abortion. Single-agent
regimens have been found to have unacceptable failure rates. In a randomised, double-blind,
placebo-controlled trial comparing a regimen of mifepristone and misoprostol with misoprostol
alone up to 56 days of gestation, complete abortion rates were 96% and 88%, respectively (P <
0.05).336 A Cochrane review examined 39 trials of early medical abortion including combined and
prostaglandin analogue only regimens.337 All but one of the five trials reported higher effectiveness
with the combined regimen.
Single-agent regimens are not considered to have a role in abortion practice in Great Britain, where
mifepristone is readily available, and are not considered further in this guideline.
In a multicentre randomised trial comparing a combination of methotrexate and misoprostol with
mifepristone and misoprostol, abortions with mifepristone were completed faster than those with
methotrexate but the overall success rate, adverse effects and complications were similar.338
Although methotrexate may have a place in countries where mifepristone is unavailable, it is not
considered further in this guideline.
Historically, the conventional prostaglandin E1 analogue used for abortion procedures was
gemeprost. A 1mg vaginal pessary costs approximately £43 and is highly temperature sensitive. A
series of studies reviewed by the GDG demonstrated that the alternative E1 analogue, misoprostol,
which costs less than £1 per dose, is as if not more effective for early medical abortion, cervical
priming and medical abortion from 13 to 24 weeks of gestation.339–345 In addition, a single-centre
study suggested that women felt more pain with gemeprost.346
The GDG therefore recommends the use of misoprostol.
The following are licensed uses for mifepristone with a prostaglandin analogue for abortion care in
Great Britain:347
• Medical abortion up to 49 days of amenorrhoea:
• 600 mg oral mifepristone followed 36–48 hours later by misoprostol 400 micrograms orally
• 600 mg or 200 mg oral mifepristone followed 36–48 hours later by 1 mg gemeprost vaginally.
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• Medical abortion between 50 and 63 days of amenorrhoea:
• 600 mg or 200 mg oral mifepristone followed 36–48 hours later by 1mg gemeprost vaginally.
• Preparation for the action of prostaglandin analogues in the termination of pregnancy for
medical reasons beyond the first trimester:
• 600 mg oral mifepristone taken 36–48 hours prior to scheduled prostaglandin administration
which will be repeated as often as indicated.
• Softening and dilating of the cervix prior to surgical termination during the first trimester:
• 200 mg oral mifepristone followed 36–48 hours later, but not beyond, by surgical termination
of pregnancy.
Several of the regimens and routes of administration of mifepristone and misoprostol recommended
in this guideline are outside of the medications’ licenses. However, the European Economic
Community Council Directive 65/65/EEC specifically permits doctors to use ‘licensed medicines for
indications or in doses or by routes of administration outside the recommendations given in the
licence’.348 Women should be properly informed before a drug is prescribed for an unlicensed
indication.349 Drugs prescribed by doctors outside the licence can be dispensed by pharmacists and
administered by nurses and midwives. It is essential to have signed local protocols or individual
prescriptions in respect of any substance prescribed outside the terms of its product licence.
Provided a medical practitioner has prepared and signed a local protocol or individual prescription,
midwives, health visitors or nurses may administer the drug. It should be noted that mifepristone
and misoprostol, when used with the intention of inducing an abortion, cannot be provided under
a patient group direction (previously known as ‘group protocol’).
Medical abortion at ≤ 63 days of gestation (early medical abortion)
RECOMMENDATION 7.19
The following regimens are recommended for early medical abortion:
• At ≤ 63 days of gestation, mifepristone 200 mg orally followed 24–48 hours later by
misoprostol 800 micrograms given by the vaginal, buccal or sublingual route.
• At ≤ 49 days of gestation, 200 mg oral mifepristone followed 24–48 hours later by
400micro grams of oral misoprostol.
RECOMMENDATION 7.20
For women at 50–63 days of gestation, if abortion has not occurred 4 hours after admin -
istration of misoprostol, a second dose of misoprostol 400 micrograms may be administered
vaginally or orally (depending upon preference and amount of bleeding).
Evidence supporting recommendations 7.19 and 7.20
Misoprostol is as or more effective when used vaginally, sublingually or buccally than when used
orally for inducing early medical abortion.350–352 As gestation advances beyond 49 days, however,
vaginal misoprostol is more effective than oral misoprostol339 and has fewer adverse effects than
sublingual or buccal misoprostol.337 Nevertheless, some women may prefer an oral route of
administration.353
Given its relative effectiveness, buccal or sublingual administration of misoprostol in combination
with mifepristone is acceptable at ≤ 63 days of gestation and oral misoprostol may be used with
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mifepristone at ≤ 49 days of gestation. Women should be advised of the greater risk of adverse
effects with non-vaginal routes.
Several studies have examined the time interval between administration of mifepristone and
misoprostol and these have been summarised in two reviews published in 2006 and 2010.354,355
These studies investigated simultaneous administration of mifepristone and misoprostol together
with separate administration at intervals of 6–8 hours, 24 hours, 36 hours, 48 hours and 72 hours.
Meta-analyses of five pooled RCTs showed no statistical difference in efficiency between shorter
and longer dosing intervals. However, there was a trend to lower success rates with intervals of less
than 8 hours.
The rate of surgical intervention following medical abortion has been shown to be the same for
women with a body mass index of less than 30 and those with a body mass index greater than 30.356
Place of misoprostol administration
RECOMMENDATION 7.21
It is safe and acceptable for women who wish to leave the abortion unit following misoprostol
administration to complete the abortion at home. There must be an adequate support strategy
and robust follow-up arrangements for these women.
Evidence supporting recommendation 7.21
In England, Scotland and Wales, according to the DH (England) interpretation of the Abortion Act,
both mifepristone and misoprostol must be given in premises licensed for abortion, although there
is no legal restriction on where the abortion actually takes place. Several studies have confirmed
that home use of misoprostol is safe, acceptable and effective up to 63 days of gestation and in
many other countries it is the standard of care.357–359
In a Swedish study of women undergoing early medical abortion at home at up to 49 days of
gestation, the home regimen was safe and 98% of women said they would use this method if they
had a further abortion.360 Furthermore, there was no difference in women’s satisfaction between
those with a gestational length of up to 49 days compared with women at 50–63 days of gestation.361
Data on home use of misoprostol in Great Britain are limited owing to legal restrictions. In 2005, a
multicentre questionnaire assessed the acceptability of home medical abortion among 553 women
who had just undergone abortion in hospital. Three hundred and sixty-six women returned the
questionnaire. Most felt that they would be able to manage the pain and bleeding associated with
a medical abortion at home, but only 36% would choose home use of misoprostol if given the
option.362 This contrasts with the opinions of women in other studies who had actually experienced
abortion at home in which consistently over 90% would choose to have a further abortion outside
a clinical setting. The DH looked at three types of community setting and conducted in-depth
interviews with women. Most were satisfied with the community rather than hospital setting but did
not feel that community or home settings would be suitable for all women. Few women were
concerned with the safety of abortion outside a hospital setting.110
In the only publication on home administration of misoprostol in Great Britain, 49 women at up to
56 days of gestation, following the administration of mifepristone 200 mg in hospital, were given
600 micrograms of misoprostol to administer sublingually at home.363 Forty-eight women took the
misoprostol and aborted at home and one woman elected to return to the hospital for misoprostol
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administration. Ninety-two percent of the women returned study questionnaires; 82% were very
satisfied and 14% satisfied with undergoing treatment at home, and none was dissatisfied.
In a recent publication, 249 women who completed their abortions at home in England and Wales
were surveyed. One hundred and sixty-two women responded and, of these, 85% preferred being
able to complete their abortion in a home rather than in a clinical setting.364 Ninety-six percent
found the experience acceptable and 96% felt that they would have been able to obtain clinical
help if required. Home completion was less acceptable among those who had a pregnancy greater
than 49 days of gestation and among Asian women.
In a recent Scottish study, 145 women elected to complete early medical abortion at home.293 Sixty-
nine percent returned a questionnaire recording their views of the experience. Eighty-one percent
of women found the bleeding, and 58% found the pain, to be ‘as expected’ or ‘not as bad as
expected’. Eighty-four percent of women would recommend early discharge to complete medical
abortion at home.
It is clear that women who are able to choose their method of abortion are more satisfied with the
outcome than women denied a choice. Neither early medical abortion nor home administration of
misoprostol suits all women. However, published data do not suggest any clinical reason why
women should remain in hospital during their abortion, and demonstrate that it is safe for women
to administer misoprostol at home.
Medical abortion at 9–13 weeks of gestation
RECOMMENDATION 7.22
The following regimen is recommended for medical abortion between 9 and 13 weeks of
gestation:
• Mifepristone 200 mg orally followed 36–48 hours later by misoprostol 800 micrograms
vaginally. A maximum of four further doses of misoprostol 400 micrograms may be
administered at 3-hourly intervals, vaginally or orally.
Evidence supporting recommendation 7.22
In a case series of 253 women at 63–83 days of gestation managed using a regimen of mifepristone
200 mg followed 36–48 hours later by a single dose of misoprostol 800 micrograms vaginally, the
complete abortion rate was 95%, rising to 96% after repeat misoprostol administration in three
women.365
In a randomised trial involving 368 women at 10–13 weeks of gestation, participants were
randomly allocated to surgical abortion by vacuum aspiration under general anaesthesia or medical
abortion with mifepristone 200 mg followed 36–48 hours later by repeated doses of misoprostol.131
Complete abortion rates were 95% in the medical group and 98% in the surgical group (difference
not significant). There were more adverse events in the medical group, but 70% indicated that they
would opt for the same method in the future.
The same group subsequently reported a consecutive series of 483 women at 64–91 days of
gestation, managed using the same regimen.366 The complete abortion rate was 95% and was
gestation related. In this series, up to five doses of misoprostol were permitted.
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A small case series (25 women at 9–12 weeks of gestation) using mifepristone 200 mg followed by
gemeprost 1 mg to a maximum of five doses reported a complete abortion rate of 96%. All women
except one were managed as day cases.367
In a randomised trial involving 340 women, oral and sublingual misoprostol were equally effective,
but there were more adverse effects with sublingual administration.368
Medical abortion at 13–24 weeks of gestation
RECOMMENDATION 7.23
The following regimen is recommended for medical abortion between 13 and 24 weeks of
gestation:
• Mifepristone 200 mg orally, followed 36–48 hours later by misoprostol 800 micrograms
vaginally, then misoprostol 400 micrograms orally or vaginally, 3-hourly, to a maximum of
four further doses.
If abortion does not occur, mifepristone can be repeated 3 hours after the last dose of 
misoprostol and 12 hours later misoprostol may be recommenced.
Evidence supporting recommendations 7.23
Second-trimester medical abortion with mifepristone followed by a prostaglandin analogue is effective
and is associated with considerably shorter induction-to-abortion intervals than methods using a
prostaglandin analogue alone.369,370 As discussed above, the dose of mifepristone recommended for
first-trimester medical abortion is 200 mg.331 Likewise, evidence from a randomised trial resulted in a
similar recommendation for the dose of mifepristone in second-trimester abortions.371
In a series of 500 cases of medical abortion at 13–24 weeks of gestation,108 only 9.4% of cases
needed subsequent surgical evacuation following medical abortion. In a similar series of 956
women, the rate was 11.5%.108
Three studies published since 1999 on combined mifepristone and prostaglandin analogue mid-
trimester regimens have been identified.
Ngai et al. reported a randomised trial of 142 women at 14–20 weeks of gestation comparing
vaginal (200 micrograms, 3-hourly) and oral (400 micrograms, 3-hourly) misoprostol after mife -
pristone 200 mg.372 The efficacy of the two regimens was similar (complete abortion rate: 81% oral
versus 75% vaginal). Although there were significantly more adverse effects in the oral group, this
route was preferred by women.
A case series of 956 women at 12–24 weeks of gestation managed using a regimen comprising
mifepristone 200 mg followed by gemeprost 1mg vaginally 6-hourly for 24 hours, followed by
gemeprost 1 mg 3-hourly for 12 hours if required, reported complete abortion rates of 96.4% and
98.8% within 24 and 36 hours, respectively.373
Bartley and Baird compared gemeprost and misoprostol in a randomised trial of 100 women at
12–20 weeks of gestation.374 All subjects received mifepristone 200 mg; the gemeprost group then
received 1 mg vaginally every 6 hours for 18 hours; the misoprostol group then received one dose
of 800 micrograms vaginally followed by 400 micrograms orally 3-hourly for 12 hours. Complete
abortion rates, induction-to-abortion intervals, surgical evacuation rates and adverse effect profiles
were similar in the two groups.
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An abortion rate of 97.9% was reported in 386 consecutive cases between 12 and 20 weeks of
gestation.375 If abortion had not occurred by 15 hours, a second dose of 200 mg mifepristone was
administered and the course of prostaglandin analogues repeated starting 24 hours after the first
dose. Over 99% of women aborted within 36 hours.
Brouns376 conducted a small randomised study of abortion between 14 and 24 weeks of gestation
using 200mg mifepristone and either 200 or 400 micrograms misoprostol. Both doses of
misoprostol were effective, but the induction-to-delivery interval was longer with the 200
micrograms dose.
A systematic review377 which included 40 RCTs addressing various regimens for abortion between
12 and 28 weeks of gestation concluded that the combination of mifepristone and misoprostol
appeared to have the highest efficacy and shortest abortion time interval. The optimal route for
administering misoprostol was vaginally, preferably using tablets at 3-hourly intervals. However, the
authors stated that conclusions from this review were limited by the gestational age ranges and
variable medical regimens, including dosing, administrative routes and intervals of medication, of
the included trials.
RECOMMENDATION 7.24
Surgical evacuation of the uterus is not required routinely following medical abortion
between 13 and 24 weeks of gestation. It should only be undertaken if there is clinical
evidence that the abortion is incomplete.
Pain relief for medical abortion
RECOMMENDATION 7.25
Women should routinely be offered pain relief (for example NSAIDs) during medical abortion.
RECOMMENDATION 7.26
Oral paracetamol has not been shown to reduce pain more than placebo during medical
abortion and is not recommended.
RECOMMENDATION 7.27
Some women may require additional narcotic analgesia, particularly after 13 weeks of
gestation.
Evidence supporting recommendations 7.25–7.27
In routine clinical practice, analgesia is offered to women both during and after medical abortion.
There is little research evidence to guide the choice of analgesic regimen. In a large case series of
early medical abortion, data on analgesic use were available for over 3000 women.130 Of these,
37% required no analgesia, 58% received oral analgesia only (paracetamol 500mg plus
dihydrocodeine 10 mg) and 5% received parenteral opiate (morphine 10 mg).
A case series of 2747 women from the USA reported on analgesic use during home abortion:358 79%
of the women used an oral narcotic analgesic on the day of the misoprostol administration. This
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level of use was higher than the 27% reported by the same investigators in a series of 2121 women
undergoing supervised medical abortion.378
A placebo-controlled, randomised trial evaluated the efficacy of ibuprofen or acetaminophen
(paracetamol) with codeine in the context of early medical abortion with methotrexate and
misoprostol.321 The agents were taken at the time of misoprostol administration, prior to the onset of
pain. Severe pain was reported by almost 25% of women. There were no significant differences in
pain scores between treatment groups. The authors concluded that pain experienced in medical
abortion causes significant distress and more research is needed to reduce it.
In a randomised study examining the effect of paracetamol and codeine or diclofenac given with
the first dose of misoprostol to women undergoing medical abortion between 13 and 22 weeks of
gestation,379 the NSAID did not interfere with the action of the misoprostol and women using
diclofenac had a reduced need for opiate injections.
In a systematic review of pain control in medical abortion, only 10 of 361 articles identified met
the inclusion criteria.380 The main positive finding was that ibuprofen given after the onset of pain
reduced further analgesic use. Acetaminophen, acetaminophen plus codeine and alvarine (an
antispasmodic) appeared to be ineffective. Despite its antiprostaglandin analogue effects, ibuprofen
did not interfere with the action of misoprostol. The authors concluded that further research is
needed to determine the optimal analgesic regimen for medical abortion.
7.3 Histopathology
RECOMMENDATION 7.28
Routine histopathological examination of tissue obtained at abortion procedures is not
recommended.
Evidence supporting recommendation 7.28
Three prospective cohort studies have examined the usefulness of routine histopathological
examination of tissue obtained at abortion.381–383 Two of them concluded that there was no obvious
benefit from routine histological examination. The third study involved review of histological
findings from 1000 consecutive induced abortions at 7–13 weeks of gestation.381–383 Pathological
findings were reported in 5.6% of cases, including one diagnosis of fetal polycystic kidney disease.
The authors reported that this information enabled the woman to undergo prenatal diagnosis in
future pregnancies and argued a case for routine histological examination of abortion material.
However, none of the pathologies reported influenced the immediate care of the woman.
The Royal College of Pathologists’ guidance on histopathological examination of tissue obtained at
abortion finds it to be of limited or no clinical value and advises that for ‘social termination of
pregnancy’, specimens should not be sent to the laboratory if fetal parts are visible.384 With early
surgical abortion, fetal parts may not be visible. Therefore, histological examination would be
indicated when a gestational sac is not seen in the aspirate (see recommendation 7.3).
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Gestational trophoblastic neoplasia (GTN)
RECOMMENDATION 7.29
Routine screening of women for GTN at the time of abortion is not recommended; providers
should be aware of the signs and symptoms and, where appropriate, facilitate referral into a
GTN monitoring programme.
Evidence supporting recommendation 7.29
The incidence of GTN in women seeking abortion has been estimated to be 1 in 600 to 1 in 2699,
with variations dependent on gestational age.385–387 The authors of a retrospective review of 51 cases
of GTN diagnosed at or following an abortion advocated routine screening, based on their finding
that those without a diagnosis at the time of their procedure were significantly more likely to have
serious complications of GTN and to require surgical intervention and chemotherapy.388
It is unclear how screening would be achieved in practice and no studies of screening protocols
have been undertaken. Gross and/or histological examination of aspirated tissue as a method of
identifying GTN may also be unreliable, as early molar pregnancies do not always conform to the
classic appearance.389 At present, there is insufficient evidence to recommend a screening strategy
for GTN in the abortion care setting.
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Chapter 8
Care after the abortion
8.1 Rhesus prophylaxis
RECOMMENDATION 8.1
Anti-D IgG should be given, by injection into the deltoid muscle, to all non-sensitised RhD-
negative women within 72 hours following abortion, whether by surgical or medical
methods.
Evidence supporting recommendation 8.1
The RCOG recommends that RhD-negative women should be given anti-D IgG immuno -
prophylaxis following abortion.390 The recommended dose is 250 iu before 20 weeks of gestation
and 500 iu thereafter. A 500 iu dose gives protection for fetomaternal haemorrhage of up to 4ml.
For abortions undertaken after 20 weeks of gestation, the size of fetomaternal haemorrhage should
be assessed using either the traditional Kleihauer acid elution test or the more accurate flow
cytometry. If the test indicates a fetomaternal haemorrhage of greater than 4ml, an additional
125 iu/ml of anti-D IgG should be administered.390 Anti-D IgG should be injected into the deltoid
muscle, as injections into the gluteal region often reach only the subcutaneous tissues and
absorption may be delayed.390
In a Cochrane review of the evidence for rhesus prophylaxis after first-trimester miscarriage, the
authors concluded that there is minimal evidence that administering Rh immune globulin for first-
trimester vaginal bleeding prevents maternal sensitisation or development of haemolytic disease of
the newborn.391 It is not difficult to argue that women undergoing medical abortion before 9 weeks
of gestation probably do not need anti-D IgG. However, a structured review that appraised ten
published studies relating to the necessity for anti-D prophylaxis for early first-trimester abortion392
concluded that, although evidence to support the use of prophylaxis in the first trimester is sparse,
there is theoretical evidence of its necessity. Since some studies indicate that fetomaternal
haemorrhage in the first trimester is of sufficient volume potentially to cause immunosensitisation,
the RCOG continues to recommend anti-D administration as routine. Other national guidelines
make similar recommendations.393 Further research is required.
It is fruitless to administer anti-D IgG to RhD-negative women who, on antibody screening, are
found to be sensitised already. It is wasteful of anti-D IgG and unnecessarily exposes women to any
risks inherent in human blood products. Inadvertent administration of prophylactic anti-D IgG to an
already sensitised woman, however, would not of itself cause any harm to her.
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8.2 Information after the abortion
RECOMMENDATION 8.2
On discharge, all women should be given a letter providing sufficient information about the
procedure to allow another practitioner elsewhere to manage any complications.
RECOMMENDATION 8.3
Following abortion, women should be provided with verbal and written information about:
• symptoms they may experience, emphasising those which would necessitate an urgent
medical consultation
• symptoms suggestive of continuing pregnancy.
RECOMMENDATION 8.4
Independent providers of abortion services should have arrangements in place for referring
women into NHS services for emergency assessment/admission.
RECOMMENDATION 8.5
A 24-hour telephone helpline number should be available for women to use after abortion if
they have any concerns.
8.3 Follow-up after abortion
RECOMMENDATION 8.6
There is no medical need for routine follow-up after surgical abortion or after medical
abortion if successful abortion has been confirmed at the time of the procedure.
Evidence supporting recommendation 8.6
Continuing pregnancy after surgical abortion is uncommon (2.3 in 1000 cases of surgical
abortion)160 and, in contrast to medical abortion, surgeons have the opportunity to check for
products of conception. Risk factors for continuing pregnancy include the presence of a uterine
anomaly, a less experienced surgeon and gestational age of less than 6 weeks.160,279,394 Two systematic
reviews concluded that routine follow-up after surgical abortion cannot therefore be justified solely
to exclude a continuing pregnancy.395,396 Since many women fail to attend for follow-up, much
outpatient time is wasted by insisting that all women be given a routine appointment. Rather, every
effort should be made to ensure that women leave the abortion facility with effective contraception
and with information about where to go for further advice or treatment of symptoms, emotional
problems or for contraception if it was declined at the time of the procedure.
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RECOMMENDATION 8.7
Women having a medical abortion in whom successful abortion has not been confirmed at
the time of the procedure should be offered follow-up to exclude continuing pregnancy.
Evidence supporting recommendation 8.7
Continuing pregnancy after medical abortion, while still uncommon, occurs in 0.5–1% of cases
after mifepristone–misoprostol regimens.161,162,336,350,397 Continuing pregnancies after misoprostol
intake are at risk of teratogenicity.398–400 Continuing pregnancy is more common in parous women,
older women who have had previous abortions and at later gestational ages.131,161,401–405 Continuing
symptoms or signs of pregnancy, or very little/no vaginal bleeding after the procedure, should alert
the clinician to the possibility of a continuing pregnancy.
For women in whom products of conception are not identified by an experienced health
professional at the time of medical abortion, and for women who choose to go home immediately
after misoprostol administration, a reliable method for excluding continuing pregnancy is import -
ant. A systematic review of nine studies examined alternative modalities to ultrasound for detecting
continuing pregnancy, including women’s self-assessment, clinician assessment, serum hCG
measurement and urine pregnancy testing.395 A woman’s self-assessment of continuing pregnancy
following medical abortion appears fairly accurate compared with ultrasound examination or
clinician assessment,115,406–408 but may be less accurate at gestations over 50 days when continuing
pregnancy is more likely.115 Studies assessing the accuracy of serum hCG and urine pregnancy
testing to detect failed medical abortion have been limited by the inherent high success rate of
medical abortion and thus the small numbers of continuing pregnancies.409–413
The largest study of alternative follow-up strategies after medical abortion (3054 women at less than
63 days of gestation) evaluated different algorithms among women who underwent clinician
assessment, self-assessment, low-sensitivity urine pregnancy test (performed by a laboratory
technician) and ultrasound.414 None was sufficiently sensitive on its own to identify all continuing
pregnancies. However, a combination of either self-assessment or clinician assessment with a
pregnancy test identified all 20 continuing pregnancies. Use of either of these algorithms would
have resulted in an additional 64 (34%) of women who were not pregnant screening ‘positive’ and
requiring ultrasound evaluation.
One small study of 139 women examined a strategy of telephone follow-up 1 week after
misoprostol administration followed by a self-performed pregnancy test at 30 days. One-third of
women ‘screened positive’ and were required to attend a clinic to confirm complete abortion.91
Further research is required to determine whether a combination of pregnancy testing at home and
questions about pregnancy symptoms/signs could be used to screen for continuing pregnancy after
medical abortion and to identify those women who require a clinic follow-up. Currently, in the
absence of evidence to recommend a particular process for routine follow-up to exclude continuing
pregnancy after medical abortion (when expulsion of the products of conception has not been
confirmed by an experienced health professional), services should agree a protocol for local use
taking into consideration the length of time an individual woman stays in the abortion service after
misoprostol, her risk factors for failure and the distance she would have to travel to attend follow-
up. It may be considered appropriate for the majority of women to be contacted by telephone to
ask about post-procedure bleeding and symptoms together with a carefully performed urine
pregnancy test or serum hCG determination.
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RECOMMENDATION 8.8
All women having an abortion should be able to choose to return for routine follow-up if they
so wish.
RECOMMENDATION 8.9
Referral should be available for any woman who may require additional emotional support
or whose mental health is perceived to be at risk.
Evidence supporting recommendation 8.9
Most women who undergo induced abortion are certain of their decision211,214,415 and are unlikely to
experience serious regret. While there is good evidence that the great majority of adult women who
have an abortion do not experience mental health problems,209,416 a few will find it hard to come to
terms with their decision and/or their experience of undergoing abortion and will require further
emotional support or counselling. Women with a past history of mental health problems, those with
a negative reaction to the abortion or those who are experiencing other stressful life events are more
likely to develop mental health problems.137 Services should be available for such women, including
the possibility of self-referral.
RECOMMENDATION 8.10
All women should be advised where to seek help if they have any concerns or if they need
further contraceptive advice or provision.
RECOMMENDATION 8.11
Ultrasound examination should not be used routinely to screen women for incomplete
abortion.
RECOMMENDATION 8.12
The decision to evacuate the uterus following incomplete abortion should be based on
clinical signs and symptoms and not on ultrasound appearances.
Evidence supporting recommendations 8.11 and 8.12
While ultrasound examination will reliably exclude continuing pregnancy, its routine use in women
suspected of incomplete abortion can be misleading. Ultrasound appearances and measurements
of endometrial thickness correlate poorly both with symptoms suggestive of retained products of
conception and with later histological examination. Ultrasound appearances are not a clinically
useful predictor for the subsequent need for surgical evacuation.417–421 The decision to undertake
uterine evacuation should be based upon the presence of signs and symptoms.
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8.4 Contraception after the abortion
RECOMMENDATION 8.13
Abortion services should be able to provide all methods of contraception, including long-
acting methods, immediately after abortion.
RECOMMENDATION 8.14
Women should be advised of the greater effectiveness of long-acting reversible methods of
contraception.
RECOMMENDATION 8.15
Before she is discharged, future contraception should have been discussed with each woman
and contraceptive supplies should have been offered.
Evidence supporting recommendations 8.13–8.15
Ovulation occurs within 1 month of first-trimester abortion in over 90% of women.422 Initiation of
contraception immediately following induced abortion has advantages. The woman is known not
to be pregnant, her motivation to use effective contraception may be high and she is already
accessing health care. There is evidence among contraceptive users in general that immediate
initiation of contraception, avoiding delays imposed by the need for return visits to a medical
facility, has short-term positive effects on contraceptive use.423 Delaying insertion of an intrauterine
device (IUD) after abortion has been shown to be a barrier to uptake.424
There is evidence that efforts to increase the uptake of effective methods of contraception can be
effective. In an RCT undertaken in Scotland, women receiving individualised, tailored contraceptive
advice and immediate provision of their chosen method after abortion were significantly more likely
to leave the abortion service with a method of contraception (particularly contraceptive implants)
than women offered a more limited choice of methods.425 In a US trial, availability of immediate
IUD insertion in the abortion facility resulted in an increase in the percentage of women leaving the
facility with an IUD.426
Long-acting reversible methods of contraception rely less (injectables) or not at all (intrauterine
methods and implants) on compliance for their effectiveness compared with oral contraceptives or
barrier methods. NICE recommends that increased uptake of long-acting reversible methods of
contraception should reduce unintended pregnancy rates.427 Increased IUD use facilitated by
immediate insertion should theoretically prevent significant numbers of repeat abortions.428–430
Evidence for the effectiveness of interventions designed to improve contraceptive use in terms of
reducing repeat abortions is hard to come by.431 However, in a US study women who chose
immediate insertion of an IUD after abortion had a lower rate of subsequent repeat abortions than
women who chose other methods.429,430,432
RECOMMENDATION 8.16
The chosen method of contraception should be initiated immediately.
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RECOMMENDATION 8.17
Intrauterine contraceptives can be inserted immediately following medical and surgical
abortion at all gestations as long as it is reasonably certain that the woman is not still
pregnant.
RECOMMENDATION 8.18
Women who choose not to start a contraceptive method immediately should be given
information about local contraceptive providers in addition to their GP.
RECOMMENDATION 8.19
Abortion services should have an agreed pathway of care to local community sexual health
services.
Evidence supporting recommendations 8.16–8.19
WHO’s Medical Eligibility Criteria and Selected Practice Recommendations for Contraceptive Use
(WHOMEC and WHOSPR, respectively) provide evidence-based recommendations on eligibility
for methods and on maximising effective contraceptive use.433,434 Both have been adapted for use in
Great Britain.435,436 The WHOMEC recommend that the benefits of combined hormonal
contraceptives started immediately following first- or second-trimester abortion outweigh any risks.
Similarly, the WHOSPR recommend that progestogen-only contraceptive pills, implants and
injectables can all be started immediately following abortion. Ideally, these methods should be
started on the day of the abortion, when contraceptive protection is immediate.
A systematic review of the literature concluded that the provision of combined oral contraceptives
immediately following surgical or medical abortion was safe.437 Use of the combined oral
contraceptive pill does not affect either duration or amount of vaginal bleeding or the complete
abortion rate. While there is no direct evidence, it seems likely that administration of combined
hormonal contraceptives by other routes (transdermal, vaginal) will have similar effects.
There are few data specifically relating to IUD or levonorgestrel-releasing intrauterine system (LNG-
IUS) insertion following medical abortion, and recommendations vary. The WHOMEC do not
distinguish between medical and surgical abortion when recommending that IUD and LNG-IUS
can be inserted without restriction following first-trimester abortion and that the benefits outweigh
the risks of immediate insertion after second-trimester abortion. The GDG suggests that an IUD/IUS
may be inserted immediately (within 48 hours) following first- or second-trimester medical abortion.
Otherwise, insertion should be delayed until 4 weeks following medical abortion (as for postpartum
insertions). The Faculty of Sexual & Reproductive Healthcare recognises that waiting for 4 weeks
may put some women at risk of pregnancy and suggests that, after counselling, an IUD/IUS can be
inserted at any time after medical abortion by an experienced clinician if it is reasonably certain
that the pregnancy is not continuing.438 Clearly, further evidence is required.
If insertion of intrauterine contraception is to be delayed, women leaving the abortion unit and
choosing an IUD or IUS for later insertion should be provided with effective contraception to use
in the interim.
A systematic review including nine randomised trials and a total of 4476 woman-years of data
suggested that the insertion of a copper-bearing intrauterine contraceptive device at the time of
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surgical abortion was safe and practical.439 No difference was found in readmission rates for pelvic
infection following abortion in 229 women having an IUD inserted at the time of first-trimester
abortion compared with 594 women not having an IUD inserted.56,439 No prophylactic antibiotics
were used and IUD continuation rates at 1 year were 72.8%. Expulsion rates were higher for
insertions following second-trimester abortion than following first-trimester abortion. However, in a
modelling exercise in which expulsion rates as high as 30% for immediate insertion after second-
trimester abortion were assumed, immediate insertion of an IUD resulted in a theoretical reduction
in repeat abortions.428 There is insufficient evidence available to compare the safety and efficacy of
IUDs inserted immediately after abortion versus delayed insertion. However, the WHOMEC
recommend the benefits of IUD insertion immediately following first-trimester abortion (category 1:
unrestricted use) or second-trimester abortion (category 2: benefits generally outweigh any risks).433
The UK Medical Eligibility Criteria (UKMEC) recommend that an IUD can be inserted immediately
following surgical abortion or after the second part of medical abortion up to 24 weeks of
gestation.53,435
There are fewer data on the use of LNG-IUS after surgical abortion. The Cochrane review cites a
small randomised trial that investigated bleeding patterns associated with an IUD or LNG-IUS
inserted following either induced abortion or menstruation.440 Women having an LNG-IUS inserted
following surgical abortion described fewer bleeding problems compared with women having one
inserted postmenstrually. This may be attributable to an enhanced effect of levonorgestrel on the
endometrium following removal of most of the superficial endometrium during the surgical
procedure. Other studies have demonstrated the safety and efficacy of the LNG-IUS inserted
immediately after surgical abortion.441–443 The UKMEC recommend that an IUS can be inserted
immediately following surgical abortion or after the second part of medical abortion up to 24 weeks
of gestation.435
Sterilisation
RECOMMENDATION 8.20
Sterilisation can be safely performed at the time of induced abortion, although may be more
likely to be associated with regret and failure.
Evidence supporting recommendation 8.20
The lifetime failure rate for sterilisation is approximately 1 in 200.444 The RCOG evidence-based
guideline on male and female sterilisation highlighted that there is potentially a higher failure rate
associated with sterilisation at the time of abortion.444 The Medico-Legal Committee of the RCOG
has commented: ‘In view of the increased failure rate of sterilisation procedures on those currently
pregnant, it is questionable whether such operations should be carried out at all’.445
Two cohort studies have shown that the immediate and short-term complications of sterilisation
performed at the time of abortion are similar to the total morbidity associated with the two
procedures when performed separately.446,447 Earlier reports, based on statutory notifications,
overestimated complications owing to most sterilisations being performed by laparotomy as
opposed to the laparoscopic techniques now favoured. There are no data on hysteroscopic
sterilisation or sterilisation by mini-laparotomy at the time of abortion.
Apart from the potential increased risk of failure, the possibility of feelings of regret has been voiced
as a reason for performing sterilisation as an interval procedure. Regret associated with sterilisation
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may be hard to predict.448 In one randomised trial, women who had requested sterilisation at the
time of abortion were randomised to a combination or an interval procedure.446 Of the women
allocated to the ‘interval’ group, 33% failed to attend for sterilisation, suggesting a change of mind
once they had been able to distance themselves from the abortion itself. This study emphasises the
need for careful counselling relating to sterilisation in association with abortion.
The WHOMEC recommend that sterilisation can be performed immediately after abortion unless
the abortion is complicated by sepsis, fever, severe haemorrhage or genital tract trauma.433
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Chapter 9
Standards for audit and
service accreditation
Women seeking induced abortion need non-directive information and support to enable them to
make the most appropriate decisions. All women should be offered comprehensive sexual health
care, including full contraceptive provision and an STI risk assessment. Referral for induced
abortion is also an opportunity to identify vulnerable women, particularly those in abusive
situations or with safeguarding/child protection needs, and enable them to disclose these matters
and receive support from, or referral to, trained advocates.
The DH Mandated Service Specification for abortion care and/or any local commissioning contracts
should be taken into account when reviewing standards as part of clinical audit and review of
commissioning arrangements.65
Abortion services must conduct regular audit of the care they provide. The recommendations within
this guideline can serve as criteria for audit. Some suggestions for audit of abortion services have
already been provided within the RCOG Standards in Gynaecology.84 Having reviewed and
updated this guideline, the members of the GDG discussed the recommendations with a view to
suggesting a list of auditable standards. While most of the recommendations could provide the basis
for audit, the GDG lists below those which they felt were the most important. The specific
recommendations being audited are shown in brackets within the list.
The RCOG publication Understanding Audit449 provides useful advice on undertaking high-quality
audit. In brief, services need to collect data to assess their performance against a specified standard,
feed back the findings to service staff (and other stakeholders), agree and then implement changes
required to improve the quality of care and repeat the data collection to determine whether care
has been improved. For most of the auditable standards listed below, data can be simply collected
by case note review or by self-completed questionnaires issued to women or staff.
All clinical staff should attend regular, minuted clinical governance meetings. Standard agenda
items should include audit, critical incidents, complaints and service development.
9.1 Pathways of care
A number of recommendations in the guideline highlight the need for services to have clear
pathways of care for the management/referral of women whose needs cannot be met by their own
service, including pathways to:
• tertiary care for women with significant medical conditions (16)
• antenatal care for women deciding to continue their pregnancy (17)
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• care (including contraception and sexual health care) for women with non-viable pregnancy (18)
• specialist services for vulnerable women (for example child protection needs, domestic/sexual
abuse) (19)
• the appropriate method of inducing abortion if that method is not available in-house (for
example D&E) or if the service is not provided for certain gestations (23)
• additional emotional support after the abortion for women who need it (104).
Services should undertake audit to determine whether their staff are familiar with all these pathways
of care and whether those pathways are being used appropriately and effectively.
9.2 Information provision
A number of recommendations highlight the need for women at various stages during their journey
through the abortion service to receive information about a range of topics, including:
• routes of access to abortion (including self-referral) (1)
• pregnancy options (11, 14)
• abortion procedures (11, 48, 77)
• complications, risks, adverse effects and sequelae (13, 31–43)
• prevention of STIs (62)
• care after abortion (including contraceptive provision) (98, 105, 109, 113).
Services should undertake regular audit to determine whether this information (including inform -
ation in an appropriate format which women can take home) is being offered to all women
undergoing abortion and that the information is understood.
9.3 Women’s choice
A number of recommendations in the guideline highlight the need for women’s choice in the
abortion process. Regular audit should be undertaken to determine whether women are being
offered (where appropriate) a choice of:
• abortion method (23)
• completion of medical abortion (before 9 weeks of gestation) at home or in the clinic (28, 86)
• routine follow-up (103)
• the full range of contraceptive methods (110).
9.4 Pre-abortion assessment
Regular audit should be undertaken to determine the percentage of women undergoing:
• determination of rhesus status (50)
• rhesus prophylaxis (96)
• VTE risk assessment (52)
• C. trachomatis screening (60)
• STI risk assessment (60)
• the process and outcome of telephone assessment (if being used) (21).
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9.5 Abortion procedures
Services should regularly audit their success in meeting the standards relating to:
• minimising delay in providing/accessing abortion (3, 24)
• rates of complications (13)
• the prevention of infective complications (58)
• failure rates (67)
• cervical preparation (73)
• provision of alternatives to general anaesthesia for surgical abortion (78).
9.6 Care after the abortion
• The robustness of follow-up arrangements (including telephone assessment) for women choosing
early discharge after medical abortion should be audited (28, 86).
• Services should regularly audit the number of staff competent to provide all methods of
contraception, including contraceptive implants and intrauterine methods, and the availability
of such staff during the working week (108).
• Services should regularly audit the percentage of women with whom contraception after
abortion has been discussed, offered and provided (110, 111) and the percentage leaving the
abortion service with one of the more effective methods of contraception (109).
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Chapter 10
Further research
In revising this guideline on abortion care, the GDG became aware of gaps in our knowledge of
how best to deliver abortion services in Great Britain. While no means an exhaustive list, the GDG
considers the following topics to be research priorities.
Organising and commissioning services
• Extending the role of nurses in abortion services.
• Models of service delivery designed to improve integration of abortion and community services
(family planning and genitourinary medicine clinics).
• The use of tele-health in the management of abortion.
• The effect on willingness to participate in abortion services of exposing undergraduates and
postgraduates to abortion provision.
Adverse effects, complications and sequelae of abortion: what women need to know
• What is meant by cervical injury and what its relevance is to the safety and long-term conse -
quences of abortion.
• Differential effects of various techniques of inducing abortion on the risk of long-term sequelae.
Pre-abortion management
• National data on the incidence of HIV infection in women requesting abortion.
• National data on the incidence of non-viable/ectopic pregnancy in women requesting abortion.
• The role of ultrasound in pre-abortion assessment in the UK.
• Optimal antibiotic prophylaxis regimens.
Abortion procedures
• The cost-effectiveness of mifepristone for cervical ripening in second-trimester abortion.
• The most cost-effective regimens for analgesia for early and late medical abortion.
• The safest and most cost-effective regimens for pain relief (including anaesthesia) for surgical
abortion, including MVA.
Care after the abortion
• The consequences of fetomaternal haemorrhage.
• The safety and cost-effectiveness of immediate insertion after medical abortion of intrauterine
contraceptives.
• The effect of interventions on continuation rates of contraception after abortion.
• The role of ultrasound in managing post-abortion complications.
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2. Do you or any member of your immediate family have any commercial interest such as
personal shares with any company related to obstetrics and gynaecology?
3. Does your department or unit receive financial support from commercial organisations related
to obstetrics and gynaecology?
4. Are you a consultant to or member of any national body, charity or pressure group whose
work is related to obstetrics and gynaecology?
5. Do you receive significant editorial fees for commissioned articles for publication (in any
format) or are you paid for editorial work for any publication related to obstetrics and
gynaecology? 
6. Do you or your department hold a patent (existing or pending) related to obstetrics and
gynaecology?
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Answers to the questions are reproduced verbatim.
Professor Anna Glasier 1. YES
Both my husband and I do occasional work for pharmaceutical
companies
2. NO
3. YES
Research funds and support for meetings
4. YES
I am a member of the Board of Trustees of the Population
Council in New York
5. YES
Honoraria for writing chapters – but never > £200
6. NO
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 89
Ms Toni Belfield 1. NO
2. NO
3. NO
4. YES
FPA, FSRH, Cochrane Fertility Regulation Group, Reproductive
Health Matters
5. YES
Not significant fees! Work undertaken includes – author, book
chapters, book editing, peer review
6. NO 
Dr Sharon Cameron 1. YES 
I received financial support from HRA Pharma to attend
‘European Society of Gynaecology’ meeting in Rome Sept 2009
and to present results of study of which I was PI (emergency
contraception)
2. NO
3. YES 
Research grant was from HRA Pharma to conduct study of
which I was PI (2006–2009) on emergency contraception
4. NO
I published article on contraception in gynaecology for ‘Best
Practice & Research Clinical Obstetrics & Gynaecology –
Elsevier’ 2009 and received fee for this
5. NO 
Ms Joanne Fletcher 1. NO
2. NO
3. NO
4. YES 
Abortion Rights, FPA
5. NO
6. NO
Dr Katharine A Guthrie 1. NO
2. YES 
Hold shares in Medivend/Engage Now, who make kiosks for
sexual health information and goods vend
3. YES 
Pharma industry support for educational events. Dept part of
multicentre trial on Implanon for Schering Plough
4. YES 
Member of FPA, DWCA, Voice for Choice, Brooke
5. NO
6. NO
The Care of Women Requesting Induced Abortion
90
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 90
Declarations of interests and good standing
91
Dr Sarah Jarvis 1. NO
2. NO
3. NO
4. YES 
Women’s Health spokesperson, RCGP
5. NO
6. NO 
Dr Patricia Lohr 1. NO
2. NO
3. NO
4. YES 
Member of Doctors for a Woman’s Choice of Abortion (UK),
Physicians for Reproductive Choice and Health (US), National
Abortion Federation (US), International Consortium on Medical
Abortion (Intl), FIAPAC (Intl)
5. NO
6. NO 
Ms Fiona Loveless 1. NO
2. NO
3. NO
4. YES
Work for Marie Stopes International
5. NO
6. NO
Dr Tahir Mahmood 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
Dr Susan Mann 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 91
Dr R Kristina A Naidoo 1. YES 
I receive a fee from ‘Ethicon – Women’s Health and Urology’ to
provide clinical education and practical training in outpatient
hysteroscopy held at the NHS trust where I am employed
2. NO
3. YES 
‘Ethicon – Women’s Health and Urology’ provide an educational
grant to an endowment fund at St Mary’s Hospital, Manchester
to provide practical training courses in hysteroscopy
4. NO
5. NO
6. NO 
Mr Kamal N Ojha 1. NO
2. NO
3. NO
4. YES 
International Society of Fallopian Tube (ISFT) – non commercial
organisation – Treasurer of the society
5. NO
6. NO
Dr Kate Paterson 1. NO
2. NO
3. NO
4. YES 
Member of bpas clinical governance committee
5. NO
6. NO
Dr Alison Richardson 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
Ms Jackie Routledge 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
Professor Allan Templeton 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
The Care of Women Requesting Induced Abortion
92
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 92
Declarations of interests and good standing
93
Nominated peer reviewers
Answers to the questions are reproduced verbatim
Ms Myat Arrowsmith 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
Dr Edna Astbury-Ward 1. NO
2. NO
3. NO
4. YES 
Member of Research & Ethics Committee of British Pregnancy
Advisory Service
5. NO
6. NO
Mrs Tracy Burton 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
Dr Lucy E Caird 1. NO
2. NO
3. NO
4. NO
5. NO
Ms Sima Chaudhury 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
Ms Dianne Crowe 1. NO
2. NO
3. NO
4. YES 
Royal College of Nursing, Women’s Health Forum
5. NO
6. NO
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 93
Ms Sarah Doran 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO 
Ms Su Everett 1. NO
2. NO
3. NO
4. YES 
Member of the clinical effectiveness Unit ‘over 40’s
contraception’ for the Faculty of Reproductive Sexual Healthcare
5. NO
6. NO
Dr Kathy French 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO 
Professor Kristina Gemzell 1. NO
Danielson 2. NO
3. NO
4. NO
5. NO
6. NO 
Professor David A Grimes 1. YES 
Consultant to Bayer + Merck
2. NO
3. NO
4. YES 
ACOG, ASRM, SFP and others
5. NO
6. NO  
Dr Sally Hope 1. NO
2. NO
3. NO
4. YES 
Am one of the two GP National reps on the Women’s Health
Advisory Board for the MHRA
5. YES 
I am one of the Deputy Editors of Maturitas [£600/year for
reviewing 2 articles/week]
6. NO 
The Care of Women Requesting Induced Abortion
94
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 94
Declarations of interests and good standing
95
Dr Allyson Lipp 1. NO
2. NO
3. NO
4. YES 
I am a member of the all-Wales Termination of Pregnancy group
which comprises nurses + midwives
5. NO
6. NO 
Ms Mandy Myers 1. NO 
Employed by British Pregnancy Advisory Service (bpas) as
Director of Nursing
2. NO
3. NO
4. YES 
Member of Steering Committee for Women’s Health Forum of
Royal College of Nursing
5. NO
6. YES 
Semi quantitative lateral flow pregnancy test
Dr Victoria M Pickles 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO 
Ms Laura Rutherford 1. NO
2. NO
3. NO
4. YES 
Member of faculty of family planning and reproductive
healthcare
5. NO
6. NO
7. NO 
Dr John A D Spencer 1. YES 
Senior Clinical Consultant, Marie Stopes International
2. NO
3. NO
4. YES 
Senior Clinical Consultant, Marie Stopes International
5. NO
6. NO 
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 95
Dr Jane Wells 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO 
Dr Christine P West 1. NO
2. NO
Possibly but I am not personally involved with any such
arrangements
3. NO
4. NO
5. NO 
Ms Maureen Whittaker 1. NO
2. NO
3. NO
4. NO
5. NO
6. NO
The Care of Women Requesting Induced Abortion
96
3270 RCOG Abortion guideline.qxd:3270 RCOG Abortion guideline.qxd  11/11/11  14:13  Page 96
97
Appendix 2
Systematic reviews
In updating this guideline, the GDG was fortunate to have access to a large number of relevant
systematic reviews. These render redundant some of the evidence tables included in the appendix
of the previous version. For the benefit of readers who would like a quick reference guide to the
sources of evidence used in the guideline, the major systematic reviews are listed according to the
topic covered. Where systematic reviews were either not available or not sufficient for our
purposes, the evidence tables are displayed. For some topics for which no systematic reviews have
been published, the tables published in the 2004 guideline are reproduced since no new evidence
was found.
Use of ultrasound
• Kaneshiro B, Edelman A, Sneeringer RK, Ponce de Leon RG. Expanding medical abortion: can
medical abortion be effectively provided without the routine use of ultrasound? Contraception
2011;83:194–201. (Ref. 239)
• Kulier R, Kapp N. Comprehensive analysis of the use of pre-procedure ultrasound for first- and
second-trimester abortion. Contraception 2011;83:30–3. (Ref. 240)
• Whitworth M, Bricker L, Neilson JP, Dowswell T. Ultrasound for fetal assessment in early
pregnancy. Cochrane Database Syst Rev 2010;(4):CD007058. (Ref. 236)
Cervical preparation
• Kapp N, Lohr PA, Ngo TD, Hayes JL. Cervical preparation for first trimester surgical abortion.
Cochrane Database Syst Rev 2010;(2):CD007207. (Ref. 291)
• Newmann SJ, Dalve-Endres A, Diedrich JT, Steinauer JE, Meckstroth K, Drey EA. Cervical
preparation for second trimester dilation and evacuation. Cochrane Database Syst Rev
2010;(8):CD007310. (Ref. 301)
• Promsonthi P, Preechapornprasert D, Chanrachakul B. Nitric oxide donors for cervical ripening
in first-trimester surgical abortion. Cochrane Database Syst Rev 2009;(4):CD007444. (Ref. 292)
Abortion methods
• Kahn JG, Becker BJ, MacIsaa L, Amory JK, Neuhaus J, Olkin I, et al. The efficacy of medical
abortion: a meta-analysis. Contraception 2000;61:29–40. (Ref. 161)
• Kulier R, Cheng L, Fekih A, Hofmeyr GJ, Campana A. Surgical methods for first trimester
termination of pregnancy. Cochrane Database Syst Rev 2001;(4):CD002900. (Ref. 267)
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• Kulier R, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester
abortion. Cochrane Database Syst Rev 2004;(1):CD002855. (Ref. 337)
• Lohr PA, Hayes JL, Gemzell-Danielsson K. Surgical versus medical methods for second trimester
induced abortion. Cochrane Database Syst Rev 2008;(1):CD006714. (Ref. 122)
• Say L, Brahmi D, Kulier R, Campana A, Gülmezoglu AM. Medical versus surgical methods for
first trimester termination of pregnancy. Cochrane Database Syst Rev 2005;(1):CD003037. (Ref.
93)
• Tuncalp O, Gülmezoglu AM, Souza JP. Surgical procedures for evacuating incomplete
miscarriage. Cochrane Database Syst Rev 2010;(9):CD001993. (Ref. 268)
• Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-
trimester termination of pregnancy. Cochrane Database Syst Rev 2011;(1):CD005216. (Ref. 377)
Pain control
• Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-
inflammatory drugs on medical abortion with mifepristone and misoprostol at 13–22 weeks
gestation. Hum Reprod 2005;20:3072–7. (Ref. 379)
• Renner RM, Jensen JT, Nichols MD, Edelman A. Pain control in first trimester surgical abortion.
Cochrane Database Syst Rev 2009;(2):CD006712. (Ref. 313)
Abortion complications: immediate
Uterine rupture
• Berghella V, Airoldi J, O’Neill AM, Einhorn K, Hoffman M. Misoprostol for second trimester
pregnancy termination in women with prior caesarean: a systematic review. BJOG.
2009;116:1151–7. (Ref. 146)
• Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean
delivery: a systematic review. Obstet Gynecol 2009;113:1117–23. (Ref. 145)
Infection
• Achilles SL, Reeves MF; Society of Family Planning. Prevention of infection after induced abortion:
release date October 2010: SFP Guideline 20102. Contraception 2011;83:295–309. (Ref. 241)
• Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the
literature. Contraception 2004;70:183–90. (Ref. 177)
• Low N, Mueller M, Van Vliet HAAM, Kapp N. Antibiotic prophylaxis for medical and surgical
first-trimester induced abortion. Cochrane Database Syst Rev. In preparation. (Ref. 243)
Abortion complications: long-term sequelae
• Thorp JM Jr, Hartmann KE, Shadigian E. Long-term physical and psychological health
consequences of induced abortion: review of the evidence. Obst Gynecol Surv 2002;58:67–79.
(Ref. 189)
Future reproductive outcome
• Gan C, Zou Y, Wu S, Li Y, Liu Q. The influence of medical abortion compared with surgical
abortion on subsequent pregnancy outcome. Int J Gynaecol Obstet 2008;101:231–8. (Ref. 203)
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• Shah PS, Zao J; Knowledge Synthesis Group of Determinants of preterm/LBW births. Induced
termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-
analyses. BJOG 2009;116:1425–42. (Ref. 199)
• Sun Y, Che Y, Gao E, Olsen J, Zhou W. Induced abortion and risk of subsequent miscarriage. Int
J Epidemiol 2003;32:449–54. (Ref. 198)
• Swingle HM, Colaizy TT, Zimmerman MB, Morriss FH Jr. Abortion and the risk of subsequent
preterm birth: a systematic review with meta-analyses. J Reprod Med 2009;54:95–108. (Ref. 206)
Mental health
• American Psychological Association. Task Force on Mental Health and Abortion. Report of the
Task Force on Mental Health and Abortion. Washington, DC: APA; 2008
[http://www.apa.org/pi/wpo/mental-health-abortion-report.pdf]. (Ref. 208)
• Charles VE, Polis CB, Sridhara SK, Blum RW. Abortion and long-term mental health outcomes:
a systematic review of the evidence. Contraception 2008;78:436–50. (Ref. 209)
• Major B, Appelbaum M, Beckman L, Dutton MA, Russo NF, West C. Abortion and mental health:
Evaluating the evidence. Am Psychol 2009;64:863–90. (Ref. 416)
• National Collaborating Centre for Mental Health. Induced abortion and mental health. A
systematic review of the mental health impact of induced abortion. London: Academy of
Medical Royal Colleges; 2011. In press. (Ref. 137)
Breast cancer
• Committee on Gynecologic Practice. ACOG Committee Opinion No. 434: induced abortion and
breast cancer risk. Obstet Gynecol. 2009;113:1417–8. (Ref. 188)
Follow-up
• Grossman D, Grindlay K. Alternatives to ultrasound for follow-up after medication abortion: a
systematic review. Contraception 2011;83:504–10. (Ref. 396)
Contraception after abortion
• Ferreira AL, Lemos A, Figueiroa JN, de Souza AI. Effectiveness of contraceptive counselling of
women following an abortion: a systematic review and meta-analysis. Eur J Contracept Reprod
Health Care 2009;14:1–9. (Ref. 431)
• Gaffield ME, Kapp N, Ravi A. Use of combined oral contraceptives post abortion. Contraception
2009;80:355–62. (Ref. 437)
• Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine
devices. Cochrane Database Syst Rev 2010;(6):CD001777. (Ref. 439)
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Evidence table 1. Studies relating to the relative safety of abortion at increasing gestations
Authors Size of study (n) Study type Outcome 
Grimes et al. 67 175 Multicentre, prospective, observational RR 1.4 (95% CI 1.2–1.7) associated with 
JAMA 1984;251:2108–11 cohort study (up to 13 weeks and later) each 2-week increment in gestation 
RCGP/RCOG 6105 Multicentre, prospective cohort study, Compared with abortion at < 9 weeks:
J R Coll Gen Pract observational with controls (up to • operations at 9–12 weeks had 5 x risk 
1985;35:175–80 17 weeks) of haemorrhage
• operations at > 12 weeks had 7 x risk 
of haemorrhage
Increasing gestation was a factor in
increasing the overall morbidity rate but
did not reach statistical significance
Jacot et al. 3772 Retrospective cohort study; Fewer complications in later gestation 
Am J Obstet Gynecol single centre (compared < 15 weeks group (P = 0.056):
1993;168:633–7 with 15–20 weeks) • 5.1% < 15 weeks
• 2.9% 15–20 weeks
Buehler et al. 82 030 Multicentre, prospective, observational Increased risk of serious complications if 
Am J Obstet Gynecol cohort study (up to 24 weeks) > 12 weeks; below 13 weeks, non-
1985;153:14–9 significant increase with gestation; after 12
weeks, RR for each 2-week increment in
gestation 1.42 (95% CI 1.30–1.55)
Increased risk of febrile morbidity at > 12
weeks: RR 1.43 (95% CI 1.21–1.69); RR for
transfusion 2.00 (95% CI 1.10–3.64) for
each 2-week gestation increment at < 12
weeks; RR for transfusion 1.48 (95% CI
1.33–1.65) for each 2-week gestation
increment at > 12 weeks
Ferris et al. 83 469 Retrospective database cohort study, Complications at:
CMAJ multicentre; abortions at all gestations • ≤ 9 weeks: 1
1996;154:1677–85 • 9–12 weeks: 1.3 (95% CI 1.02–1.63)
• 17–20 weeks 3.3 (95% CI 2.23–5.00)
Glasier and Thong 1988: 2204; Surgical abortions up to 20 weeks; Change of referral system in November 
Health Bull (Edinb) 1989: 2210 before and after study 1988
1991;49:254–9 Analysed notes for first half of 1989; only
referrals from family planning service were
compared in the before and after study (88
before and 71 after)
Outcome of change in referral system:
• reduction in wait to be assessed from 11
to 5 days
• increase in proportion of abortions
performed at early gestations (from 40%
to 60% at ≤ 9 weeks and from 21% to
under 10% at ≥ 12 weeks)
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Evidence table 2. Studies relating to induced abortion and subsequent breast cancer risk
Authors Study design Subjects (n) Conclusions 
Thorp et al. Narrative review Cannot exclude a significant association; 
Obst Gynecol Surv OR 1.3 (95% CI 1.2–1.4) 
2002;58:67–79
Tavani et al. Case–control 579 cases Abortion was not related to risk of breast cancer at age 
Eur J Cancer 668 controls < 40 years; OR 0.87 (95% CI 0.63–1.22) 
1999;35:1361–7
Marcus et al. Case–control 862 cases Abortion during adolescence does not influence breast 
Am J Public Health 790 controls cancer risk; RR 1.2 (95% CI 0.6–2.7) 
1999;89:1244–7
Fioretti et al. Case–control 1041 cases Abortion was not related to breast cancer risk in 
Br J Cancer 1002 controls nulliparous women; OR 0.97 (95% CI 0.64–1.47) 
1999;79:1923–8
Newcomb and Mandelson Case–control 138 cases Abortion was not related to risk of breast cancer; 
Cancer Causes Control 252 controls RR 0.9 (95% CI 0.5–1.6) 
2000;11:777–81
Lazovich et al. Cohort 37 247 No excess risk of breast cancer among women who 
Epidemiology reported having an abortion; RR 1.1 (95% CI 0.8–1.6) 
2000;11:76–80
Tang et al. Case–control 463 cases Abortion does not increase risk of breast cancer; 
Epidemiology 2201 controls RR 0.9 (95% CI 0.7–1.2)
2000;11:177–80
Robertsona et al. Case–control 624 cases Abortion was not associated with a statistically 
Breast 2001;10:291–8 624 controls significant elevated risk in any parity group 
Sanderson et al. Case–control 1459 cases There was no relation between abortion and breast 
Int J Cancer 1556 controls cancer; OR 0.9 (95% CI 0.7–1.2) 
2001;92:899–905
Goldacre et al. Case–control 28 616 cases Abortion does not increase the risk of breast cancer; 
J Epidemiol Community 325 456 controls OR 0.83 (95% CI 0.74–0.93)
Health 2001;55:336–7
Ye et al. Cohort and 267 040 (cohort) Abortions are not an important cause of breast cancer; 
Br J Cancer case–control 652 cases RR 0.51 (95% CI 0.31–1.50)
2002;87:977–81 694 controls
Mahue-Giangreco et al. Case–control 744 cases Does not support the hypothesis that abortion increases 
Cancer Epidemiol 744 controls breast cancer risk; OR 0.71 (95% CI 0.49–1.02) 
Biomarkers Prev
2003;12:209–14
Becher et al. Case–control 706 cases A history of abortion showed no significant effect 
Int J Epidemiol 1633 controls
2003;32:48–50
Erlandsson et al. Case–control 1759 cases Abortion is not associated with an increased risk of 
Int J Cancer 1759 controls breast cancer; OR 0.80 (95% CI 0.64–1.00)
2003;103:676–9
Paoletti et al. Cohort 92 767 There is no relationship between breast cancer and 
Int J Cancer induced abortion; RR 0.91 (95% CI 0.82–0.99)
2003;106:270–6
Reeves et al. Cohort 267 361 Induced abortion is not associated with risk of breast 
Int J Cancer cancer; OR 1.07 (95% CI 0.99–1.14)
2006; 119:1741–5
Michels et al. Cohort 105 716 Induced abortion was not associated withan increased 
Arch Intern Med risk of breast cancer; OR 1.01 (95% CI 0.88–1.17) 
2007:167:814–20
Rosenblatt et al. Cohort 267 400 Induced abortion was not associated with increased risk 
Cancer Causes Control of breast cancer; OR 1.01 (95% CI 0.92–1.12)
2006;17:1275–80
Lash et al. Case–control 1665 cases Induced abortion was not associated with increased risk 
Int J Cancer 4972 controls of breast cancer; adjusted OR 0.91 (95% CI 0.79–1.0) 
2004;110:443–8
Henderson et al. Cohort 109 893 Induced abortion was not associated with increased risk 
Contraception of breast cancer in nulliparous or gravid women; 
2008;77:391–6 OR 0.96 (95% CI 0.79– 1.18) and OR 1.05 (95% CI
0.92–1.20), respectively
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Evidence table 3. Studies relating to the rate of uterine perforation during termination of pregnancy
Authors Size of study (n) Gestation Perforation rate 
Andolsek et al. 3004 in Ljubljana 7–12 weeks 1.3 in 1000 in Ljubljana
Stud Fam Plann 1466 in Singapore 1.4 in 1000 in Singapore 
1977;8:118–24
Lindell et al. 84 850 < 18 weeks 145 (1.7 in 1000) 
Acta Obstet Gynecol 
Scand 1995;74:373–5
Hakim-Elahi et al. 170 000 First trimester 16 (0.09 in 1000) 
Obstet Gynecol
1990;76:129–35
Kaali et al. (a) 6408 First trimester Before direct visualisation:
Am J Obstet Gynecol (b) 706 (a) 8 (1.3 in 1000)
1989;161:406–8 b = at time of (b) 2 (2.8 in 1000)
laparoscopic Unsuspected perforations:
sterilisation 12 (15.6 in 1000)
True incidence in the laparoscopic group was 14 (2 +
12) in 706 or 19.8 in1000
Heisterberg et al. 5851 ≤ 9 weeks 10 (0.4 in 1000)
Acta Obstet Gynecol 10–12 weeks 12 (0.3 in 1000)
Scand 1987;66:201–4 All gestations 22 (0.4 in 1000)
RCGP/RCOG 6105 9–12 weeks 22 (3.6 in 1000)
J R Coll Gen Pract Women treated in private sector had one-third the risk of
1985;35:175–80 trauma compared with women treated in NHS 
Grimes et al. 67 175 Up to 24 weeks 0.9 in 1000 
JAMA 1984;251:2108–11 (86% < 13 weeks) 
King et al. 11 885 8238 in first trimester 9 perforations
Am J Obstet Gynecol 3647 in second ? all first trimester; if so 1.1 in 1000 perforation rate 
1980;137:530–3
Hodgson et al. 104 453 < 14 weeks 10 (1.1 in 1000) 
Am J Obstet Gynecol
1974;120:802–7
Nathanson et al. 26 000 First trimester 36 (1.4 in 1000) 
N Engl J Med
1972;286:403–7
Beric et al. 14 261 by curettage Up to 12 weeks 18 (1.2 in 1000)
Lancet 1971;2:619–21 22 905 by vacuum 13 (0.4 in 1000)
aspiration 
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Evidence table 4. Summary of the incidence of cervical injury during first-trimester abortion by vacuum aspiration
reported in illustrative large case series
Study Gestation Abortions (n) Cervical injury Rate/1000 
Andolsek et al. 7–12 weeks 6655 4 0.6 
Stud Fam Plann
1977;8:118–24
Ferris et al. 87% < 13 weeks 83 460 63 0.7 
CMAJ
1996;154:1677–85
RCGP/RCOG 88% < 13 weeks 6105 11 1.8 
J R Coll Gen Pract 
1985;35:175–80
Jacot et al. 5–14 weeks 3225 1 0.3 
Am J Obstet Gynecol
1993;168:633–7
Hakim-Elahi et al. Up to 14 weeks 170 000 18 0.1 
Obstet Gynecol
1990;76:129–35
Heisterberg et al. First trimester 5851 5 0.8 
Acta Obstet Gynecol 
Scand 1987;66:201–4
Schulz et al. ≤ 12 weeks 15 438 159 10.3
Lancet 1983;1:1182–84
Evidence table 5. Summary of the incidence of cervical injury during second-trimester abortion by dilatation and
evacuation in illustrative large case series
Authors Gestation Abortions (n) Cervical injury Rate/1000 
Jacot et al. 15–26 weeks 547 0  
Am J Obstet Gynecol
1993;168:633–7
Schulz et al. 13–20 weeks 6213 72 11.6 
Lancet 1983;1:1182–4
Peterson et al. 14–16 weeks 9916 109 11.6
Obstet Gynecol
1983;62:185–90
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Evidence table 6. Effect of routine uterotonics on blood loss during vacuum aspiration abortion in randomised
controlled trials
Authors Population Intervention Findings 
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Nygaard et al.
Acta Obstet Gynecol
Scand 2011;90:174–8
309 women at no more than
12 weeks gestation
undergoing VA abortion 
Single-blind RCT of 5 units
syntocinon IV or no oxytocic. All
women received misoprostol for
cervical preparation. Procedures
performed under general
anaesthetic with propofol, in some
cases combined with alfentanyl
and nitrous oxide. Vaginal
bleeding recorded by weighing
pads immediately after the
surgical procedure and counting
pads during the 3 following days.
Pain and nausea assessed using
visual analogue scales.
Mean blood loss at the hospital was
5 g (range 0–70) in the syntocinon
group and 5 g (range 0–64) in the no
treatment group, which was not a
statistically significant difference 
(P = 0.81). Blood loss at home, pain
and nausea scores were also not
statistically significantly different
between the groups. 
Ali and Smith
Anaesthesia
1996;51:483–5
64 women at ≥ 9 weeks
gestation undergoing VA
abortion 
Single-blind RCT of 10 units
syntocinon or 1 ml saline IV
following cervical dilation. All
women received gemeprost
pessary for cervical preparation.
Procedures performed under
general anaesthetic with propofol
and fentanyl. Blood loss
calculated colorimetrically.
Uterine contractility graded by
blinded surgeon. 
Median gestation age 10 weeks (SD
1.3) in syntocinon group, 10 weeks
(SD 1.0) in placebo group. Median
blood loss in syntocinon group 17.6ml
(range 6.1–72.7 ml). Median blood
loss in placebo group 24.5 ml (range
6.7–94.3 ml; P = 0.02). 6 patients in
saline group had unsatisfactory uterine
contraction compared with 0 in
syntocinon group (P = 0.025);
however, no intervention was required.
Beeby and Morgan Hughes
Anaesthesia
1984;39:764–7
88 women up to 14 weeks of
gestation undergoing VA for
spontaneous miscarriage. 
Double-blind RCT of 10 units
syntocinon, 0.25 mg ergometrine
or 1 ml saline IV. Procedures
performed under general
anaesthetic with fentanyl and
methohexitone. Blood loss
measured calorimetrically. 
Uterine contractility considered
satisfactory if no other uterotonic
given. Postoperative vomiting
recorded until discharge. 
Of 88 women enrolled, 32 excluded
because of protocol errors. Information
on mean (SD) for gestational age not
reported. Mean blood loss for
syntocinon was 10 ml (range 0–50ml),
ergometrine 46.7 ml (range 5–185ml)
and normal saline 45 ml (range
0–180ml), but were not statistically
significantly different. 3 women in the
ergot group and 2 in the saline group
received oxytocics for poor uterine
contractility; however, the differences
in contractility were not statistically
significantly different between groups.
Less vomiting when no oxytocic used
but not statistically significantly
different.
Cochrane et al.
Br J Obstet Gynaecol
1981;88:1120–3
276 women undergoing VA
at ≤ 12 weeks of gestation for
abortion. 
Double-blind RCT of 0.5mg
ergometrine, 5 units syntocinon 
or sterile water IV. Procedures
performed under general
anaesthetic with Althesin and
diazepam. Total volume of
aspirated fluid recorded (blood +
amniotic fluid) measured as well
as immediate complications and
adverse effects. 
No statistically significant difference in
total amount of fluid aspirated
between groups. No statistically
significant difference in postoperative
vaginal loss. No difference in pain
between oxytocin and water; more
moderate and severe pain with
ergometrine than oxytocin (P < 0.001).
Ergometrine caused more vomiting
than oxytocin in the immediate
postoperative period and up to 4 hours
after (P < 0.001).
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Evidence table 7. Studies relating to local compared with general anaesthesia
Author Size of study (n) Type of study Outcome 
De Jonge et al. 142 Prospective randomised Randomised into 2 groups:
S Afr Med J trial • those for evacuation under systemic analgesia
1994;84:481–3 • those under general anaesthesia (GA)
Both groups compared in terms of safety, efficacy,
acceptability, blood consumption and time delay
between admission and evacuation
Significantly less blood use in ward group (37 units for
13 women) than in theatre group (65 units for 24
women) (P < 0.003)
Significantly less time taken between admission and
evacuation in ward group (median 7 hours 15 minutes)
than in theatre group (median 12 hours 38 minutes; P <
0.003)
Evacuation under fentanyl and midazolam was safe,
effective and acceptable for majority of women
compared with evacuation users
MacKay et al. 4147 GA Randomised trial Women who had D&E under GA had a relatively high 
Obstet Gynecol 5389 LA risk of complications of 2.6 (95% CI 1.4–4.9) compared 
1985;66:661–5 with women who underwent D&E under local 
anaesthesia (LA)
LA for second-trimester abortion appears to be both safer
and less expensive than GA
Grimes et al. 36#430 Case study Significant differences between LA and GA for 
Am J Obstet Gynecol specific complications
1979;135:1030–5 LA associated with higher rates of febrile and convulsive
morbidity
GA associated with higher rates of haemorrhage, cervical
injury and uterine perforation
Evidence table 8. Randomised controlled trials evaluating outcomes in postoperative complications with and without
the use of ultrasound
Author Population Intervention Findings 
Acharya et al.
Eur J Obstet Gynecol
Reprod Biol
2004;114:69–74
230 women at < 13
weeks of gestation
undergoing VA for
abortion under general
anaesthetic 
Single-blind RCT of VA performed 
with or without continuous abdominal
ultrasound guidance by a single
operator. Procedure completion
determined ultrasonographically in 
the intervention group and by sharp
curette check in the control group.
Women > 11 weeks of gestation
received gemeprost cervical
preparation. All women received
syntocinon 5 iu IV during the
procedure. 
Follow-up available for 215 women.
Ultrasound imaging was determined
to be satisfactory in all but one case.
Overall complications higher in
control group. No statistically
significant difference in intraoperative
complications. More women in the
control group had a postoperative
infection (n = 8 vs n = 2; P < 0.005)
or an ERPC (n = 5 vs n = 0; P <
0.023). Those in the intervention
group had lower mean procedure
times, estimated blood loss, days of
analgesic requirements, postoperative
bleeding and convalescence.  
Debby et al.
Ultrasound Obstet
Gynecol 2006;27:61–4
809 women at 7–14
weeks of gestation
admitted for VA under
general anaesthetic for
abortion or management
of early fetal demise 
Non-blinded RCT of VA performed 
with or without transvaginal
sonography at the end of the surgical
procedure. Laminaria tents inserted in
all primigravidae or at ≥ 12 weeks of
gestation. Immediately after evacuation,
5–10 iu syntocinon were administered
IV. The procedure was completed by
sharp curettage in all participants. 
In the first 59 subjects, re-curettage 
was immediately performed if the
endometrium appeared irregular but
afterward only if endometrial thickness
was ≥ 8 mm. The women were
followed up by gynaecological and
ultrasound examinations 5–8 days
following the surgical procedure. 
The incidence of RPOC was
statistically significantly lower in the
intervention group (0.7% vs 7.1%; 
P < 0.05), but there were no other
differences in complications (vaginal
bleeding, endometritis, or
perforation). There was no difference
in the mean duration of bleeding
post-procedure or of endometrial
thickness when measured at the
follow-up visit. 
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Evidence table 9. Randomised controlled trials evaluating prophylactic paracetamol on post-abortion pain
Author Population Intervention Findings 
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Cade and Ashley
Anaesth Intensive Care
1993;21:93–6
834 women undergoing
VA under general
anaesthesia up to 12
weeks of gestation 
Double-blind placebo-controlled
randomised trial of 1000mg oral sachet
of paracetamol 30 minutes prior to VA.
Anaesthesia was induced with propofol
and maintained with nitrous/oxygen if
needed. Some women also received
fentanyl. All women received
syntocinon 10 iu at the end of surgery.
Outcomes were pain (as indicated by
need for additional analgesia), nausea
and vomiting.
Analgesia was required in 35% of
women overall. Administration of
paracetamol was not associated with
a statistically significant difference in
the incidence of pain (P = 0.52),
nausea (P = 0.57) or vomiting 
(P = 0.65). There was no difference
between paracetamol and placebo
groups in pain relative to the receipt
of volatile anaesthetic or fentanyl in
addition to propofol.
Hein et al.
Acta Anaesthesiol Scand
1999;43:248–51
140 women undergoing
VA under general
anaesthesia at 7–12
weeks of gestation 
Double-blind placebo-controlled
randomised trial of 1g rectal
paracetamol or placebo administered at
the end of VA. Anaesthesia was induced
with propofol/fentanyl and maintained
with nitrous/oxygen if needed. All
women received routine syntocinon 5 iu
at the end of surgery. Outcomes were
the need for rescue analgesia and pain
as assessed by visual analogue scale
(VAS) (0 = no pain, 10 = unbearable
pain) at 30 minutes and 60 minutes
post-operatively and at discharge.
Overall 29% of subjects required
rescue analgesia (37% [26/70] in
paracetamol group vs 23% [16/70] in
the placebo group; a non-significant
difference). The mean VAS scores
were lower in the placebo group at
30 minutes (2.1±1.9 vs 1.4±1.71; 
P < 0.05), but there was no difference
at 60 minutes or at discharge.  
Hein et al.
Ambul Surg 2001;9:91–4
210 women from 8 to 
13 weeks of gestation
undergoing VA under
general anaesthetic 
Double-blind placebo-controlled
randomised trial of 1 g oral paracetamol
and 8mg oral lornoxicam given 60
minutes prior to vacuum aspiration
abortion under general anaesthetic.
Anaesthesia induced with propofol and
fentanyl and maintained with
nitrous/oxygen if needed. All subjects
received 5 iu syntocinon at the end of
surgery. Outcomes were pain VAS
scores (0 = no pain, 100 = unbearable
pain) at 30 and 60 minutes
postoperatively and at discharge, need
for rescue medication and time to
discharge.
Equal numbers of women receiving
paracetamol and placebo required
analgesia (23/70 in each group).
Fewer women receiving lornoxicam
(10/70) required analgesia than
paracetamol (OR 0.36, 95% CI
0.17–0.78), but the difference
compared with placebo was not
statistically significantly different.
There was no statistically significant
difference in the VAS scores or time
to discharge between groups. 
Lowenstein
Contraception
2006;74:345–8
217 women undergoing
VA under general
anaesthetic at 6–12
weeks of gestation 
Double-blind RCT of 1000mg
paracetamol, 100mg tramadol or
100mg idomethacin suppository
compared with no treatment inserted 
at the end of a VA. GA was performed
with propofol and fentanyl. Women 
and recovery room staff were blinded 
to the treatment. The gynaecologists
who inserted the suppositories were 
not involved in the pain assessment and
pain treatment in the recovery room.
Outcomes were the need for rescue
analgesia (dipyrone 1g orally) and pain
as assessed by visual analogue scale
score. Pain VAS (0 = no pain, 10 =
worst pain imaginable) was assessed at
15, 30, 60, 90 and 120 minutes
postoperatively. 
The need for rescue analgesia was
required by 40% (22/55) of controls,
18% (10/55) of those in the tramadol
group, 13% (7/54) of those in the
paracetamol group and 9% (5/53) of
those in the indomethacin group (P <
0.001). Pain as ranked on the VAS in
the control group was 4.98±3.2 cm,
3.35±2.9 cm, 1.49±2, 0.78±1.6 cm
and 0.24±0.69 cm at each time
point. Compared with the control
group, the mean VAS score was
lower in the paracetamol group at 15
minutes postoperatively but higher
than the control group at every other
time point. Compared with controls,
women who had received an
indomethacin suppository reported
lower VAS pain scores at every time
point (difference in mean scores
2.72 cm, 1.12 cm, 0.57 cm, 0.42 cm
and 0.22 cm, respectively).
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